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Abstract 
Follicle stimulating hormone (FSH) promotes granulosa cell (GC) proliferation, 
differentiation, and steroidogenesis.  This series of events is critical for female fertility, 
and culminates in the formation of mature follicles responsive to the surge of luteinizing 
hormone (LH) that triggers ovulation. Ephrins (Efn genes) and Eph receptors (Eph genes) 
are membrane-associated signaling molecules that mediate communication at sites of 
cell-cell contact, and have been extensively studied in the context of embryonic 
development. The published literature contains several reports of ovarian Eph and Efn 
expression, although their precise roles in the ovary are unknown. Dysregulation of Efna5 
in GCs of the subfertile Esr2-/- mouse suggests a role for Eph-ephrin signaling in ovarian 
function. We sought to investigate Eph receptors and ephrins in the mouse ovary using 
gonadotropin-stimulated animal models and cultured GCs. We identified several Efn and 
Eph genes for which expression is enhanced in GCs of the gonadotropin-stimulated 
mouse. Furthermore, we determined that cultured GCs stimulated with recombinant 
ephrin-A5 or EphA5 exhibit reduced cell spreading or adhesion, respectively, indicating a 
cell-autonomous response to Eph-ephrin stimulation. In order to ascertain the importance 
of ephrin-A5 in female fertility, we performed a reproductive assessment of females 
lacking Efna5, the sole ephrin-encoding gene upregulated by FSH in GCs. Efna5-/- 
females are subfertile and exhibit an impaired response to LH, displaying attenuated 
ovulatory potential, reduced ovarian expression of Pgr, Ptgs2, and Adamts4, as well as 
abnormal follicle rupture. We also found an increased incidence of multi-oocyte follicles 
in adult, but not juvenile, Efna5-/- females, indicating follicle merging. Finally, we 
determined that the mouse genomic region upstream of Epha5 is transcriptionally 
activated by cAMP in a protein kinase A-dependent manner. Transcriptional activation of 
Efna5, Epha3, Epha5, Epha8, and Ephb2 is reduced in GCs of eCG-treated Esr2-/- 
females, which exhibit impaired cAMP production. These results suggest that cAMP is a 
novel transcriptional regulator for several Eph and Efn genes. Our findings establish a 
place for ephrins and their receptors within the current model of gonadotropin-dependent 
follicle growth and ovulation, and identify cAMP as a novel transcriptional regulator of 
Epha5 and possibly other Efn and Eph genes. 
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1 Chapter 1: Introduction 
1.1 Stages of Ovarian Follicle Growth 
1.1.1 Introduction to Folliculogenesis 
In female mammals, the ovary has two primary functions. The first is the synthesis 
of steroid hormones such as testosterone, 17β-estradiol, and progesterone. These 
hormones are necessary for the development of secondary sex characteristics, 
communication with the neuroendocrine components of the reproductive system, and 
communication with the uterus to induce changes that are necessary for establishing and 
maintaining pregnancy. The second function is the ovulation of a healthy and fertilizable 
oocyte. Both functions are performed by the functional unit of the ovary, the follicle. The 
ovarian follicle is an aggregate unit of a germ cell and its associated somatic cells, 
consisting of an oocyte, surrounded by granulosa cells (GCs), which are in turn 
surrounded by a basement membrane and thecal cells (Figure 1-1). The formation and 
maturation of the follicle, known as folliculogenesis, begins in the developing embryo. 
This process culminates in the generation of one or more mature follicles that are 
competent to ovulate and produce a fertilizable oocyte. 
1.1.2 Formation of primordial follicles 
In female mammals, folliculogenesis begins during embryonic development. 
Within the embryo, mitotic division of primordial germ cells (PGCs) gives rise to clusters 
of germ cells, known as “oocyte nests” (1). Prior to birth in humans and at birth in 
rodents (2), these clusters break down into individual germ cells called oogonia. Oogonia 
are then enclosed by a single layer of flat pre-granulosa cells derived from the ovarian 
stroma, forming a primordial follicle (3) (Figure 1-2). The mechanisms underlying these 
events are not fully understood, but loss-of-function studies have identified some factors 
that are required for this process (4). After formation, primordial follicles remain dormant 
and will not mature until they are activated at puberty. It is thought that this pool of 
primordial follicles will provide all of the oocytes required for the duration of the 
female’s reproductive life (5). However, some evidence indicates that adult mouse and 
human ovaries contain small numbers of stem cells that have the capacity to give rise to 
2 
 
oocytes in culture and in vivo (6). Whether this population of stem cells contributes to 
and/or replenishes the pool of primordial follicles in adults is not known. 
1.1.3 Follicle-stimulating hormone-independent follicle growth 
Once a female mammal reaches sexual maturity, cohorts of quiescent primordial 
follicles are selected for activation, acquiring the potential to grow, mature, and ovulate. 
The current body of evidence suggests that primordial follicles are maintained in a state 
of dormancy by inhibitory pathways within the follicle. One primordial follicle may 
remain dormant while the follicle adjacent to it is recruited for activation, suggesting 
inhibition by intra-ovarian factors (7). Deletion of the Amh gene in mice, which encodes 
the anti-mullerian hormone, results in decreased numbers of primordial follicles and 
increased numbers of growing follicles (8). Furthermore, oocyte-specific deletion of the 
phosphoinositide 3-kinase (PI3K) pathway inhibitor gene Pten in mice results in 
recruitment and activation of all primordial follicles, depletion of the ovarian reserve and 
infertility (9). Therefore, recruitment of primordial follicles likely involves relief of these 
and possibly other pathways that suppress activation. 
Once a primordial follicle has been recruited, a series of events is initiated that 
results in the formation of primary and then secondary follicles (Figure 1-2), which 
occurs independently of gonadotropins. This is supported by histological observations in 
ovaries from Fshb-/- mice, which lack the follicle-stimulating hormone (FSH) beta 
subunit and therefore do not produce FSH. Ovaries from these mice contain follicles at 
the primordial, primary, and secondary stages, indicating that FSH is not required for 
growth up to the secondary stage (10). During the transition from the primordial to the 
primary stage, the morphology of the single layer of pre-granulosa cells changes from flat 
to cuboidal, followed by Foxl2 (forkhead box L2)-dependent granulosa cell proliferation 
(11). Progression to the secondary stage involves continued proliferation of GCs and 
recruitment of cells from the ovarian stroma to the outer periphery of the follicle. These 
cells differentiate into thecal cells (12). This stage of growth is dependent on GDF9 
(growth differentiation factor 9), an oocyte-secreted protein and member of the TGFB 
(transforming growth factor beta) family. The requirement for GDF9 is supported by the 
observations that Gdf9-/- female mice are infertile, have ovaries that contain only follicles 
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at the primordial and primary stages (13), and lack markers for thecal cells (14). 
Importantly, it is generally accepted that the secondary follicle stage is also the stage at 
which GCs begin to express Fshr, which encodes the FSH receptor (FSHR) (15), 
although some evidence suggests that primordial follicles respond to FSH (16). This 
permits the follicle to acquire responsiveness to FSH, the gonadotropin that promotes 
continued follicle growth. 
1.1.4 FSH-dependent follicle growth 
In contrast to growth of primordial and primary follicles, growth of secondary 
follicles to the antral stage is dependent on FSH, an idea supported by the observation 
that ovaries from Fshb-/- female mice contain primordial, primary, and secondary follicles 
but lack antral follicles (10). Acting through FSHR, its cognate G protein coupled 
receptor in GCs, FSH initiates a number of changes in the secondary follicle, including 
increased proliferation of GCs, differentiation of GCs into more specialized cell types, 
increased production of autocrine, paracrine and endocrine messengers, formation of a 
fluid-filled antrum, and acquisition of responsiveness to LH (17). 
As GCs continue to proliferate, they differentiate into two specialized subtypes: 
mural GCs and cumulus cells. These GC subtypes comprise distinct populations that are 
spatially segregated and serve different purposes in the follicle. Spatially, they are 
separated by the formation of a fluid-filled antrum, or cavity. The fluid within the antrum 
has a composition similar to that of serum, but with much lower concentrations of plasma 
proteins that have molecular weights greater than 100 kDa (18). 
Several layers of mural GCs line the interior periphery of the follicle and are the 
primary site of estradiol synthesis in the ovary, producing increasing amounts of estradiol 
as the follicle grows. During early FSH-dependent follicle growth, estradiol output from 
the follicle is low and has a suppressive effect on hypothalamic GNRH (gonadotropin-
releasing hormone) secretion. In this way, GNRH secretion is reduced but pulse 
frequency is unaltered, resulting in reduced pituitary FSH secretion (19). As follicle 
growth proceeds, estradiol production rises due to the increasing number of GCs and 
increased expression of steroidogenic genes (20). In contrast to low serum estradiol 
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concentration, high concentrations have the effect of increasing GNRH production and 
frequency, favouring production of LH (21). In addition to estradiol, mural GCs also 
produce the peptide hormones activin, inhibin, and follistatin, which are members of the 
TGFβ family. These hormones were named based on their effect on FSH production, 
with activins having a stimulatory effect and inhibins having an inhibitory effect (22). 
Follistatin, which is present in serum, binds to activins with high affinity (23) and 
“neutralizes” them by preventing their interaction with activin receptors (24). Ovarian 
production of inhibins increases during FSH-dependent follicle growth (25), and acts to 
suppress FSH secretion (26). Therefore, mural GCs are responsible for producing the 
endocrine messengers that feed back on the hypothalamus and anterior pituitary. 
In contrast to mural GCs, cumulus cells surround and are closely associated with 
the oocyte. Cumulus cells exhibit different patterns of gene expression compared to 
mural GCs, thought to be caused by a currently unidentified oocyte-secreted factor that 
establishes opposing gradients of FSH- and SMAD2/3-dependent signaling in the follicle, 
such that expression of FSH-responsive genes is strong in mural granulosa cells and weak 
in cumulus cells (27). During FSH-dependent follicle growth, the primary purpose of 
cumulus cells is to provide nutrients to the oocyte via gap junctions (28). Later in 
folliculogenesis, cumulus cells play crucial roles in the events leading to ovulation. 
1.1.5 LH-dependent oocyte maturation, cumulus expansion, ovulation, and corpus 
luteum formation 
Once the follicle reaches the preovulatory stage, estradiol levels are sufficiently 
high to trigger an acute release of LH from the anterior pituitary, known as the LH surge. 
Within the follicle, LH acts primarily on mural GCs, which express high levels of LH 
receptor (LHR). In cumulus cells, expression of Lhcgr is much lower than in mural GCs 
(29). LH promotes secretion of epidermal growth factor (EGF) and EGF-like factors from 
mural GCs, which are delivered to cumulus cells via the follicular fluid. These factors, 
which include amphiregulin, epiregulin, and betacellulin, activate EGF receptors 
expressed by cumulus cells (30). Therefore, the LH response in cumulus cells is mediated 
largely by these mural granulosa cell-derived, EGF-like factors. These and other factors 
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initiate several events that are critical for fertility: resumption of oocyte meiosis, cumulus 
expansion, follicle rupture, and formation of the corpus luteum. 
1.1.5.1 Resumption of meiosis 
During primordial follicle formation, oocytes are arrested during meiosis I (31), 
and resumption only occurs following the LH surge. Meiotic resumption is necessary for 
the production of a fertilizable oocyte, although the exact mechanism by which meiotic 
resumption is initiated has not been elucidated. The current body of evidence indicates 
that follicle-derived factors maintain the oocyte in a state of meiotic arrest. Arrested 
oocytes removed from the follicle and placed in culture resume meiosis spontaneously, 
suggesting that a follicle-derived factor inhibits meiotic resumption in oocytes (32,33). 
Presumably, the LH surge inhibits the production or activity of this factor, resulting in 
meiotic resumption. While this factor has not been identified, there is evidence 
suggesting that its action on the oocyte is dependent on GPR3 (G-protein coupled 
receptor 3) (34-36), since oocytes from mice lacking GPR3 undergo meiotic resumption 
within antral follicles independently of LH, indicating that oocyte-expressed GPR3 is 
required for suppression of meiotic resumption (37). In addition, mouse oocytes cultured 
in the presence of the GPR3 ligands sphingosylphosphorylcholine or sphingosine-1-
phosphate exhibit delayed meiotic resumption (38). 
1.1.5.2 Cumulus expansion 
Cumulus expansion involves the production of an extracellular matrix by the 
cumulus cells, resulting in increased COC volume (39). This matrix is rich in hyaluronan 
and hyaluronan-binding proteins including TNFAIP6 (tumor necrosis factor-inducible 
gene 6 protein) (40), VCAN (versican) (41), as well as laminins and FN1 (fibronectin) 
(42). Cumulus expansion is critical for ovulation. Pharmacological blockade of 
hyaluronan precursor synthesis during expansion in mice reduces ovulation and fertility 
(43). Furthermore, knockout mouse studies have revealed that many genes critical for 
ovulation are involved in cumulus expansion (44), including Has2 (hyaluronan synthase 
2), Tnfaip6, Ptx3 (pentraxin 3), and Ptgs2 (Prostaglandin-endoperoxide synthase 2). 
Cumulus expansion also requires the presence of oocyte-derived factors. Removal of the 
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oocyte from COCs blocks cumulus expansion in culture (45). More recent evidence 
suggests that the role of the oocyte in promoting cumulus expansion is dependent on 
SMAD2/3 signaling in cumulus cells (46). This finding is consistent with evidence 
indicating that a gradient of SMAD2/3 signaling occurs in GCs of the antral follicle, with 
SMAD2/3 phosphorylation highest near the oocyte and lowest at the periphery of the 
follicle near the basement membrane (27). The cumulus matrix has been proposed to 
facilitate extrusion from the follicle and its capture by oviductal fimbria (47). This idea is 
supported by evidence indicating an association between cumulus expansion and a 
transient increase in COC invasiveness and motility, properties that may be necessary for 
oocyte release from the follicle (48). 
1.1.5.3 Follicle rupture 
Successful ovulation requires release of the oocyte and its associated somatic cells 
to the exterior of the follicle, necessitating rupture of the follicle wall at a location 
adjacent to the exterior periphery of the ovary (the apical follicle surface). Degradation of 
the ECM at the site of rupture results in the formation of a rounded protuberance known 
as the stigma, which ruptures and releases the oocyte. This event is mediated by proteases 
that are expressed in the follicle in response to LH, including members of the MMP 
(matrix metalloproteinase) and ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin-like repeats) families. Several members of these families are upregulated 
during follicle rupture in rhesus macaques, and injection of the dominant follicle with an 
MMP inhibitor blocks ovulation (49). The observation that multiple proteases are 
upregulated suggests that all are involved in follicle rupture, however only one protease 
knockout model has been reported to exhibit a reproductive phenotype. Adamts1-/- female 
mice are subfertile and exhibit reduced ovulation and fertilization rates, indicating that 
this protease is critical for ovulation (50). Knockout mouse models lacking other LH-
induced MMP- and ADAMTS-encoding genes do not exhibit reproductive phenotypes 
(51-55), suggesting that other proteases may compensate for their loss. 
1.1.5.4 Luteinization and formation of the corpus luteum 
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Following ovulation, the remaining cells of the follicle form a structure known as 
the corpus luteum (CL). The CL contains two types of steroid-producing luteal cells: 
those derived from mural GCs (granulosa-luteal cells), and those derived from thecal 
cells (thecal-luteal cells). Like the parental cells from which these luteal cells arise, they 
play different roles in the CL. Granulosa-luteal, but not from thecal-luteal cells, exhibit 
strong immunoreactivity against CYP19A1, suggesting that granulosa-luteal cells are the 
primary sites of estradiol synthesis in the CL. In the macaque CL, luteal cells derived 
from thecal cells exhibit strong immunoreactivity against CYP17A1 (cytochrome P450, 
family 17, subfamily A, polypeptide 1), suggesting that thecal-luteal cells are the primary 
sites of androgen synthesis. Both luteal cell types exhibited immunoreactivity against 
CYP11A1 (cytochrome P450, family 11, subfamily A, polypeptide 1) and HSD3B 
(hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase), indicating 
that both cell types produce progesterone (56). Progesterone produced by the CL is 
required for the initiation and maintenance of pregnancy, while estradiol and inhibins 
produced in the CL suppress FSH secretion. As a result, FSH-dependent follicle growth 
is generally inhibited until the CL regresses and its endocrine influence diminishes. 
In addition to producing endocrine messengers, the CL also undergoes extensive 
neovascularization. This is driven primarily by an increase in both VEGF (vascular 
endothelial growth factor) and FGF (fibroblast growth factor), which is stimulated by the 
LH surge (57-59). This provides the CL with a direct interface to the circulation, allowing 
efficient access to cholesterol for steroid synthesis and release of endocrine messengers 
into the blood. 
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Figure 1-1: Histology of an antral follicle. 
The antral follicle consists of an oocyte, surrounded by granulosa cells, a basement 
membrane, and thecal cells. Under the influence of FSH, granulosa cells that are in close 
proximity to the oocyte differentiate into cumulus cells. Granulosa cells that line the 
interior periphery of the follicle differentiate into mural granulosa cells. 
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Figure 1-2: Stages of ovarian follicle growth. 
Primordial follicles undergo FSH-independent growth (A-C), becoming responsive to 
FSH at the secondary stage. FSH-dependent growth (D-E) results in the formation of a 
large follicle responsive to LH. Under the influence of LH (F-G), cumulus expansion 
occurs, followed by ovulation. 
 
10 
 
1.2 The hypothalamic-pituitary-gonadal axis 
In all reproductively mature, non-pregnant female mammals, follicle growth and 
ovulation are controlled by communication between the hypothalamus, the anterior 
pituitary, and the ovaries. In general, communication between these organs is mediated 
by GNRH, FSH, LH, and steroid hormones including estradiol and progesterone. The 
hypothalamus is the “master regulator” of female reproductive function, and may thus 
serve as a control point to integrate external information about stress and resource 
availability in order to modulate reproductive function. This integration of information 
may allow fertility to be limited during times of physiological stress or poor nutrition 
(60). 
At the onset of puberty, a subset of cells within the hypothalamus called GNRH 
neurons begin to secrete GNRH into the circulation in a pulsatile manner, with the 
frequency of release determining the gonadotropin secreted. Pulsatile GNRH secretion is 
dependent on KISS1 (kisspeptin), a hormone that is secreted by kisspeptin neurons also 
located in the hypothalamus and acts on GNRH neurons which express Kiss1r (KISS1 
receptor). Engineered mice with a GNRH neuron-specific depletion of Kiss1r fail to 
undergo puberty (61). GNRH secreted from the hypothalamus reaches the anterior 
pituitary and stimulates gonadotrope cells that express Gnrhr (gonadotropin-releasing 
hormone receptor). Upon stimulation, these gonadotrope cells synthesize and secrete 
gonadotropins into the circulation. Low GNRH pulsatile frequency favours secretion of 
FSH and high frequency favours secretion of LH. 
When FSH reaches the ovaries via the circulation, growth of several preantral 
follicles is initiated, which may vary with respect to size and responsiveness to FSH. The 
exact number is species specific, with a range of 4-14 preantral follicles recruited in 
humans (62). Ultimately, most of these follicles will undergo apoptosis during a process 
known as atresia. These are known as subordinate follicles. Only a small subset of 
recruited follicles, and in some species only one, will reach the preovulatory stage. These 
are known as dominant follicles. These follicles are likely to be the ones that were the 
largest and/or most mature when FSH levels began to rise. 
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Once growth of preantral follicles has been initiated, proliferation of GCs and 
expression of Cyp19a1 (cytochrome P450, family 19, subfamily A, polypeptide 1) is 
enhanced. CYP19A1, commonly referred to as aromatase, catalyzes the aromatization of 
testosterone and is the rate-limiting step in estradiol biosynthesis. The combination of 
increased numbers of GCs and increased expression of Cyp19a1 results in elevated serum 
estradiol, which serves as a messenger to the hypothalamus to secrete GNRH at a higher 
frequency. Increased frequency of GNRH secretion serves two purposes: suppression of 
FSH secretion and promotion of LH production, causing a switch in the gonadotropin 
output of the anterior pituitary. FSH levels then begin to fall, which has important 
consequences for growing follicles. During the early stages of FSH-driven follicle 
growth, survival of the follicle is dependent on elevated serum concentration of FSH. 
Once the follicle reaches a threshold size, such elevated FSH levels are no longer 
required for survival (63). Subordinate follicles still require elevated FSH levels for 
survival, and the decline in FSH triggers atresia in these follicles. However, follicles that 
were initially more mature and responsive to FSH, the dominant follicle(s), no longer 
require such elevated FSH for survival. Therefore, as FSH levels fall, subordinate 
follicles die, leaving the dominant follicle(s) to reach the preovulatory stage. 
Furthermore, dominant follicles also produce large quantities of estradiol and inhibin. In 
fact, production of inhibin-B peaks during the follicular phase in humans (64). These 
endocrine messengers act together to suppress FSH secretion, and in this way the 
dominant follicles hasten the demise of subordinates (65). 
In some cases, none of the preantral follicles that were initially recruited for growth 
by FSH become dominant, and all undergo atresia. In this case, another cohort of 
preantral follicles is recruited for growth, constituting a second “wave” of follicle growth. 
This process may repeat, with the recruitment of additional waves, until a dominant 
follicle arises. Evidence for waves of follicle growth came from transvaginal ultrasound 
data, which demonstrated that two thirds of women experience 2 waves per 
interovulatory interval (IOI) and one-third experience 3 waves per IOI (66). 
As growth of the dominant follicles continue, expression of LHR in mural GCs 
increases and estradiol production continues to rise. Once a threshold concentration of 
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serum estradiol is met, an acute release of LH is triggered from the anterior pituitary. 
This “LH surge” acts on the preovulatory follicle to trigger resumption of meiosis, 
cumulus expansion, ovulation and formation of the CL. The CL produces large quantities 
of estradiol, progesterone, and inhibin A, which all suppress FSH secretion (67). This is 
when the follicular phase ends, and the luteal phase, characterized by the dominating 
influence of CL, begins. It should be noted that basal levels of FSH continue to recruit 
cohorts of preantral follicles for growth during the luteal phase. However, until the 
influence of the CL is diminished, FSH levels do not reach levels sufficient for a 
dominant follicle to arise, and the likely outcome for these follicles is atresia. 
If pregnancy is not initiated, the CL undergoes a process known as luteolysis, 
which involves apoptosis of luteal cells, regression of the CL, and a corresponding 
decline in steroid and inhibin A production. As serum levels of these endocrine 
messengers decline, their suppressive effect on FSH production is relieved. As the CL 
regresses further and is reabsorbed into the ovary, rising FSH levels once again initiate 
growth of the next cohort of preantral follicles. Thus, the luteal phase gives way to the 
follicular phase, and the ovarian cycle begins again. 
On the other hand, if the ovulated oocyte is fertilized and pregnancy is initiated, the 
CL is rescued from luteolysis by chorionic gonadotropin (CG) produced in the placenta, 
and then maintained by other factors of placental origin (68). For the remainder of 
pregnancy, the CL continues to produce endocrine messengers that suppress FSH 
secretion. 
1.3 Eph receptors and Ephrins 
1.3.1 Overview 
The first Eph receptor was discovered and characterized during a human genomic 
library screen for novel receptor tyrosine kinases (RTKs). Probing for sequences 
homologous to the tyrosine kinase domain of v-fps, a viral oncogene, revealed a novel, 
highly-conserved gene that is highly expressed in the erythropoietin-producing human 
hepatocellular carcinoma cell line ETL-1. The novel gene was termed eph, after the cell 
type in which it was initially discovered (69). Since then, the family of identified Eph 
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receptors has expanded and now comprises the largest known family of receptor tyrosine 
kinases (RTKs) in vertebrates. In vertebrates, 16 receptors (encoded by Eph genes) and 9 
ephrin ligands (encoded by Efn genes) have been identified. These can be further 
classified into two classes each of receptor and ligand, designated A and B based on 
sequence similarity and receptor-ligand affinity. In general, Eph receptors and ephrins 
have higher binding affinity for partners of the same class, and bind within these classes 
promiscuously. 
Eph receptors and their ephrin ligands exhibit a number of features that distinguish 
them from other RTK families and their ligands. For example, all Eph receptors and 
ephrin ligands are associated with the cell membrane by either a transmembrane domain 
or a glycosylphosphatidylinositol (GPI) linkage. As such, Eph-ephrin signaling is 
initiated exclusively at points of cell-cell contact. 
Another unique aspect of Eph-ephrin signaling is that it is bidirectional, allowing 
signaling cascades to propagate into both receptor-bearing (forward signaling) and 
ligand-bearing (reverse signaling) cells. Forward signaling is mediated by Eph tyrosine 
kinase activity and adaptor proteins that enable crosstalk with downstream signaling 
pathways. Reverse signaling via B-class ephrins occurs in a similar manner, where the 
receptor-bound ligand can interact with intracellular signaling elements via adaptor 
proteins. Much less is known about reverse signaling via A-class ephrins, which are 
associated with the cell membrane but lack a transmembrane domain. It has been 
proposed that clustering of A-class ephrins into higher-order signaling clusters favours 
the recruitment of transmembrane proteins, which in turn interact with intracellular 
signaling elements. To date, several such partners have been identified (70-72) . 
Eph-ephrin signaling has been characterized primarily in the context of 
developmental processes and other functions in complex animals. However, it is likely 
that Eph-ephrin signaling played important roles in much more primitive organisms, as 
suggested by the identification of an Eph receptor in the sponge (73). This suggests that 
Eph receptors were present prior to the divergence of parazoans and eumetazoans (74), 
which is estimated to have occurred roughly 940 million years ago (75). Evidence from a 
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recent phylogenetic analysis of Eph receptors and ephrins indicates that ancient chordates 
had one A-class ephrin, one B-class ephrin, and one Eph receptor that was capable of 
binding both classes of ligand. Since then, duplication and diversification has likely 
resulted in the large families of Eph receptors and ephrins that are expressed in modern 
organisms (76). 
1.3.2 Ephrins 
Like Eph receptors, all ephrins are membrane-associated signaling elements and 
can be classified into two subtypes, A and B, based on sequence similarity. However, the 
inter-class structural differences are greater for ephrins than for Eph receptors. A-class 
ephrins consist of one extracellular receptor-binding domain (RBD) that contains a 
hydrophobic pocket, which serves as an acceptor site for a G-H loop present in the 
ligand-binding domain (LBD) of cognate Eph receptors. This RBD is linked to the 
plasma membrane via a glycosylphasphatidylinositol (GPI) linkage; A-class ephrins do 
not possess transmembrane or cytoplasmic domains (). The lack of a cytoplasmic domain 
means that cytoplasmic signaling partners could not be inferred based on known 
interacting motifs. However, a growing body of evidence indicates that A-class ephrins 
transmit downstream signals via cis interactions of A-class ephrins with partners that 
contain transmembrane domains. This occurs during the formation of signaling clusters, 
and such partners include NTRK2 (neurotrophic tyrosine kinase, receptor, type 2) (71), 
NGFR (nerve growth factor receptor) (70), and RET (ret proto-oncogene) (72). 
Like A-class ephrins, B-class ephrins also contain a RBD, which interacts with the 
LBD of cognate Eph receptors in a manner similar to that of A-class ephrins. However, in 
B-class ephrins the RBD is linked to a transmembrane helix, which is in turn linked to the 
cytoplasmic region of the ligand. The intracellular region contains several conserved 
tyrosine residues as well as a PDZ (postsynaptic density protein 95/disks large homolog 
4/zona occludens protein 1) domain. Upon activation and formation of signaling clusters, 
the ephrin-B PDZ domain is phosphorylated by SRC (v-src avian sarcoma (Schmidt-
Ruppin A-2) viral oncogene homolog) kinases. The phosphorylated PDZ domain 
recognizes and binds adaptor proteins that facilitate downstream signaling. Such adaptor 
proteins include RGS3 (regulator of G-protein signaling 3) (77) and NCK2 (NCK adaptor 
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protein 2) (78). Disruption of the ephrin-B PDZ domain in mice results in lymphatic 
defects (79) and defective formation of the corpus callosum (80). 
1.3.3 Eph receptors 
Like classic RTKs, Eph receptors have an ectodomain (a region that extends into 
the extracellular space), a transmembrane region spanning the cell membrane, and an 
intracellular region involved in propagation of downstream signals. The ectodomain 
contains residues that serve to interact with ephrin ligands as well as other Eph receptors. 
The LBD of the Eph receptor contains a hydrophobic pocket that interacts with a 
hydrophobic loop in the RBD of cognate ephrin ligands. This high-affinity interaction is 
believed to be the primary thermodynamic driver for complex formation (81). The 
cysteine-rich region is important for cis-interactions with other Eph receptors during the 
formation of higher-order signaling clusters (82). To date, no functions have been 
assigned to the two fibronectin type-III domains of the ectodomain. 
The membrane-spanning region consists of a transmembrane helix that links the 
ectodomain to the cytoplasmic region. The cytoplasmic region consists of a 
juxtamembrane domain (JM) proximal to the interior of the cell membrane, a kinase 
domain (KD), and two regions that bind downstream signaling proteins: a sterile-alpha 
motif (SAM) and a PDZ domain. In the inactive Eph receptor monomer, the JM occludes 
the KD, suppressing kinase activity. Activation of the Eph receptor by a cognate ligand 
favours recruitment of another receptor-ligand pair, forming a heterotetramer. 
Autophosphorylation of the JM results in phosphorylation at two conserved tyrosine 
residues, which in turn initiates a conformational change that disrupts the JM-KD 
interaction (83).  
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Figure 1-3: Ephrin and Eph receptor domains.  
Eph receptors and ephrins are classified into 2 subtypes, A and B, based on receptor-
ligand affinity and sequence similarity. Eph receptors of both A and B subtypes consist of 
a ligand-binding domain, a cysteine-rich domain, 2 fibronectin type III domains, a 
transmembrane helix, a juxtamembrane region, a kinase domain, a sterile-alpha motif 
(SAM), and a PDZ-binding domain. A-class ephrins consist of a receptor-binding domain 
associated with the cell membrane via a GPI-linkage. B-class ephrins consist of a 
receptor-binding domain, a transmembrane helix, an intracellular domain, and a PDZ-
binding domain. 
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1.3.4 Initiation of Eph-Ephrin Signaling 
All Eph receptors and ephrin ligands are membrane-associated, and as such, 
signaling is initiated from points of cell-cell contact. Initiation of signaling begins with 
the thermodynamically favourable insertion of the ephrin receptor-binding domain G-H 
loop into a hydrophobic pocket present in the ligand-binding domain of the cognate Eph 
receptor (84). The conformational flexibility of this hydrophobic pocket varies amongst 
different Eph receptors, which contributes to the promiscuity and variable affinities of 
Eph-ephrin pairs (85-88). 
These heterodimers then combine resulting in the formation of heterotetramers. 
Heterotetramer formation is facilitated by interactions between the LBDs of the Eph 
receptor from each heterodimer. Interactions at this interface are mostly polar, consisting 
of van der Waals contacts, hydrogen bonds, and ionic interactions (89). Heterotetramers 
also comprise the fundamental unit of ephrin signaling, due to the nature of RTK 
activation. The Eph receptor KD is autoinhibited by the receptor’s own activation loop. 
This loop obstructs the KD active site, preventing access to ATP and tyrosine substrates. 
Ligand-induced Eph receptor dimerization initiates autophosphorylation, and promotes 
phosphorylation of conserved tyrosine residues in the JM and activation loop of one Eph 
receptor by its partner (90). This results in relief of the autoinhibitory activation loop-KD 
interaction, allowing the KD to enter an “active” conformation and to access ATP and 
tyrosine substrates (91). 
Oligomerization of active heterotetramers into higher-order signaling clusters is 
facilitated by interactions in cis between the LBD and cysteine-rich domains of Eph 
receptors. Interactions at the LBD-cysteine-rich domain interface are also mostly polar, 
consisting of van der Waals contacts, hydrogen bonds, and ionic interactions (88). 
Continued recruitment of heterotetramers enlarges the heterooligomer, resulting in the 
formation of higher-order Eph-ephrin signaling clusters that also behave as adhesive 
contacts between cells. The size of these signaling clusters is not currently known, and is 
a subject of continued investigation (89). 
1.3.5 Eph-ephrin Signal Transduction 
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Transduction of Eph-ephrin signaling begins at points of cell-cell contact, and is 
notable for its bidirectionality, with signaling cascades propagating via receptors as well 
as ligands. Signal tranduction via Eph receptors is termed “forward signaling” while 
transduction via ephrins is termed “reverse signaling”. 
Forward signaling is mediated primarily by conserved tyrosine residues in the 
intracellular regions of the activated Eph receptor. Upon activation by ephrin ligands and 
formation of heterotetramers, autophosphorylation by the Eph kinase domain results in 
phosphorylation of these tyrosine residues. In addition to triggering conformational 
changes that enhance kinase domain activity, these residues also serve as docking sites 
for intracellular proteins that facilitate further signal propagation. These include Src 
family kinases, Abl family kinases, guanine-exchange factors, GTPase-activating 
proteins, as well as adaptor proteins that facilitate recruitment of additional kinases and 
GTPase-modulating proteins. Recruitment of these cytoplasmic signaling elements 
permits the activated Eph receptor to impinge on intracellular signaling pathways that 
control cytoskeletal remodeling, migration, adhesion, proliferation, and gene expression. 
For example, stimulation of EPHA2 in MDA-MB-231 breast cancer cells with 
recombinant ephrin-A1 results in recruitment of the adaptor proteins SHC (Src homology 
2 domain containing) and GRB2 (Growth factor receptor-bound protein 2), which enables 
phosphorylation of ERK (Extracellular regulated kinase) (92). In another example, 
stimulation of EPHA3-expressing human epithelial kidney 293T cells with recombinant 
ephrin-A5 promotes recruitment of the adaptor protein CRK (V-Crk Avian Sarcoma 
Virus CT10 Oncogene Homolog) and activation of the GTPase RHOA (Ras homolog 
family member A), which in turn induces membrane blebbing and retraction of cellular 
protrusions (93). These examples illustrate how Eph receptors can sense physical contact 
with another cell and trigger various cellular responses. Some are transient, such as 
cytoskeletal rearrangement, while others, such as ERK activation, may have lasting 
effects via phosphorylation of ERK substrate proteins that regulate gene expression. 
In addition to kinase domain-dependent signaling, some evidence supports kinase 
domain-independent signaling. These studies involved mice that express Eph receptors 
which lack cytoplasmic domains (94,95) or possess KD-inactivating mutations (96), but 
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are capable of rescuing the phenotype of the full-Eph receptor knockout. It has been 
proposed that in such cases, the extracellular Eph domains may potentiate signaling 
activity of other membrane-associated receptors (95), or that induction of reverse 
signaling via ephrins in adjacent cells was sufficient for phenotype rescue (94,96). 
Reverse signaling is less understood. Little is known about the mechanisms 
underlying signal transduction via A-class ephrins, which are associated with the cell 
membrane via a GPI-linkage. Since these ephrins lack transmembrane domains, it was 
proposed that the formation of large signaling clusters resulted in recruitment of 
transmembrane signaling proteins that facilitate signal transduction. This was confirmed 
with the discovery that the transmembrane protein NGFR (p75 neurotrophin receptor) co-
localizes and physically interacts with ephrin-A5 in mouse retinal axons. The same study 
found that retinal axons from mice lacking NGFR did not exhibit a response to EphA7, 
indicating that this transmembrane receptor is required for reverse signaling via ephrin-
A5 in mouse retinal axons (70). 
Signaling via B-class ephrins is better understood. In contrast to A-class ephrins, 
the B-class ephrin extracellular domain is associated with the cell membrane via a 
transmembrane helix, which is in turn linked to a cytoplasmic region that contains a PDZ 
domain. As is the case with Eph receptors, the intracellular domains of B-class ephrins 
contain conserved tyrosine residues that are phosphorylated by SRC kinases upon 
receptor binding. These residues serve as docking sites for adaptor proteins that facilitate 
downstream signaling. 
In addition to forward and reverse signaling, which are initiated by Eph receptors 
and cognate ephrins interacting in trans, Eph-ephrin interactions in cis have also been 
reported. It has been proposed that these interactions suppress activation of Eph receptors 
that are co-expressed with ephrins, resulting in silencing of forward signaling (97). 
Interaction of ephrin-B2 and EPHA3 in cis has also been reported in H226 and A549 
lung cancer cells, resulting in attenuation of EPHA3 activation. This suggests that Eph-
ephrin interactions in cis do not necessarily require a cognate ligand-receptor pair (98). 
1.3.6 Termination of Eph-ephrin Signaling 
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In many biological systems in which Eph-ephrin signaling has been studied, the 
main roles of Eph receptors and ephrins are to mediate adhesive and repulsive responses 
in order to control cell positioning. Eph-ephrin signaling clusters are adhesive structures 
that physically tether interacting cells, meaning that the initial interaction between cells 
bearing cognate Eph receptors and ephrins is adhesive in nature. Depending on the cell 
type, the outcome of this interaction may involve maintenance of adhesion or initiation of 
a repulsive response. This is especially relevant in biological processes such as axon 
guidance, tissue segmentation, and tissue remodeling, where repulsive responses are 
crucial in guiding cells to the correct position or maintaining boundaries between 
different populations of cells (99). In order for these repulsive responses to occur, the 
initial adhesive Eph-ephrin interaction must be terminated so that Eph-ephrin tethered 
cells can disengage and migration may proceed. So far, two disengagement mechanisms 
have been identified: proteolytic cleavage of Eph receptor or ephrin ectodomains, and 
endocytosis of the cell membrane region that contains the Eph-ephrin signaling cluster. 
The first reported mechanism of disengagement involved proteolytic cleavage of 
ephrin-A2 by the ADAM10 metalloprotease (100). Further studies revealed that 
ADAM10 is constitutively associated with EphA3, interacting with this Eph receptor via 
its LBD. Formation of the Eph-ephrin heterodimer positions the protease domain of 
ADAM10 such that cleavage of the ephrin-A2 ectodomain occurs in trans, which severs 
the Eph-ephrin tether between cells (101,102). More recently, proteolytic cleavage of Eph 
receptor ectodomains has also been reported. In contrast to cleavage of ephrins, which is 
mediated by ADAM-family metalloproteases, cleavage of Eph receptors is mediated by 
gamma-secretase (103,104). 
For B-class Eph-ephrin pairs, the current body of evidence suggests that the 
predominant mechanism for disengagement is endocytosis. ADAM13 has been reported 
to cleave the ephrin-B1 ectodomain in Xenopus embryos, although this may not be a 
general mechanism that is conserved across species (105). Disengagement via 
endocytosis has been reported for forebrain neurons expressing EphB2 and ephrin-B1, 
where immunofluorescence studies demonstrated that vesicles containing both receptor 
and ligand are transported into both cells (106). Another study published simultaneously 
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reported that adjacent Swiss 3T3 fibroblasts expressing EphB4 and ephrin-B2 exhibit 
endocytosis of vesicles containing both receptor and ligand into both cells. Small-
molecule blockade of the RAC1 (ras-related C3 botulinum toxin substrate 1) pathway 
prevented endocytosis and retraction, indicating that endocytosis is RAC1-dependent in 
this model (107). Neither of these studies investigated the fate of endocytosed signaling 
elements. However, it was later reported that activation of EphB1 in Chinese hamster 
ovary cells results in phosphorylation of CBL (Cbl proto-oncogene, E3 ubiquitin protein 
ligase) and ubiquitination of EphB1, suggesting subsequent proteasomal degradation of 
EphB1 (108). 
Thus, the mechanisms underlying termination of signaling for Eph-ephrin 
complexes is class-dependent. In general, A-class Eph-ephrin complexes are severed via 
cleavage of the ephrin ectodomain, while B-class Eph-ephrin complexes are endocytosed 
into adjacent cells and subsequently undergo ubiquitination and degradation. Future 
studies may identify additional mechanisms for termination of Eph-ephrin signaling. 
1.4 Rationale 
Since the first Eph receptor was identified in 1987, several reports have provided 
evidence that Eph-ephrin signaling occurs in the adult ovary. LacZ (beta-galactosidase) 
staining of ovarian sections from mice expressing an ephrin-B2-beta-galactosidase fusion 
protein revealed that ephrin-B2 is expressed by thecal cells of preovulatory ovarian 
follicles and blood vessels in the CL, suggesting that Eph-ephrin signaling is involved in 
ovarian angiogenesis (109). Subsequent RT-PCR studies detected transcripts for EPHB1, 
EPHB2, EPHB3, EPHB4, EPHB6, EFNB1, EFNB2, and EFNB3 in the human CL, 
suggesting that these Eph receptors and ephrins are involved in CL formation (110). 
Lastly, transcripts for Efna4, Efnb1, Efnb2, Epha2, Epha4, and Epha7 were detected in 
human GCs (111), suggesting a role for these Eph receptors and ephrins in the 
preovulatory follicle. 
These reports indicated that Eph receptors and ephrins are expressed in the ovarian 
follicle and the CL. However, the first evidence suggesting their involvement in follicle 
growth came from microarray data indicating that Efna5 expression is reduced in GCs 
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from eCG-treated Esr2-/- mice (112). These mice lack estrogen receptor beta (ERβ) and 
exhibit a severe reproductive phenotype, with females exhibiting impaired follicle growth 
and subfertility (113) due to impaired FSH-induced differentiation of GCs and an 
attenuated response to LH (114). Taken together, these reports indicate that Efna5 
expression is reduced in GCs of a mouse model that is subfertile and exhibits an impaired 
response to gonadotropins. Therefore, reduced expression of Efna5 in GCs may be 
involved in the reproductive phenotype of this mouse. 
Taken together, these reports suggest that Eph-ephrin signaling occurs in the ovary 
during follicle growth and formation of the CL. However, there have been no published 
investigations of Eph receptor and ephrin expression and/or function in a gonadotropin-
stimulated animal model of follicle growth and ovulation. Understanding how Eph-ephrin 
signaling is involved in these critical events will define a novel role for Eph receptors and 
ephrins in ovarian function, a system outside the current scope of ephrin biology. 
1.5 Hypothesis 
The work presented in this thesis aims to test the hypothesis that ephrin-A5 is required 
for gonadotropin-dependent follicle growth and ovulation, as well as optimal fertility. 
1.6 Objectives 
In order to test this hypothesis, I pursued the following objectives: 
1. Characterize expression of Efn and Eph genes in granulosa cells of an eCG-
stimulated mouse model and a granulosa cell line, and determine whether 
cultured GCs respond to stimulation with Eph receptors and ephrins. 
2. Perform a reproductive assessment of Efna5-/- female mice to determine 
whether absence of ephrin-A5 alters fertility. 
3. Characterize transcriptional regulation of Epha5 by FSH and downstream 
cAMP-dependent pathways. 
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2 Chapter 2: The ephrin signaling pathway regulates 
morphology and adhesion of mouse granulosa cells in vitro 
This chapter is based on a peer-reviewed journal article: 
Buensuceso AV, Deroo BJ. The ephrin signaling pathway regulates morphology and 
adhesion of mouse granulosa cells in vitro. Biol Reprod. 2013;88(1):25. 
2.1 Introduction 
The successful formation of a preovulatory follicle in response to follicle-
stimulating hormone (FSH) requires dramatic changes in the follicle, including an 
increase in follicle size and granulosa cell (GC) number, GC differentiation, and 
formation of an antrum. FSH also induces changes in GC morphology and adhesion that 
are essential for preovulatory follicle development both in vivo and in vitro (1). 
Interestingly, changes in GC morphology and adhesion can also be induced by proteins of 
the extracellular matrix (ECM) during preovulatory follicle formation (1). Alterations in 
GC morphology are largely attributed to modifications of the cytoskeleton resulting from 
signals from the ECM or adherens junctions, whereas GC adhesion and contact are 
primarily mediated by gap junctions, tight junctions, and adherens junctions (1). 
However, few other mechanisms regulating GC morphology and contact have been 
identified. Recently, the Eph-ephrin family of molecules, a family that consists of ephrin 
ligands and their Ephrin (Eph) receptors, has been shown to regulate both cellular shape 
and adhesion during development, cancer, and the normal function of many different 
tissues (2,3). Although members of the Eph-ephrin family have been identified in the 
ovary, Eph-ephrin signaling and the role it may play during folliculogenesis have not 
been well-characterized. 
Eph receptors comprise the largest known family of receptor tyrosine kinases 
(RTKs), with 16 Eph receptors (encoded by Eph genes) and 9 ephrin ligands (encoded by 
Efn genes) (Table 2-1) (2,4-6). Both Eph receptors and ligands are divided into either A-
class or B-class, based on receptor-ligand affinity and sequence similarity. Eph receptors 
and their ephrin ligands are membrane-associated; thus, signaling is initiated exclusively 
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from points of cell-to-cell contact upon binding of the ephrin ligand of one cell to the Eph 
receptor of an adjacent cell. Ephrin signaling is bidirectional, with signals propagating 
into both the receptor-bearing cells (forward signaling) and ligand-bearing cells (reverse 
signaling) (2). Eph receptors and ephrins were initially implicated in cell positioning and 
migration during development, particularly of the nervous system; however, ephrins have 
since been shown to regulate cell positioning, migration, adhesion, and differentiation 
during the development of many other tissues, including the retina (7), thyroid (8), 
vasculature (9), and mammary gland (10,11). Eph-ephrin signaling also regulates 
keratinocyte adhesion and differentiation (12) and hematopoietic stem cell adhesion (13). 
Compelling evidence also suggests that Eph-ephrin signaling plays several important 
roles in cancer development and progression (3). Expression of ephrin ligands and 
receptors is often reduced in advanced-stage tumors, and Eph-ephrin signaling regulates 
tumor growth, metastasis, and angiogenesis by altering cell proliferation, motility, 
invasion, and migration (3). Given that FSH induces changes in GC morphology and 
adhesion during formation of a preovulatory follicle, we speculated that FSH may 
regulate Eph-ephrin gene expression, and that Eph-ephrin signaling may regulate GC 
function. 
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Table 2-1: The Ephrin receptors and their ephrin ligand specificities. 
Ligands are listed in approximate order of decreasing affinity for each receptor. 
Table adapted from (4) and updated (i (5), ii (6), and iii (6)). 
 
 
Eph receptors Ligands 
EphA1 ephrin-A1 
EphA2 ephrin-A3, ephrin-A1, ephrin-A5, ephrin-A4, ephrin-A2 
EphA3 ephrin-A5, ephrin-A2, ephrin-A3, ephrin-A1, ephrin-A4, ephrin-B1 
EphA4 ephrin-A5, ephrin-A1, ephrin-A3, ephrin-A2, ephrin-B2, ephrin-B3, ephrin-A4 
EphA5 ephrin-A5, ephrin-A1, ephrin-A2, ephrin-A3, ephrin-A4 
EphA6 ephrin-A2, ephrin-A1, ephrin-A3, ephrin-A4, ephrin-A5 
EphA7 ephrin-A2, ephrin-A3, ephrin-A1, ephrin-A4, ephrin-A5 
EphA8 ephrin-A5, ephrin-A3, ephrin-A2 
EphB1 ephrin-B2, ephrin-B1, ephrin-A3 
EphB2 ephrin-B1, ephrin-B2, ephrin-B3, ephrin-A5i 
EphB3 ephrin-B1, ephrin-B2, ephrin-B3 
EphB4 ephrin-B2, ephrin-B1 
EphB6 ephrin-B2ii, ephrin-B3iii 
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To date, a limited number of reports have described Eph-ephrin gene expression in 
the mammalian ovary (14-16). Gale et al. (14) identified ephrin-B2 (EPHB2) in the 
endothelium of vessels surrounding and invading the theca interna of mouse preovulatory 
follicles and in the highly vascularized corpus luteum. Those authors suggested that 
EPHB2 regulates angiogenesis during the formation of preovulatory follicles and the 
corpus luteum. Egawa et al. (15) investigated the mRNA levels of all B-class ephrins in 
the human ovary during formation of the corpus luteum. They also demonstrated that 
EPHB1 localized to the theca interna and that EPHB2 bound to the surface of freshly 
isolated human GCs. Xu et al. (16) characterized the mRNA levels of ephrin A and B 
ligands and receptors in human GCs and detected expression of EPHA2, EPHA4, 
EPHA7, EFNA4, EFNB1, and EFNB2. This expression was unaffected by treatment of 
GCs with human chorionic gonadotropin (hCG) (16). Finally, expression of EPHA4 has 
been detected in bovine theca cells (17). 
None of these studies investigated whether FSH regulates the expression of Eph-
ephrin genes in the ovary, nor did they demonstrate a functional or behavioral effect of 
Eph-ephrin signaling on follicular cells, such as changes in cell shape and adhesion. 
Therefore, given that changes in cell shape and contact occur during GC differentiation 
both in vitro and in vivo in response to FSH signaling, and given that a subset of ephrins 
has been identified in GCs, we hypothesized that Eph-ephrin signaling may be a novel 
mechanism by which GC shape and adhesion are regulated and that expression of ephrin 
family members may be regulated by gonadotropins. 
To determine if FSH regulates Eph-ephrin gene expression in mouse GCs, we 
examined the expression of the entire family of Eph-ephrin genes after FSH treatment of 
primary mouse GCs and an immortalized, FSH-responsive rat GC line (GFSHR-17) (18). 
Using these models and recombinant ephrin ligands and receptors, we also investigated 
the functional effects of Eph-ephrin signaling on GC morphology and adhesion and 
identified beta-catenin as a potential downstream target of EFNA5 signaling in GCs. 
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2.2 Materials and Methods 
2.2.1 Cell Culture 
The GFSHR-17 cell line is an immortalized, gonadotropin-responsive rat GC line 
(18) that we obtained from Dr. Abraham Amsterdam (Weizmann Institute of Science). 
GFSHR-17 cells were maintained in Dulbecco modified Eagle medium/F12 
(DMEM/F12; Wisent, Inc.) containing 5% fetal bovine serum (FBS; Wisent, Inc.) at 
37°C in 5% CO2 before use in experiments. 
2.2.2 Mice and Treatments 
Experiments were performed in compliance with the guidelines set by the Canadian 
Council for Animal Care and the policies and procedures approved by The University of 
Western Ontario Council on Animal Care. Investigations were conducted in accordance 
with the National Research Council's Guide for Care and Use of Laboratory Animals. 
C57BL/6 female mice (Postnatal Day [PND] 23–28) were used in all experiments. For 
quantitative RT-PCR (qRT-PCR) studies, mice were treated either with saline or with 
3.25 or 5.0 IU of equine chorionic gonadotropin (eCG; Sigma Chemical Co.) for 48 h 
before isolation of GCs. For immunofluorescence studies, immature females were treated 
with either saline for 48 h, 5.0 IU of eCG for 48 h, or 5.0 IU of eCG for 48 h followed by 
5.0 IU of hCG for 24 h (Sigma). 
2.2.3 Isolation of GCs 
Ovaries were removed and immediately transferred to a 100-mm cell-culture dish 
containing 15 mL of ice-cold M199 medium supplemented with 1 mg/mL of bovine 
serum albumin (BSA), 2.5 μg/mL of amphotericin B, and 50 μg/mL of gentamicin (all 
reagents from Invitrogen). Ovaries were pooled, and the GCs from each pool were then 
expressed by manual puncture with 25-gauge needles followed by pressure applied with a 
sterile spatula. Follicular debris was removed manually, and the GC suspension was 
filtered through a 150-μm Nitex nylon membrane (Sefar America, Inc.) mounted in a 
Swinnex filter (Millipore). The GCs were then pelleted by centrifugation at 250 × g for 5 
min at 4°C followed by two washes in DMEM/F12 medium containing 1% 
penicillin/streptomycin solution (15070-063; Invitrogen). The final cell pellet was frozen 
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at −80°C for qRT-PCR studies or cultured in DMEM/F12 supplemented with 10% FBS 
for GC spreading and adhesion studies. For qRT-PCR studies, human recombinant FSH 
was obtained from Dr. A.F. Parlow (National Hormone and Peptide Program, National 
Institute of Diabetes and Digestive and Kidney Diseases). Forskolin was purchased from 
Sigma Chemical Co. 
2.2.4 RNA Isolation and qRT-PCR 
Frozen pellets of GCs were solubilized in TRIzol (Invitrogen), and RNA was 
isolated according to the manufacturer's protocol. RNA was further treated with DNase I, 
then reverse-transcribed using Superscript II (Invitrogen). Complementary DNA (cDNA) 
levels were detected using qRT-PCR with the ABI PRISM 7900 Sequence Detection 
System (Applied Biosystems) and SYBR Green I dye (Applied Biosystems). Primers 
were generated using Primer Express Software (Version 2.0; Applied Biosystems) (). 
Fold-changes in gene expression were determined by quantitation of cDNA from target 
(treated) samples relative to a calibrator sample (vehicle). The gene for ribosomal protein 
L7 (Rpl7) was used as the endogenous control for normalization of initial RNA levels. 
Expression ratios were calculated according to the mathematical model described by 
Pfaffl (19), where ratio = (Etarget)ΔCt(target)/(Econtrol)ΔCt(control) and E = efficiency of the 
primer set, calculated from the slope of a standard curve of log(ng of cDNA) versus cycle 
threshold (Ct) for a sample that contains the target according to the formula E = 10−(1/slope) 
and ΔCt = Ct(vehicle) − Ct(treated sample). Three independent experiments were carried out, and 
the results were averaged for statistical analysis by a one-way ANOVA followed by a 
Tukey multiple comparison post-hoc test (Figure 2-1) or by a two-tailed unpaired 
Student t-test (Figure 2-2). 
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Table 2-2: Primer sequences used for quantitative RT-PCR. 
Gene  Forward Primer Reverse Primer 
 
MOUSE 
Rpl7 
Epha1 
Epha2 
Epha3 
  
 
5’ – AGCTGGCCTTTGTCATCAGAA – 3’ 
5’ – CCTGGAGGGAATCTGAGCTATG – 3’ 
5’ – CCAGGAAGGCTACGAGAAGG – 3’ 
5’ – CCGCAGTCAGCATCACAACT – 3’ 
 
 
5’ – GACGAAGGAGCTGCAGAACCT – 3’ 
5’ – CCTGGGTTCCAACACCATCT – 3’ 
5’ – TCAGATGCCTCAGACTTGAAG – 3’ 
5’ – TTTCTGGAAGTCCGATCTTTCTTAA – 3’ 
Epha4 
Epha5 
 5’ – GACAACGATGCAGCCTCCAT – 3’ 
5’ – GCTGGTTCCCATTGGGAAAT – 3’ 
5’ – TCTCGTTGACATTAGAAATCAA – 3’ 
5’ – CACATTGGTGACTGGAGAAGGA – 3’ 
Epha6 
Epha7 
Epha8 
Ephb1 
Ephb2 
Ephb3 
Ephb4 
Ephb6 
Efna1 
Efna2 
Efna3 
Efna4 
Efna5 
Efnb1 
Efnb2 
Efnb3 
 
 
 5’ – CTCCCAAGCCATTCACAGCTAT – 3’ 
5’ – TCTTCGCTGCTGTTAGCATCA – 3’ 
5’ – CTCGGATGAAGAGAAGATGCATT – 3’ 
5’ – CAAGATGTGTTTCCAGACTCTGACA – 3’ 
5’ – ACCTCAGTTCGCCTCTGTGAA – 3’ 
5’ – AGCGGGTTACGGACAGTATAGC – 3’ 
5’ – GATCCTCACGGAATTCATGGA – 3’ 
5’ – GGCAGCAGCCATCAATGTC – 3’ 
5’ –AGTGCTTGAAGCTGAAGGTGA– 3’ 
5’ – TTTTCCCTGGGCTTTGAGTTC – 3’ 
5’ – TGCCGGCCAAGAATACTACTACA – 3’ 
5’ – GGCCGGTGCCTGAGACT – 3’ 
5’ – TCTGCAATCCCAGACAACGGAAGA – 3’ 
5’ – TCGCACCCGCACTATGAA – 3’ 
5’ – CAGACAAGAGCCATGAAGATCCT – 3’ 
5’ – CAGAGGCATGAAGGTGCTTCT – 3’ 
 
 
5’ – GCCCAGTCCTTTCTCATCATACC – 3’ 
5’ – GCAGTACTCGCTCCTTCATGACT – 3’ 
5’ – TGGTTCAAGGGCAAGAAGACA – 3’ 
5’ – TGCCGAGCCAGCAATCA – 3’ 
5’ – GGCTCACCTGGTGCATGAT – 3’ 
5’ – AGCTGCTGGGCACCTGAA – 3’ 
5’ – ACTGTGAACTGCCCGTCGTT – 3’ 
5’ – GGCTCACCTGGTGCATCAC – 3’ 
5’ –TCTTCTCCTGTGGGTTGACAT– 3’ 
5’ – GGGTCGGTCCACGAGGTT – 3’ 
5’ – ACCTTCATCCTCAGACACTTCCA – 3’ 
5’ – CCCGGACGTACCGCTTT – 3’ 
5’ – TCATGTACGGTGTCATCTGCTGGT – 3’ 
5’ – TCAACTGCTCGGGTGTCACA – 3’ 
5’ – GACCGTGATTCCTGGCTGAT – 3’ 
5’ – GCATTTCAGACACAGGTTTTCG – 3’ 
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RAT 
Rpl7 
Epha5 
Efna5 
 
5’ – CGCTGCGCCAGGAACCCTTA – 3’ 
5’ – TCCTTGCTCACACAAACTATACCT – 3’ 
5’ – TGGAAGAAGATCCTGCCTAAAGC – 3’ 
 
5’ – GCCTTTCGCAGTGTCTTCAGGGC – 3’ 
5’ – TACATTTACAGACACATACTGCCG – 3’ 
5’ – CGATCACGAACACCTATAGTTTTCA – 3’ 
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2.2.5 Immunofluorescence 
Dissected ovaries were immediately embedded in Cryomatrix (Fisher Scientific, 
Inc.) and frozen using liquid nitrogen. Tissues were cut into sections (section thickness, 6 
μm), mounted onto slides (Fisher), and stored at −20°C until use. Sections were fixed 
with 4% formaldehyde for 10 min, rinsed three times with PBS, then permeabilized with 
0.1% Triton X-100 for 15 min. Sections were again rinsed three times with PBS, blocked 
for 30 min with blocking solution (5% BSA in 0.1% Triton X-100), then rinsed three 
times with blocking solution. The tissue was then incubated for 1 h with primary 
antibody specific to each target—namely, rabbit anti-EFNA5 (1:50; sc-20722; Santa Cruz 
Biotechnology, Inc.), rabbit anti-EPHA5 (1:50; ab5397-100; Abcam), and rabbit anti-
pan-cadherin (1:100; ab6529; Abcam). Sections were then rinsed three times in blocking 
solution and incubated in secondary antibody (fluorescein isothiocyanate-conjugated goat 
anti-rabbit secondary antibody, 1:250; F9887; Sigma). The tissue was then rinsed twice in 
PBS followed by a 5 min incubation in 4′,6-diamidino-2-phenylindole (1:1000; Sigma), 
and slides were mounted with VECTASHIELD (Vector Laboratories). Slides were stored 
at 4°C and visualized the following day with an AX70 Provis upright microscope 
(Olympus). Images were captured using Image-Pro 6.2 software (Media Cybernetics). 
2.2.6 Cell Spreading and Adhesion Assays 
Cell spreading and adhesion assays were based on similar assays used by others 
(20-23) to study the effects of Eph-ephrin interactions on cell rounding, spreading, and 
adhesion. In these assays, recombinant ephrin ligand or Eph receptor protein is spotted 
onto tissue-culture plastic, after which cells are seeded onto the plates and allowed to 
attach. Rounding or adhesion is then quantified within the spotted area. In the present 
experiments, both primary mouse GCs and GFSHR-17 cells were used. 
In these assays, recombinant human EFNA5/human Fc (immunoglobulin [Ig] G) 
chimera (374-EA; R&D Systems), rat EPHA5/human Fc chimera (541-A5; R&D 
Systems), or human Fc (IgG; 009-000-008; Jackson ImmunoResearch) was used. (Eph-
ephrin recombinant proteins are commercially available only as Fc-fusion proteins, which 
42 
 
interact with the preclustering antibodies.) Each of these recombinant proteins was first 
preclustered before application to tissue-culture surfaces by combining Fc with F(ab′)2 
fragment rabbit anti-human IgG antibody (Fcγ fragment specific; 309-006-008; Jackson 
ImmunoResearch) at a 5:1 molar ratio followed by gentle agitation at room temperature 
for 2 h. Preclustering of recombinant Eph receptor and ephrin fusion proteins is necessary 
to activate either the ephrin ligands or the Eph receptors, because this mimics the 
membrane Eph receptor or ephrin ligand clustering that occurs in vivo upon activation 
(24-26). Serial dilutions in PBS were then prepared as follows: EFNA5/Fc at 74, 37, 
18.5, and 9.25 μg/mL for the cell rounding/spreading assay and EPHA5/Fc at 83, 42, 21, 
and 10 μg/mL for the cell adhesion assay. These concentrations were chosen based on 
those used by Yin et al. (23) in similar experiments and resulted in equimolar amounts of 
EFNA5 and EPHA5 in each dilution. Droplets (3.5 μl) of preclustered Fc or EFNA5/Fc 
or EPHA5/Fc were placed onto a 60-mm tissue-culture dish (Sarstedt) and incubated at 
37°C for 1.5 h to allow the protein to adsorb to the tissue-culture surface. For both assays, 
serial dilutions of the Fc (IgG) fragment were also spotted to correspond to each 
concentration of EFNA5/Fc or EPHA5/Fc to control for differences in the number of 
micrograms of protein spotted at each concentration; however, only the highest Fc 
concentration is reported as the control in Figure 2-4, Figure 2-5, Figure 2-6, and 
Figure 2-7 because no differences in either cell shape (see Figure 2-4 and Figure 2-5) or 
cell adhesion (Figure 2-6 and Figure 2-7) were observed between the different Fc (IgG) 
dilutions. Droplets were outlined using fine permanent marker on the underside of the 
dish to distinguish between treated and untreated areas, and the dish was rinsed twice 
with 4 mL of ice-cold PBS to remove nonadsorbed EFNA5/Fc or EPHA5/Fc. The dish 
was then seeded with 1.4 million cells in a 4-mL volume of DMEM/F12 containing 10% 
FBS. Cells were incubated at 37°C with 5% CO2 for 2 h to allow the cells to adhere and 
spread. (The minimum time required to observe maximal cell spreading [i.e., 2 h] had 
been previously determined experimentally). Cells were then rinsed twice with PBS to 
remove media and nonadhered cells and fixed in 4% paraformaldehyde in PBS for 10 
min at room temperature. 
Quantitation of the effects of recombinant EFNA5/Fc on cell spreading. One 100× 
image (1020 × 768 μm) was taken from the center of each spotted region using an IX70 
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microscope attached to an DP71 camera (both from Olympus). All cells within one 100× 
field were visually scored as being “spread” (characterized by the presence of 
lamellipodia) or “round” (characterized by round morphology and complete absence of 
lamellipodia). The fraction of spread cells was determined by dividing the number of 
spread cells in each image of the EFNA5/Fc surface by the number of spread cells in the 
image from the control Fc (IgG) surface. Three independent experiments were carried 
out, and the results (Figure 2-4 and Figure 2-5) were analyzed for statistical significance 
by a one-way ANOVA followed by a Tukey multiple comparison post-hoc test. 
Quantitation was based, as described, on an image taken from the center of the spotted 
region (Figure 2-6A, asterisk). 
Quantitation of the effects of recombinant EPHA5/Fc on cell adhesion.The total 
number of cells within one 100× field image obtained from the EPHA5/Fc surface was 
divided by the number of cells on the control Fc (IgG) surface, resulting in a value of one 
for the Fc-coated plates and fractions of one for the EPHA5/Fc surfaces. Note that the 
exact images in Figure 2-6 were not used for quantitation; they are presented to show the 
dramatic difference in adhesion between EPHA5-coated and noncoated regions. Three 
independent experiments were carried out, and the results (see Figure 2-6 and Figure 
2-7) were analyzed for statistical significance by a one-way ANOVA followed by a 
Tukey multiple comparison post-hoc test. 
2.2.7 Human Phospho-Kinase Array 
To screen for potential downstream targets of EFNA5-induced signaling in GCs, 
such as the phosphorylation of kinases and their protein substrates, we used the Human 
Phospho-Kinase Array Kit (ARY003B; R&D Systems), which simultaneously detects the 
relative site-specific phosphorylation of 46 phosphorylated proteins or their targets 
(Supplemental Table 6-1). GFSHR-17 cells were seeded onto tissue-culture surfaces 
coated with EFNA5/Fc or Fc alone, and lysates were harvested at 15 and 20 min after 
seeding. We chose 15- and 20-min time points based on a search of the literature, which 
indicated that many of the signaling elements captured by the array exhibit maximum 
phosphorylation within 15 min of stimulation. These lysates were applied to the Human 
Phospho-Kinase Arrays, which were then developed according to the manufacturer's 
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instructions. Spot intensities were also quantified using ImageJ software (National 
Institutes of Health, http://rsb.info.nih.gov/ij/) according to the manufacturer's directions. 
2.2.8 Immunoblot Analysis: Beta-Catenin 
The EFNA5/Fc or Fc (IgG) were preclustered before application to tissue-culture 
surfaces by combining with F(ab′)2 fragment rabbit anti-human IgG antibody (Fcγ 
fragment specific) at a 5:1 molar ratio followed by gentle agitation at room temperature 
for 2 h. The preclustered recombinant protein was then used to coat 60-mm tissue-culture 
dishes and incubated at 37°C for 1.5 h, then rinsed twice with 4 mL of ice-cold PBS. The 
dish was then seeded with 2.1 million GFSHR-17 cells in a 4-mL volume of DMEM/F12 
containing 5% FBS. Cells were incubated at 37°C with 5% CO2 for 15 and 20 min. At 
each time point, lysates were generated by placing the dishes on ice, gently rinsing the 
cells twice with ice-cold PBS, and scraping the cells in 100 μl of ice-cold RIPA buffer 
(50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, and 0.1% SDS) supplemented with a protease inhibitor cocktail (1:100; 
P8340; Sigma) and a phosphatase inhibitor cocktail (1:100; P2850; Sigma). Lysates were 
then transferred to a 1.5-mL microcentrifuge tube, incubated on ice for 20 min with mild 
agitation, and then centrifuged at 15 000 × g for 20 min at 4°C. The supernatant was 
boiled in Laemmli buffer for 5 min and then analyzed using SDS-PAGE. The separated 
proteins were transferred to a polyvinylidene fluoride membrane at 100 V (constant 
voltage) for 2 h at 4°C. After blocking for 1 h in Tris-buffered saline and Tween 20 
(TBST)/5% nonfat milk, the membrane was probed with rabbit IgG specific to beta-
catenin (1:1000 in TBST/5% nonfat milk; D10A8; Cell Signaling). The membrane was 
then probed with horseradish peroxidase-conjugated donkey IgG against rabbit IgG 
(1:10 000 in TBST/5% nonfat milk) and visualized using ECL Plus (Amersham 
Biosciences) and Hyperfilm (Amersham). To assess equal protein loading, the membrane 
was subsequently probed using a rabbit monoclonal IgG against histone deacetylase 4 
(HDAC4, sc-11418; Santa Cruz Biotechnology, Inc.). Densitometric analysis of 
immunoblot data (ImageLab 4.1; Bio-Rad) was then carried out to quantitate the ratio of 
beta-catenin:HDAC4. 
45 
 
2.3 Results 
2.3.1 Identification of FSH-Regulated Ephrin Ligands and Eph Receptors in Mouse 
GCs 
To determine if FSH regulates Eph-ephrin expression in GCs of immature PND 
23–28 female mice, we initially screened the mRNA levels of all known mouse ephrin 
(Efn) and Eph receptor (Eph) genes in GCs isolated from immature female mice treated 
for 48 h with either saline or 5.0 IU of eCG (Supplemental Figure 6-1 and 
Supplemental Figure 6-2). Eph-ephrin gene expression was determined by qRT-PCR. 
Based on this screening, we chose a subset of Efn and Eph genes that appeared to be 
regulated by eCG to further verify and to investigate the possibility of a dose-dependent 
response to eCG. To do this, we purified mRNA from GCs isolated from immature 
female mice treated for 48 h with either saline, 3.25 IU of eCG, or 5.0 IU of eCG. Eph-
ephrin gene expression was again determined by qRT-PCR. We verified that the mRNA 
levels of one Efn gene and three Eph genes were significantly increased by eCG (Figure 
2-1). At 3.25 IU of eCG, significant increases in the ephrin ligand Efna5 and the Eph 
receptors Epha5 and Epha3 (Figure 2-1, A, B, and D) were observed. At 5.0 IU of eCG, 
significant increases in Efna5, Epha5, Ephb2, and Epha3 (Figure 2-1, A–D) were 
observed, along with an apparent increase in Epha8, though the effect was not significant 
(P = 0.08 by Student t-test). To demonstrate that these eCG-dependent increases in Efna5, 
Epha5, Ephb2, and Epha3 were specific to this subset of Eph-ephrin family members—
that is, that eCG did not affect the expression of all Eph-ephrin family members—we also 
examined the mRNA levels of the ligand Efna1 and the Eph receptor Epha2 (Figure 
2-1F) in response to eCG. Efna1 mRNA levels did not increase in response to 5.0 IU of 
eCG; in fact, a significant decrease was observed (P < 0.01). In addition, expression of 
Epha2 was not significantly changed in response to eCG treatment (Figure 2-1F). These 
results indicate that FSH increases the expression of a subset of ephrin ligands and Eph 
receptors in GCs of immature mice. 
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Figure 2-1: Expression of a subset of ephrin ligands and Eph receptors is stimulated 
by FSH in mouse GCs. 
Wild-type PND 23–28 C57Bl/6 mice were treated with saline or eCG (3.25 or 5.0 
IU/mouse) for 48 h. GCs were isolated by ovarian puncture and pooled, and then mRNA 
was isolated. The mRNA levels of Efna5 (A), Epha5 (B), Ephb2 (C), Epha3 (D), and 
Epha8 (E) as determined by qRT-PCR were compared to an Rpl7 control. Efna1 and 
Epha2 were similarly analyzed (F) to indicate that not all Eph-ephrin ligand and receptor 
mRNA levels are increased by eCG. Data represent the gene expression compared with 
the Rpl7 control and are presented as the average ± SEM of three independent 
experiments. Differences in average mRNA levels between vehicle treatment and 3.25 or 
5.0 IU of eCG were analyzed by a one-way ANOVA followed by a Tukey multiple 
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comparison post-hoc test (Tukey test). A) Efna5. A statistically significant difference was 
found between the three treatments as determined by one-way ANOVA (F2,6 = 18, P = 
0.003). Tukey test revealed that statistically significant differences between vehicle and 
3.25 IU of eCG (a: P < 0.05), between vehicle and 5.0 IU of eCG (a: P < 0.05), and 
between 3.25 and 5.0 IU of eCG (a: P < 0.05). B) Epha5. A statistically significant 
difference was found between the three treatments as determined by one-way ANOVA 
(F2,6 = 14, P = 0.006). Tukey test revealed statistically significant differences between 
vehicle and 3.25 IU of eCG (a: P < 0.05), between vehicle and 5.0 IU of eCG (a: P < 
0.05), but not between 3.25 and 5.0 IU of eCG. C) Ephb2. No statistically significant 
difference was found between the three treatments as determined by one-way ANOVA, 
but comparison of means between vehicle and 3.25 or 5.0 IU of eCG by a two-tailed 
unpaired Student t-test revealed a statistically significant difference between vehicle and 
5.0 IU of eCG (b: P < 0.02). D) Epha3. A statistically significant difference was found 
between the three treatments as determined by one-way ANOVA (F2,6 = 14, P = 0.005). 
Tukey test revealed statistically significant differences between vehicle and 3.25 IU of 
eCG (P < 0.05), between vehicle and 5.0 IU of eCG (P < 0.05), but not between 3.25 and 
5.0 IU of eCG. E) Epha8. No statistically significant difference was found between the 
three treatments as determined by one-way ANOVA. F) Efna1 and Epha2. Not all Eph-
ephrin ligand and receptor mRNA levels are increased by eCG. Data represent the gene 
expression compared with the Rpl7 control and are presented as the average ± SEM of 
three independent experiments. Differences in average mRNA levels between vehicle 
treatment and 5.0 IU of eCG were analyzed by a two-tailed unpaired Student t-test (d: P 
< 0.01). 
  
49 
 
2.3.2 FSH and cAMP Regulate Efna5 and Epha5 Expression in a Rat GC Line 
To determine if FSH increased the expression of Efna5, Epha3, Epha5, Epha8, and 
Ephb2 in a species other than mouse, we treated GFSHR-17 cells (an immortalized, FSH-
responsive cell line derived from primary rat GCs (18)) with human recombinant FSH 
(50 ng/mL) for 24 or 48 h and determined mRNA levels by qRT-PCR (Figure 2-2). Of 
the five Eph-ephrin family members increased by eCG in primary GCs (Figure 2-1), we 
found that expression of two of these genes, Efna5 and Epha5, increased in response to 
FSH in GFSHR-17 cells (Figure 2-2, A and B). Indeed, Efna5 mRNA levels were 
increased after 24 and 48 h of FSH treatment (Figure 2-2A), whereas Epha5 mRNA 
levels (Figure 2-2B) increased only after 24 h of FSH treatment. Because FSH regulates 
many of its target genes in GCs via the cAMP-dependent protein kinase A (PKA) 
pathway (27), we next wanted to determine if forskolin, a direct activator of adenylate 
cyclase, would increase Efna5 and Epha5 mRNA levels in GFSHR-17 cells. Again, 
Efna5 mRNA levels were increased after 24 and 48 h of forskolin treatment (Figure 
2-2C), whereas Epha5 mRNA levels (Figure 2-2D) increased only after 24 h of forskolin 
treatment. We also investigated whether any of the other eCG-responsive Eph-ephrin 
family members identified in Figure 2-1 responded to forskolin in GFSHR-17 cells, but 
only Efna5 and Epha5 mRNA levels were affected. These results indicate that Efna5 and 
Epha5 are increased by FSH in both mouse and rat GCs and that this increase is 
mediated, at least in part, through a cAMP-dependent pathway. Because Efna5 and 
Epha5 were the two Eph-ephrin family members from our screen that were both 
expressed in both mouse and rat GCs and were regulated by FSH and cAMP in both 
model systems, we chose to further investigate the localization and function of these 
genes during the rest of the present study. 
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Figure 2-2: FSH and forskolin increase Efna5 and Epha5 mRNA levels in the 
immortalized rat GC line GFSHR-17. 
GFSHR-17 cells were treated for 24 and 48 h with recombinant FSH (50 ng/mL; A and 
B) or forskolin (fsk; 10 μM; C and D), and mRNA levels of Efna5 and Epha5 were 
determined by qRT-PCR and compared to an Rpl7 control. Data are presented as the 
mean ± SEM of three independent experiments. Differences in average mRNA levels 
between vehicle treatment (veh) and fsk or FSH were analyzed by a two-tailed unpaired 
Student t-test (a: P < 0.01; b: P < 0.05). 
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2.3.3 Localization of EFNA5 and EPHA5 in the Mouse Ovary 
Quantitative RT-PCR experiments indicated that Efna5 and Epha5 mRNA was 
present within mouse primary GCs. Therefore, we wanted to investigate EFNA5 and 
EPHA5 protein localization within the whole mouse ovary using immunofluorescence 
(Figure 2-3). To investigate EFNA5 and EPHA5 localization in follicles of various sizes 
and in the corpus luteum, immature mice were exposed to one of the following three 
treatments: saline for 48 h, 5.0 IU of eCG for 48 h, or 5.0 IU of eCG for 48 h followed by 
5.0 IU of hCG for 24 h. 
EFNA5 (Figure 2-3, A, C, E, G, and I) localized to the periphery (Figure 2-3, G 
and I) of GCs in a punctate pattern (Figure 2-3I) in follicles ranging in size from primary 
to preovulatory. Small preantral follicles generally expressed less EFNA5 (Figure 2-3A, 
arrowhead) than larger preantral or antral follicles. In both preantral and antral follicles, 
we frequently observed that EFNA5 immunoreactivity was higher in mural GCs than in 
cumulus cells (Figure 2-3, A and G), and this difference often appeared as a gradient, 
with EFNA5 density being highest near the basement membrane and lowest near the 
antrum (Figure 2-3G, arrow). Interestingly, EFNA5 immunoreactivity was lower in 
corpora lutea (Figure 2-3E) than in preantral and antral follicles. Weak EFNA5 staining 
was also observed in the theca and interstitial cells (Figure 2-3C). 
Localization of EPHA5 was similar to that of EFNA5, with immunoreactivity 
localized to the periphery of GCs in follicles ranging in size from primary to preovulatory 
(Figure 2-3 B, D, F, H, and I), again with weaker staining in smaller follicles (Figure 
2-3B, arrowhead). However, staining appeared to be uniform around the GC periphery, 
without the punctate appearance that characterized EFNA5 (compare Figure 2-3, I vs. J). 
Finally, EPHA5 immunoreactivity appeared to be weaker in corpora lutea than in 
preantral or antral follicles (Figure 2-3F). Weak EPHA5 staining was also observed in 
the theca and interstitial cells (Figure 2-3D). 
To verify that EFNA5 and EPHA5 localized to the GC membrane, we stained 
ovarian sections with a pan-cadherin antibody (Figure 2-3, K and L) to detect the 
transmembrane cadherin proteins that form adherens junctions between GCs. We 
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observed similar localization of both EFNA5 and EPHA5 and pan-cadherin (compare 
Figure 2-3, A and B vs. K, and G and H vs. L), indicating that both EFNA5 and EPHA5 
are membrane-localized in GCs. 
Note that for each primary antibody, no signal was observed in sections stained 
with secondary antibody alone, indicating the signal we observed was not due to 
nonspecific binding of the secondary antibody (data not shown). 
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Figure 2-3: Localization of EFNA5 and EPHA5 in the mouse ovary. 
Immature mice were treated either with saline for 48 h (A and B), eCG for 48 h (C, D, G, 
H, K, L, M, N, O, and P), or eCG for 48 h followed by hCG for 24 h (E and F). Ovaries 
were isolated and frozen, and EFNA5 and EPHA5 localization was determined by 
immunofluorescence with anti-EFNA5 and anti-EPHA5 antibodies. A pan-cadherin 
antibody was also used to detect membrane localization within the ovary (I and J). 
EFNA5 was found in the periphery of GCs of small primary to large antral follicles (A, 
C, E, G, and I) and often took on a punctate appearance (arrowhead in I). Expression was 
lower in small preantral follicles (arrowhead in A) than in larger preantral or antral 
follicles. EFNA5 expression was reduced in corpora lutea (E). We observed similar 
localization of both EFNA5 (A and B) and pan-cadherin (K and L). Weak EFNA5 
staining was also observed in the theca and interstitial cells (see, e.g., A and C). No 
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EFNA5 signal was observed in sections stained with secondary antibody alone, indicating 
the EFNA5 signal observed was not due to nonspecific binding of the secondary antibody 
(FITC: M and O) and (FITC + DAPI merge: N and P). EPHA5 was localized to the 
periphery of GCs in follicles from primary to preovulatory (B, D, F, H, and J), with 
weaker staining in small follicles (arrowhead in B). EPHA5 expression was weaker in 
corpora lutea than in larger preantral or preovulatory follicles (F). Weak EPHA5 staining 
was also observed in the theca and interstitial cells. EFNA5 and EPHA5 
immunoreactivity was stronger in mural GCs than in cumulus cells of antral follicles 
(arrowhead in D and G). We observed similar localization of both EPHA5 (B and H) and 
pan-cadherin (K and L). No EPHA5 signal was observed in sections stained with 
secondary antibody alone (M, N, O, P), indicating the EPHA5 signal observed was not 
due to nonspecific binding of the secondary antibody. Original magnification ×100 (A, B, 
M, and N), ×200 (C–H and L, O, and P), and ×400 (I and J). 
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2.3.4 Inhibition of GC Spreading by EFNA5/Fc 
Although ephrins have been previously identified in the ovary, no functional role 
for ephrins in GCs has been shown. Therefore, we investigated what roles Eph-ephrin 
signaling may play in GC morphology or function. Because Eph-ephrin signaling inhibits 
spreading and causes cell rounding in vitro in other cell types (20,28), and because FSH 
induces GC rounding in both cultured primary cells (1) and GFSHR-17 cells (18), we 
investigated the effect of EFNA5 on GC morphology using both GFSHR-17 and primary 
mouse GCs. To do this, we used a cell spreading assay used previously by others (20-23) 
to study the effects of Eph-ephrin interactions on cell rounding, spreading, and adhesion 
in other cell types. Specifically, we seeded GFSHR-17 cells onto tissue-culture surfaces 
spotted with serial dilutions of a recombinant human EFNA5/Fc chimera (74, 37, 18.5, 
and 9.25 μg/mL) or onto surfaces spotted with Fc alone as a negative control (Figure 2-4, 
A and B). GFSHR-17 cells plated onto the EFNA5/Fc surface were notably rounder and 
less spread (having fewer lamellipodia) than those on the Fc-coated surface (Figure 2-4, 
A and B). To quantitate the extent of cell spreading, we visually scored each cell as 
exhibiting either a rounded or a spread morphology (see Materials and Methods for 
details). We then calculated the ratio of rounded (nonspread) cells to the total number of 
cells scored (Figure 2-4A, bar graph). Spreading was significantly inhibited on 
EFNA5/Fc-coated surfaces but not on Fc-coated surfaces. The number of rounded cells 
increased approximately 3-fold on the 74 and 37 μg/mL of EFNA5/Fc-coated surfaces 
compared to Fc alone (Figure 2-4A, bar graph). To determine if this EFNA5-induced cell 
rounding could be observed in primary GCs, we conducted an identical experiment with 
primary GCs isolated from untreated immature mice. Again, EFNA5/Fc significantly 
inhibited cell spreading and increased cell rounding, although to a lesser extent than 
GFSHR-17 cells (Figure 2-5A, bar graph; compare to Figure 2-5A to Figure 2-4A). At 
an EFNA5/Fc concentration of 74 μg/mL, the number of rounded primary GCs was 
approximately 2-fold higher than when plated onto Fc alone (Figure 2-5). Thus, EFNA5 
reduces cell spreading of both a rat GC line and primary mouse GCs. 
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2.3.5 Inhibition of GC-Substrate Adhesion by EPHA5 
Given that GCs express both ephrin ligands and Eph receptors, and given that Eph-
ephrin signaling regulates cellular adhesion (29), we wanted to determine the effect of 
EPHA5 signaling on GFSHR-17 and primary mouse GC adhesion (Figure 2-6 and 
Figure 2-7). The coating/spotting technique in this experiment was similar to that used 
for the EFNA5/Fc cell spreading experiments (Figure 2-4 and Figure 2-5), with serial 
dilutions of EPHA5/Fc (83, 42, 21, and 10 μg/mL). GFSHR-17 cells were seeded onto 
tissue-culture surfaces spotted with dilutions of EPHA5/Fc or Fc alone. We noticed a 
dramatic and significant reduction in cells adhering to the EPHA5/Fc-coated surface 
compared to those coated with Fc alone (Figure 2-6A) that occurred in an EPHA5/Fc 
dose-dependent manner (Figure 2-6B). We quantified the extent of this reduced adhesion 
by counting the number of cells in the center of the EPHA5/Fc-coated surface (Figure 
2-6B) and comparing this to the total number of adherent cells on the Fc-coated surface 
(EPHA5-Fc:Fc ratio). As the coating density of EPHA5/Fc was reduced, the number of 
cells adhering to the coated surface increased (Figure 2-6B). We were then curious to 
know if EPHA5 would also inhibit adhesion of primary mouse GCs. Using a similar 
procedure, primary mouse GCs were plated onto EPHA5/Fc-coated surfaces, and the 
number of adherent cells was again counted (Figure 2-7). As observed for the GFSHR-
17 cell line, cell adhesion was significantly reduced by approximately 70% at the highest 
concentration of EPHA5/Fc (83 μg/mL), resulting in an inverse relationship between cell 
adhesion and EPHA5/Fc concentration (Figure 2-7B). These results suggest that EPHA5, 
acting through ephrin ligands present on GC membranes, can alter the adhesive 
properties of both mouse and rat GCs. 
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Figure 2-4: EFNA5 inhibits spreading and induces rounding of immortalized rat 
GCs. 
GFSHR-17 cells were seeded onto tissue-culture plates that had been previously spotted 
with serial dilutions of a recombinant human EFNA5/Fc chimera or the Fc fragment 
alone (top left) as a negative control. GFSHR-17 cells displayed significantly less 
spreading and a more rounded morphology when plated onto EFNA5/Fc-coated surfaces 
compared to Fc-coated surfaces, as determined by the absence of lamellipodia (A: 9.25–
74 μg/mL; B: 74 μg/mL only). The fraction of rounded cells was quantified by dividing 
the number of rounded cells by the total number of cells in the field of vision at ×100 (see 
Materials and Methods for further quantification details). Three independent experiments 
were conducted, and the difference in the ratio of rounded cells to total cells between Fc-
alone and each concentration of EFNA5/Fc was plotted (A; bar graph shows average ± 
SEM). Differences in the average ratio of rounded cells to total cells were analyzed for all 
conditions by a one-way ANOVA followed by a Tukey test. A statistically significant 
difference was found between the five conditions as determined by one-way ANOVA 
(F4,5 = 64, P = 0.0002). Tukey test revealed numerous statistically significant (P < 0.05) 
differences between many of the conditions. The following comparisons were statistically 
significant (P < 0.05) but are not shown on the bar graph for clarity: Fc versus 74 μg/mL, 
Fc versus 37 μg/mL, Fc versus 18.5 μg/mL, 74 μg/mL versus 18.5 μg/mL, 74 μg/mL 
versus 9.25 μg/mL, 37 μg/mL versus 18.5 μg/mL, and 37 μg/mL versus 9.25 μg/mL. 
Original magnification ×100 (A) and ×200 (B). 
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Figure 2-5: EFNA5 inhibits spreading and increases rounding of primary mouse 
GCs. 
GCs isolated from the ovaries of immature mice were seeded onto tissue-culture plates 
that had been previously spotted with serial dilutions of a recombinant human EFNA5/Fc 
chimera or the Fc fragment alone (top left) as a negative control. Primary mouse GCs 
displayed significantly less spreading and a more rounded morphology when plated onto 
EFNA5/Fc-coated surfaces compared to Fc-coated surfaces, as determined by the 
absence of lamellipodia (A: 9.25–74 μg/mL; B: 74 μg/mL only). The fraction of rounded 
cells was quantified by dividing the number of rounded cells by the total number of cells 
counted in the field of vision at ×100 (see Materials and Methods for further 
quantification details). Three independent experiments were conducted, and the 
difference in the ratio of rounded cells to total cells between Fc-alone and each 
concentration of EFNA5/Fc was plotted (A; bar graph shows average ± SEM). 
Differences in the average ratio of rounded cells to total cells were analyzed for all 
conditions by a one-way ANOVA followed by a Tukey post-test. A statistically 
significant difference was found between the five conditions as determined by one-way 
ANOVA (F4,10 = 6, P = 0.01). Tukey post-test revealed several statistically significant (P 
< 0.05) differences between many of the conditions. The following comparisons were 
statistically significant (P < 0.05) but are not shown on the bar graph for clarity: Fc 
versus 74 μg/mL, 74 μg/mL versus 18.5 μg/mL, and 74 μg/mL versus 9.25 μg/mL. 
Original magnification ×100 (A) and ×200 (B). 
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Figure 2-6: EPHA5 receptor inhibits adhesion of immortalized rat GCs to cell 
culture surfaces. 
A) GFSHR-17 cells were plated onto tissue-culture plates previously spotted with serial 
dilutions of a recombinant rat EPHA5/human Fc chimera or the Fc fragment alone (top 
left) as a negative control. The spotted region is marked by an asterisk and outlined by a 
dotted line; the uncoated region outside the spotted area is marked by a circle. B) The 
total number of cells within a single ×100 field image obtained from the EPHA5/Fc 
surface was divided by the number of cells on the control Fc (IgG) surface, resulting in a 
value of one for the Fc-coated plates, and fractions of one for the EPHA5/Fc surfaces. 
Three independent experiments were carried out, with the results presented as the average 
± SEM for statistical analysis by a one-way ANOVA followed by a Tukey test. A 
statistically significant difference was found between the five conditions as determined 
by one-way ANOVA (F4,10 = 13, P = 0.0005). Tukey test revealed numerous statistically 
significant (P < 0.05) differences between many of the conditions. The following 
comparisons were statistically significant (P < 0.05) but are not shown on the bar graph 
for clarity: Fc versus 83 μg/mL, Fc versus 42 μg/mL, 83 μg/mL versus 10 μg/mL, and 42 
μg/mL versus 10 μg/mL. 
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Figure 2-7: EPHA5 inhibits substrate adhesion of mouse primary GCs. 
A) Primary GCs were plated onto tissue-culture plates previously spotted with serial 
dilutions of a recombinant rat EPHA5/human Fc chimera. Mouse primary GCs adhered 
less to EPHA5/Fc-coated surfaces than Fc-coated surfaces. The total number of cells 
attached to the EPHA5/Fc surface was divided by the number of cells on the control Fc 
surface, resulting in a value of one for the Fc-coated plates and fractions of one for the 
EPHA5/Fc surfaces. B) Three independent experiments were carried out, with the results 
presented as the average ± SEM for statistical analysis by a one-way ANOVA followed 
by a Tukey test. A statistically significant difference was found between the five 
conditions as determined by one-way ANOVA (F4,10 = 20, P < 0.0001). Tukey test 
revealed numerous statistically significant (P < 0.05) differences between many of the 
conditions. The following comparisons were statistically significant (P < 0.05) but are 
not shown on the bar graph for clarity: Fc versus 83 μg/mL, Fc versus 42 μg/mL, Fc 
versus 21 μg/mL, 83 μg/mL versus 21 μg/mL, 83 μg/mL versus 10 μg/mL, and 42 μg/mL 
versus 10 μg/mL. 
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2.3.6 Beta-Catenin Is a Downstream Target of EFNA5-Induced Signaling in GCs 
To screen for potential intracellular targets of EFNA5-induced forward signaling in 
GCs, we used the Human Phospho-Kinase Array Kit, which simultaneously detects the 
relative site-specific phosphorylation of 46 phosphorylated proteins and/or their targets. 
GFSHR-17 cells were seeded onto tissue-culture surfaces coated with EFNA5/Fc (37 
μg/mL) or Fc alone, and lysates were harvested at 15 and 20 min after seeding. These 
lysates were applied to the arrays, and the blots were processed and the spot intensities 
quantified according to the manufacturer's directions (Supplemental Figure 6-3, 
Supplemental Table 6-2, and Supplemental Table 6-3). Only two proteins, beta-catenin 
and phospho-STAT5, were observed at both 15- and 20-min time points at different 
levels when comparing the blots for Fc (IgG) alone versus EFNA5/Fc. Beta-catenin 
protein levels were reduced to 0.16 and 0.51 of control values at 15 and 20 min, 
respectively. Similarly, phospho-STAT5 protein levels were reduced to 0.30 and 0.58 of 
control values at 15 and 20 min, respectively. 
We decided to focus on the observation of reduced beta-catenin levels after 
exposure to EFNA5 based on beta-catenin's known association with adherens junctions 
and the actin cytoskeleton (30), which would be relevant to the changes in cell 
morphology that we observe when GFSHR-17 cells are exposed to EFNA5. Therefore, 
we verified the reduced beta-catenin levels observed in the array by immunoblot analysis 
to detect beta-catenin under the same culture conditions used in the array. This analysis 
revealed that GFSHR-17 cells seeded onto EFNA5/Fc contained lower beta-catenin 
protein levels at 20 min after seeding (Figure 2-8) than cells seeded onto Fc alone, 
confirming the reduction observed using the Human Phospho-Kinase Array. No 
differences were observed between EFNA5/Fc and Fc at 15 min after seeding. These 
results suggest that beta-catenin may be a downstream target of EFNA5 signaling. 
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Figure 2-8: Beta-catenin protein levels in GFSHR-17 cells are reduced in response to 
EFNA5. 
A) GFSHR-17 cells were seeded onto 60-mm tissue-culture dishes coated with 
preclustered ephrinA5-Fc or Fc (37 μg/mL). Lysates were collected 15 min (lanes 1 and 
2) and 20 min (lanes 3 and 4) after seeding. Lysate from non-treated HeLa cells (lane 5) 
was used as a positive control for the beta-catenin antibody. Fifty micrograms of each 
lysate were separated by SDS-PAGE, and beta-catenin protein levels were assessed by 
immunoblot analysis. To assess equal protein loading, the membrane was subsequently 
probed using a rabbit monoclonal IgG against HDAC4. B) Densitometric analysis of 
immunoblot data (ImageLab 4.1) showing the ratio of beta-catenin to HDAC4. 
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2.4 Discussion 
In the present study, we have shown that FSH increases the expression of a subset 
of ephrin ligands and Eph receptors in primary mouse and immortalized rat (GFSHR-17) 
GCs and that exposure of GCs to EFNA5 and EPHA5 alters GC morphology and 
adhesion, respectively. These results suggest that Eph-ephrin signaling may play a role in 
the changes in GC contact and organization that occur within the follicle during 
folliculogenesis. 
2.4.1 Eph-Ephrin Gene Expression Is Regulated by FSH via the cAMP/PKA Pathway in 
GCs 
We have observed that eCG increases the expression of Efna5 and several of its 
receptors (Epha3, Epha5, Epha8, and Ephb2) in mouse GCs. Interestingly, all Eph 
receptors that we observed to be increased in response to eCG bind preferentially to 
EFNA5 (4) (Table 2-1 and Figure 2-1), the sole ligand increased in response to FSH in 
our mouse GC model. This coordinate increase of an ephrin and several of its cognate 
receptors suggests an attractive model in which the expression of an ephrin ligand and its 
receptors are coordinately increased during the response to FSH, resulting in increased 
Eph-ephrin signaling that contributes to the formation of the developing follicle. 
Coordinated increases in Eph receptors and ephrin ligands have been previously observed 
in mouse skin cells under conditions of hypoxia (31). In theory, this coordinated 
regulation by FSH would increase Eph-ephrin signaling when cell movement occurs, 
such as during antrum formation. 
We found that treating rat GCs with FSH and forskolin resulted in increased 
expression of Efna5 and Epha5, suggesting that these genes are activated via the 
cAMP/PKA pathway (27), as are many FSH target genes. Why only Efna5 and Epha5, 
but not Ephb2, Epha3, and Epha8, expression increased in response to FSH in GFSHR-
17 cells is likely due to differences in species (mouse vs. rat) and in primary GCs 
compared to an immortalized GC line. To date, little is known about what signaling 
molecules regulate the expression of ephrin ligand and Eph receptor genes, and to our 
knowledge, this is the first demonstration that cAMP regulates Eph-ephrin family 
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members in GCs. Our data indicate that in GCs, cAMP increases Eph and Efn expression, 
suggesting that cAMP may similarly regulate Eph and Efn expression in other model 
systems. 
 
2.4.2 EFNA5 and EPHA5 Localization During Folliculogenesis 
In general, both EFNA5 and EPHA5 were more highly expressed in larger follicles, 
such as preantral follicles with many layers of GCs or antral follicles, than in smaller 
ones, such as primary follicles with one or two layers of GCs (Figure 2-3). This suggests 
that expression of EFNA5 and EPHA5 may be driven, at least in part, by FSH. Although 
primordial and primary follicle development is commonly accepted to be independent of 
FSH, recent evidence indicates that in immature mice (the model in the present study), 
primordial follicles respond to FSH (32), suggesting that FSH may regulate GC 
differentiation and development in small preantral follicles as well, because the FSH 
receptor is expressed in mouse primary follicles (33). Thus, FSH may be one factor 
increasing the expression of EFNA5 and EPHA5 in both small preantral and larger antral 
follicles, which would be consistent with our data that Efna5 and Epha5 mRNA levels 
increase in GCs of mice treated with eCG (Figure 2-1) and in GFSHR-17 cells treated 
with FSH. In addition, the punctate pattern of staining that we observe for EFNA5 
(Figure 2-3, G and I) has also been observed for other ephrins, notably EFNA3 in glial 
cells of the hippocampus (34). 
An interesting observation was that EFNA5 and EPHA5 immunoreactivity was 
stronger in mural GCs than in cumulus cells of antral follicles (Figure 2-3G), with a 
gradient of staining between the two. A similar graded pattern of expression has been 
reported for mRNA of the luteinizing hormone receptor (Lhcgr); cytochrome P450, 
family 11, subfamily A, polypeptide 1 (Cyp11a1); and Cd34 mRNA and is hypothesized 
to result from an oocyte-stimulated MAD homolog 2/3 (Smad2/3) signaling gradient that 
is strongest in cumulus GCs (35). A mural-to-antral gradient of expression has also been 
reported for connective tissue growth factor (Ctgf) mRNA in rat follicles (36). Therefore, 
we hypothesize that EFNA5 and EPHA5 expression may also be regulated by an oocyte-
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derived factor, such as bone morphogenetic protein 15 (BMP15) or growth differentiation 
factor 9 (GDF9) (35). Although little is known about what factors regulate EFNA5 or 
EPHA5 expression, evidence indicates that EFNA5 expression is regulated by anti-
Müllerian hormone (AMH) and glial cell-derived neurotrophic factor (GDNF) (37), both 
of which affect the transition from primordial to primary follicles. 
Based on our immunofluorescence data, we cannot identify whether individual 
mouse GCs express EFNA5 alone, EPHA5 alone, or EFNA5 and EPHA5 simultaneously. 
Whereas activation of an Eph receptor on one cell by an ephrin ligand on a nearby cell is 
the most commonly reported interaction, overlapping coexpression of cognate Eph 
receptor-ligand pairs within the same cell has been frequently observed. For example, 
EFNA5 and EPHA5 are coexpressed in pancreatic beta-cells (38), and EFNA5 and 
EFNA4 are coexpressed in motor neurons of embryonic chick spinal cord (39). 
Therefore, it is possible that GCs express both EFNA5 and EPHA5 and, therefore, that 
neighboring GCs could activate each other through forward signaling, reverse signaling, 
or both. 
 
2.4.3 EFNA5 Inhibits Spreading and Increases Rounding of GCs 
Our observation that exposure of primary GCs and rat GFSHR-17 cells to EFNA5 
induces cell rounding is consistent with the ability of EFNA5 to induce cell rounding in a 
number of other model systems. This cell rounding, often referred to as reduced cell 
spreading, has been associated with both increased and decreased cell migration, 
depending on the cell type. For example, spreading of rat primary vascular smooth 
muscle cells is inhibited on tissue-culture surfaces coated with EFNA1, resulting in a 
rounded cell morphology (20). Similarly, addition of EFNA5 to cell-culture medium 
induces rounding of both immortalized human melanoma cells and EPHA3-expressing 
293T cells (28), which correlates with reduced adhesion. Those authors suggest this 
reduced adhesion would lead to increased cell motility. Similarly, Foo et al. (40) show 
that smooth muscle cells lacking EPHB2 are defective in spreading and show increased 
motility (40). On the other hand, many reports suggest that reduced spreading (cell 
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rounding) leads to reduced migration, such as the EPHA1-induced rounding and reduced 
migration observed in Human Embryonic Kidney 293 (HEK293) cells stably transfected 
with EPHA1 (41). Thus, in the ovary, changes in GC shape and spreading may regulate 
migration during folliculogenesis. 
In addition to changes in cell shape, “[e]xtensive and intricate changes in the 
physical arrangement of cells” (p. 6 (42)) occur within a developing follicle during 
folliculogenesis, and for these rearrangements to occur, GCs must migrate within the 
follicle. Several stages occur during folliculogenesis when GCs (both mural and cumulus) 
are thought to migrate within the follicle. GCs migrate to surround the oocyte during the 
formation of primordial follicles (to form multiple GC layers during proliferation and 
formation of preantral follicles) and also during the formation of the antrum, which 
requires a significant creation of space within the follicle. Both older and more recent 
studies of cultured follicles indicate that on a two-dimensional surface in the absence of 
FSH, GCs disperse and migrate across tissue-culture plastic away from the oocyte but 
reorganize to form an antrum when exposed to FSH (43). Three-dimensional culture in 
hydrogels minimizes the extent of GC migration, yet GC outgrowth still occurs, allowing 
antrum formation (43). In either model, GC movement clearly is critical to the formation 
of the antrum. Treatment with hCG enhances cumulus cell migration as determined by in 
vitro migration assays (44). Finally, during formation of the corpus luteum, luteinizing 
GCs migrate toward the center of the luteinizing follicle (45) and can be shown to 
migrate using in vitro migration assays (46). Numerous studies have shown that Eph-
ephrin signaling simultaneously induces cell rounding, reduces cell spreading, and 
enhances cell migration and motility of a number of diverse cell types (22,28,41,47,48). 
Therefore, the GC rounding we observe in response to EPHA5 could potentially regulate 
GC migration in vivo. 
2.4.4 EPHA5 Inhibits Adhesion of GCs 
Granulosa cell movement and differentiation during folliculogenesis are thought to 
require changes in cell-cell adhesion and cellular junctions during this time (49). Not 
surprisingly, the type of junctions connecting GCs within the follicle change in both 
number and type during follicle growth (50). Four types of cell-cell junctions have been 
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identified in the ovary of various species: adherens junctions, gap junctions, desmosomes, 
and tight junctions (50-52), with adherens and gap junctions being the best characterized. 
In smaller follicles, gap junctions exist, but adherens junctions and desmosomes 
predominate (50,53). As the follicle grows under the influence of FSH and other factors, 
the number of gap junctions increases, whereas the number of desmosomes and adherens 
junctions decreases (50,53). Gap junction number and size increase dramatically to their 
maximum frequency in the preovulatory follicle (1), concomitant with a decrease in 
adherens junctions, and it is believed that this change leads to reduced cell-cell adhesion, 
allowing the formation of the antrum (54). 
In the present study, we observe that primary GCs resist binding when reverse 
signaling (i.e., signaling into the cell containing the ephrin ligand) is activated through 
the Eph receptor coated onto tissue-culture surfaces. This suggests that reverse signaling 
through an EPHA5-compatible ephrin ligand on the GC surface results in reduced 
adhesion and repulsion. Several recent reports support a role for ephrin ligand-mediated 
reverse signaling in reducing cell adhesion. In mice lacking EFNA5, midline fusion 
occurs in the developing neural tube (55), and those authors propose that this fusion 
results from loss of Eph-ephrin reverse signaling that would normally promote cell 
repulsion. In that same study, “an inverse correlation” (p. 203 (55)) was observed 
“between Efna5 gene dosage and [cell] adhesion” (p. 203 (55)), and cells from Efna5-null 
mice displayed decreased adhesion compared to wild-type cells. In another study, ephrin-
A-expressing retinal neurons avoid EPHA7-Fc surfaces during axonal outgrowth, 
suggesting that reverse signaling via A-class ephrin ligands promotes repulsion and/or 
reduced adhesion (56). We speculate that in vivo, this reverse signaling through EFNA5 
on GCs could lead to reduced cell-cell contact during, for example, formation of the 
antrum, when reduced cell-cell adhesion is required for GC migration. This would be 
similar to the role that Eph-ephrin signaling plays in the repulsive guidance of migrating 
neurons (29). 
Interestingly, Eph-ephrin signaling has been shown to cross-talk with adherens 
junctions, tight junctions, and gap junctions in other model systems (2). In various 
tissues, gap junctions are critical for Eph-ephrin function in processes as diverse as cell 
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sorting, insulin secretion, and osteogenic differentiation (38,57,58). Thus, cross-talk 
between these junctions and Eph-ephrin signaling may also be occurring in GCs. 
Although several published reports have described Eph receptor and ephrin 
expression in the mouse and human ovaries, none of these demonstrated an effect of 
ephrin signaling on GC characteristics or function. Gale et al. (14) found that EFNB2 is 
expressed in the neovasculature of corpora lutea and the theca cell layer of preluteinized 
follicles. Egawa et al. (15) showed that EFNB1 is expressed in luteal cells of the human 
corpus luteum. These reports suggest roles for ephrin ligands in the vascularization of the 
theca and corpora lutea as well as in luteal cells. Xu et al. (16) demonstrated that EPHA2, 
EPHA4, EPHA7, EFNA4, EFNB1, and EFNB2 mRNA are present in cultured human 
luteinized GCs. In line with the findings of Xu et al., we detected expression of several 
Eph receptors and ephrins in mouse GCs. 
2.4.5 EFNA5 Reduces Beta-Catenin Protein Levels in GCs 
We observed a reduction in beta-catenin protein levels in GFSHR-17 cells seeded 
onto EFNA5/Fc concomitant with rounding/reduced spreading. Beta-catenin has two 
primary functions in cells. First, in conjunction with alpha-catenin and E-cadherin, it 
forms a link between adherens junctions and the actin cytoskeleton. Second, it serves as a 
transcription factor in conjunction with proteins of the T-cell factor (TCF)/lymphoid 
enhancer-binding factor (LEF) family of transcription factors in the nucleus (59,60). In 
the cytoplasm, beta-catenin undergoes constant turnover, with phosphorylation, 
ubiquitination, and then proteasomal degradation (61). We speculate that activation of 
Eph receptors cognate to EFNA5 in GFSHR-17 cells may regulate adherens junction 
assembly and/or degradation or lead to transcriptional effects through interactions of 
beta-catenin with TCF/LEF family members. In the context of the growing follicle, beta-
catenin degradation may affect remodeling of adherens junctions, leading to changes in 
the cytoskeleton, which occur during changes in cell shape (62). In turn, changes in cell 
shape have been associated with changes in cell migration (28,40,41). Reduced levels of 
beta-catenin may also influence expression of TCF/LEF target genes in GCs that may 
influence cellular morphology. Further experiments will be required to fully delineate the 
relationship between EFNA5 and beta-catenin. 
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In summary, we have shown that EFNA5 and EPHA5 are expressed in mouse GCs, 
that forward signaling induced by EFNA5 regulates GC morphology by inhibiting cell 
spreading, and that reverse signaling induced by EPHA5 inhibits cell adhesion. The 
expression of EPHA5 and EPHA5 in follicles of various sizes suggests that they may 
play multiple roles during different stages of folliculogenesis. We speculate that further 
studies will indicate that these and other members of the Eph-ephrin signaling system 
play important roles in the development of healthy preovulatory follicles and corpora 
lutea throughout folliculogenesis. 
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3 Chapter 3: Ephrin-A5 is required for optimal fertility and a 
complete ovulatory response to gonadotropins in the mouse 
This chapter is based on a manuscript submitted to Endocrinology: 
Buensuceso AV, Son A, Paquet M, Withers BM, Zhou R, and Deroo BJ. (2015) Ephrin-
A5 is required for optimal fertility and a complete ovulatory response to gonadotropins in 
the female mouse. Manuscript ID# EN-15-1216. 
3.1 Introduction 
Folliculogenesis is a dynamic and carefully-timed process during which a 
primordial follicle develops into a fully mature preovulatory follicle capable of expelling 
a fertilizable oocyte. This process requires a tremendous amount of cell proliferation, 
migration, directional cell growth, extracellular (ECM) synthesis, and changes in cell 
adhesion and morphology. These dramatic changes are not surprising given that the 
diameter of a human preovulatory follicle is approximately 600 times larger than a 
primordial follicle (1). Although changes in cell morphology and migration during 
folliculogenesis are critical to the production of a healthy preovulatory follicle, the 
factors regulating these two processes are not well understood. 
The Eph-ephrin family of molecules consists of ephrin ligands and their cognate 
tyrosine kinase receptors, Eph receptors. Eph-ephrin family members regulate both 
cellular shape and adhesion during development, cancer, and the normal function of 
many different tissues (2). Since Eph receptors and ephrins are membrane-associated, 
signaling is initiated exclusively from points of cell-to-cell contact. Eph-ephrin signaling 
is bidirectional, with signal transduction occurring in both receptor-bearing cells (forward 
signaling) and in ligand-bearing cells (reverse signaling). Eph receptors and ephrin 
ligands are both classified into two types, designated A or B, based on receptor-ligand 
specificity. Receptors and ligands of the same class bind preferentially. In forward 
signaling, ligand-bound Eph receptors interact with signaling elements via adapter 
proteins, and may also phosphorylate targets directly. Reverse signaling via B-class 
ephrins occurs in a similar manner, where the receptor-bound ligand can interact with 
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intracellular signaling elements via adapter proteins. As well-established regulators of 
cell positioning, ephrins and Eph receptors are likely candidates for involvement in 
follicle growth and ovulation. Although members of the Eph-ephrin family have been 
identified in the ovary, Eph-ephrin signaling and the role it may play during 
folliculogenesis have not been well-characterized.  
We previously reported that FSH increases the expression of a subset of ephrin 
ligands and Eph receptors in primary mouse and immortalized rat granulosa cells (GCs), 
and that exposure of GCs to the ligand ephrin-A5 (EFNA5) and its receptor EPHA5 alters 
GC morphology and adhesion, respectively (3). Expression of ephrins and Eph receptors 
has also been described in mouse (4), human (5,6), and bovine ovaries (7). Furthermore, 
in bovine ovaries Efna5 expression is higher in large antral follicles, ie. with a mean 
diameter five times higher than small follicles (8). These studies suggest that Eph-ephrin 
signaling may be required for normal folliculogenesis. 
To test the hypothesis that Eph-ephrin signaling regulates folliculogenesis, we 
characterized the reproductive capacity and characteristics of female mice lacking ephrin-
A5. Previous studies of these mice revealed axon guidance defects (9) and disrupted 
organization of lens cells in the eye (10-12), but have not been previously characterized 
with respect to reproductive function. We report compromised fertility in adult Efna5-
null (Efna5-/-) females, indicating a novel role for Eph-ephrin signaling in female 
reproductive function. 
3.2 Materials and Methods 
3.2.1 Mice and treatments 
All mouse experiments described in this study were conducted in accordance with 
the accepted standards of humane animal care, as outlined in the journal’s Ethical 
Guidelines. Experiments were performed in compliance with the guidelines set by the 
Canadian Council for Animal Care, and the policies and procedures approved by the 
University of Western Ontario Council on Animal Care (Protocol Number: 2007-042). 
The generation of Efna5-null (Efna5-/-) mice has been described previously (9). Immature 
Efna5-/- female mice and their wildtype (WT) littermates were generated by breeding 
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heterozygous (Efna5+/-) males with heterozygous (Efna5+/-) females. All females were 
weaned at post-natal day (PND) 21 and genotyped as previously described (9). 
For studies examining ovulation capacity, serum steroid levels, ovarian gene 
expression, and histology, mice were treated with: a) 100 µL saline, b) 5.0 IU equine 
chorionic gonadotropin (eCG) (Sigma Chemical Co., St. Louis, MO) for 48 hours, or c) 
5.0 IU equine chorionic gonadotropin (eCG) for 48 hours followed by 5.0 IU human 
chorionic gonadotropin (hCG) (Sigma). Whole ovaries were harvested 4, 14, or 24 hours 
post-hCG treatment. 
3.2.2 Continuous breeding study 
PND 60 Efna5+/+ and Efna5-/- females were paired with PND 60 Efna5+/+ males for 
6 months. Cages were checked twice weekly for pregnant females, daily thereafter for 
newborn pups, and the dates of birth and number of pups were recorded. After 6 months, 
the average litter size and the average number of days between litters was calculated for 
each female. 
3.2.3 Assessment of ovulatory potential in response to gonadotropin treatment 
Reproductively immature female mice were subjected to a standard superovulation 
protocol and counted the number of ovulated oocytes. PND 21 Efna5+/+ and Efna5-/- 
females were injected subcutaneously (sc) with 5 IU eCG, followed 48 h later by 5 IU 
hCG. Oviducts were harvested 14 h post-hCG and placed in a 25 µL drop of saline on a 
60 mm tissue culture dish. After harvest was completed, oviducts were transferred to a 25 
µL droplet of M2 medium containing hyaluronidase. Oviducts were then ruptured using a 
0.5 inch 30-gauge needle, releasing the ovulated cumulus-oocyte-complexes (COCs) into 
the surrounding medium. Presence of hyaluronidase resulted in dissociation of oocytes 
and associated granulosa cells, yielding easily discernible individual oocytes. Upon 
dissociation, oocytes were counted using a dissecting microscope and a click-counter. 
3.2.4 Assessment of serum steroid levels 
To determine serum 17β-estradiol (estradiol) levels, PND 21-22 females were 
injected sc with 5 IU eCG alone or 5 IU eCG followed by 5.0 IU hCG 48 h later. Blood 
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was collected from the vena cava 48 h post-eCG for estradiol quantitation and 14 or 24 h 
post-hCG for progesterone quantitation. Serum was analyzed by the University of 
Virginia Center for Research in Reproduction Ligand Assay and Analysis Core 
(Charlottesville, VA) for estradiol (ELISA) and progesterone (RIA) concentrations. 
3.2.5 RNA isolation and quantitative RT-PCR 
Frozen whole ovaries were homogenized in Trizol (Invitrogen, Carlsbad, CA) and 
RNA was isolated according to the manufacturer's protocol. RNA was further treated 
with DNaseI, then reverse-transcribed using Superscript II (Life Technologies, Carlsbad, 
CA). Complementary DNA (cDNA) levels were detected using quantitative RT-PCR 
with the ViiA™ 7 Real-Time PCR System (Life Technologies) and SYBR Green I dye or 
Taqman Gene Expression Analysis probe sets. Primers were generated using Applied 
Biosystems Primer Express Software version 3.0 or obtained from published literature 
(Table 3-1) and Taqman probe sets were purchased from Life Technologies (Table 
3-2).Fold changes in gene expression were determined as previously described (3). 
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Gene GenBank 
accession no. Forward (5' to 3') Reverse (5' to 3') 
Referenc
e 
Rpl7 NM_011291 AGCTGGCCTTTGTCATCAGAA GACGAAGGAGCTGCAGAACCT  
Adamts
1 NM_009621 CACATGCAAGAAGATGTCAGG CCCTTTGATTCCGATGTTTC (13) 
Adamts
4 NM_172845 TCAACACCCCTAACGACTCA TGCATGGCTTGGAGTTATCA (14) 
Cyp11a
1 NM_019779 CCAGTGTCCCCATGCTCAAC TGCATGGTCCTTCCAGGTCT (15) 
Cyp17a
1 NM_007809 GATCTAAGAAGCGCTCAGGCA GGGCACTGCATCACGATAAA (16) 
Hsd17b
1 NM_010475 TGTTCGCCTAGCTTCTGACC AGCAGCCACAGATTTGGAGT (15) 
Hsd17b
7 NM_010476 AATGTGGCTCCTTCGCTTTT GAGACTCCGGTTTTTGGTGG  
Hsd3b1 NM_008293, 
CTCAGTTCTTAGGCTTCAGCAATTA
C 
CCAAAGGCAAGATATGATTTAGG
A (17) 
 
NM_00130480
0    
Fshr NM_013523 ATGTGTTCTCCAACCTACCCA GCTGGCAAGTGTTTAATGCCTG (15) 
Star NM_011485 CCGGAGCAGAGTGGTGTCA CAGTGGATGAAGCACCATGC (15) 
 
Table 3-1: Primer sequences used for quantitative RT-PCR. 
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Gene Genbank accession no. Taqman probe set 
Rpl7 NM_011291.5 Mm02342562_gH 
Pgr NM_008829.2 Mm00435628_m1 
Ptgs2 NM_011198.3 Mm00478374_m1 
Cyp19a1 NM_007810.3 Mm00484049_m1 
Lhcgr NM_013582.2 Mm00442931_m1 
 
Table 3-2: Taqman probe sets used for quantitative RT-PCR in Figure 3-4. 
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3.2.6 Fixation, sectioning, and preparation of ovaries for histological examination 
Immediately after harvest, ovaries were placed into previously weighed 1.5 mL 
microcentrifuge tubes on ice, and weighed again. The microcentrifuge tubes were filled 
with 1.4 mL cold fixative solution (paraformaldehyde, 4% v/v in PBS). Microcentrifuge 
tubes were placed into a 50 mL conical tube which was then placed into a rotisserie 
rotator for 24 h at 4°C. The fixative solution was aspirated and replaced with 1.4 mL 4°C 
PBS. The microcentrifuge tubes were rotated for 24 h at 4°C, PBS was aspirated, 
replaced with 1.4 mL 4°C PBS, and rotated for 24 h at 4°C. The PBS was aspirated and 
replaced with 1.4 mL ethanol (70% v/v in MilliQ water). Fixed ovaries were then sent to 
the Molecular Pathology Core Facility (Robarts Research Institute, London, ON, Canada) 
for paraffin embedding, sectioning, and staining with hematoxylin/eosin (H&E). 
3.2.7 Histological quantitation of COCs, corpora lutea, and multi-oocyte follicles 
H&E-stained ovary sections were scanned using an Aperio ScanScope slide 
scanner (Leica Biosystems) at 200x. COCs and corpora lutea (CLs) were counted in 
every fifth section and multi-oocyte follicles (MOFs) in every third section throughout 
the entire ovary. When necessary, additional sections were reviewed to ensure that the 
same COCs, CLs, or MOFs were not counted twice. 
3.3 Results 
3.3.1 Ephrin-A5 is required for normal female fertility 
In order to assess the fertility of female Efna5-/- mice, we conducted a continuous 
breeding study (Figure 3-1A). Eight-week old Efna5+/+ or Efna5-/- females were housed 
individually with 8-week old Efna5+/+ males for 6 months, and the litter sizes and dates of 
birth were recorded. Efna5-/- females produced 40% smaller litters (P < 0.001) than 
Efna5+/+ control females (Figure 3-1A). Average litter sizes for Efna5+/+ females were 
13.1 (± 0.6, n=9) pups/litter compared to 8.0 (± 0.9, n=9) pups/litter for Efna5-/- females 
(Figure 3-1A). No difference in litter frequency was observed between genotypes 
(Figure 3-1B). These results indicate that fertility is compromised in female mice lacking 
ephrin-A5. Therefore, to begin to understand the basis of this decreased fertility, we 
assessed the ovarian response to gonadotropin stimulation. 
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3.3.2 Efna5-/- females ovulate fewer oocytes than controls 
In order to determine the ovulatory potential of Efna5-/- females, PND 23-25 
Efna5+/+ and Efna5-/- females were hormonally stimulated (superovulated) by treatment 
with eCG for 48 h, followed by hCG for 14 h, after which the oocyte yield per animal 
was determined. The oocyte yield for Efna5-/- females was 38% lower than for Efna5+/+ 
females (P < 0.01, Figure 3-1C). An average of 49.3 (± 3.4, n=11) COCs/animal was 
retrieved from Efna5+/+ females, compared to 30.7 (± 4.3, n=12) oocytes/animal from 
Efna5-/- females (Figure 3-1C). 
3.3.3 Serum estradiol and progesterone levels are unaffected by loss of ephrin-A5 
The circulating levels of 17β-estradiol (estradiol) and progesterone can be used as 
parameters for evaluating the ovarian response to gonadotropin stimulation, and can 
provide insight into the reason for decreased fertility. Therefore, we assessed serum 
estradiol and progesterone levels in gonadotropin-stimulated, PND 23-28 Efna5+/+ and 
Efna5-/- females. No significant difference in serum estradiol levels was detected between 
Efna5+/+ and Efna5-/- females 48 h post-eCG (Figure 3-2A). Similarly, no significant 
difference in serum progesterone levels was detected between Efna5+/+ and Efna5-/- 
females after either 14 h or 24 h hCG (Figure 3-2B). 
3.3.4 Ovary to body weight ratio is unaffected by loss of ephrin-A5 
In order to determine whether loss of ephrin-A5 alters the ovary-to-body weight 
ratio in immature or adult mice, ovarian weights from Efna5+/+ and Efna5-/- females were 
measured at 21, 60, and 120 days of age and normalized to body weight. No differences 
were detected in the ovary-to-body weight ratio between Efna5+/+ and Efna5-/- females at 
any of these ages (Figure 3-3, A-C). 
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Figure 3-1: Reproductive assessment of Efna5-/- females. 
Efna5+/+ or Efna5-/- PND 60 females were paired with an Efna5+/+ PND 60 male for a 6 
month continuous breeding study to determine litter size (mean ±SEM) (A) and time 
between births (mean ±SEM) (B). Released oocytes from superovulated Efna5+/+ or 
Efna5-/- PND 21-23 females were counted to determine ovulatory capacity (mean ±SEM) 
(C). A) “Litter size” and “time between litters” for Efna5+/+ and Efna5-/- genotypes were 
compared using the Student two-tailed unpaired t-test. A statistically significant 
difference was found between genotypes for both litter size and time between litters as 
determined by Student’s unpaired t-test; t(16)=4.849. ***, p=0.0002. B) “Time between 
births” for Efna5+/+ and Efna5-/- genotypes was compared using the Student two-tailed 
unpaired t-test. No statistically significant difference was found between genotypes as 
determined by Student’s unpaired t-test; t(15)=0.1008, p=0.9211. C) “Ovulation 
capacity” for Efna5+/+ and Efna5-/- genotypes was compared using the Student two-tailed 
unpaired t-test. A statistically significant difference was found between genotypes as 
determined by Student’s unpaired t-test; t(21)=3.356. **, p=0.0030. 
A B
C
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Figure 3-2: Serum estradiol and progesterone concentrations are unaffected by loss 
of ephrin-A5.  
Serum estradiol (mean ±SEM) (A) was measured for eCG-treated Efna5+/+ and Efna5-/- 
females and serum progesterone (mean ±SEM) (B) for superovulated females. A) “Serum 
estradiol” for Efna5+/+ and Efna5-/- genotypes was compared using the Student two-tailed 
unpaired t-test. No statistically significant difference was found between genotypes as 
determined by Student’s unpaired t-test; t(9)=1.142, p=0.2830. B) “Serum progesterone” 
for Efna5+/+ and Efna5-/- genotypes was compared at 14 h and then at 24 h post-hCG 
using the Student two-tailed unpaired t-test. At 14 h post-hCG, no statistically significant 
difference was found between genotypes as determined by Student’s unpaired t-test; 
t(19)=0.5520, p=0.5874. At 24 h post-hCG, no statistically significant difference was 
found between genotypes as determined by Student’s unpaired t-test; t(6)=0.9392, 
p=0.3839. 
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Figure 3-3: Ovary/body weight ratio is normal in Efna5-/- females at PND 23, 60, 
and 120. 
Ovaries from Efna5+/+ and Efna5-/- females were harvested, weighed, and normalized to 
body weight (mean ±SEM) at PND 23 (A), 60 (B) and 120 (C). “Ovary/body weight 
ratio” for Efna5+/+ and Efna5-/- genotypes was compared using the Student two-tailed 
unpaired t-test. A) At PND 23, no statistically significant difference was found between 
genotypes as determined by Student’s unpaired t-test; t(5)=1.212, p=0.2795. B) At PND 
60, no statistically significant difference was found between genotypes as determined by 
Student’s unpaired t-test; t(5)=0.04437, p=0.9663. C) At PND 120, no statistically 
significant difference was found between genotypes as determined by Student’s unpaired 
t-test; t(6)=1.460, p=0.1946. 
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3.3.5 Ovarian gene expression is altered in Efna5-/- females after gonadotropin 
stimulation 
Because ovulatory capacity in response to gonadotropin stimulation was impaired 
in Efna5-/- females (Figure 3-1C), we determined whether expression of gonadotropin-
responsive genes known to be involved in follicle growth and ovulation was altered in 
Efna5-/- ovaries. Immature Efna5-/- and Efna5+/+ females were treated with eCG for 48h 
+/- hCG for 4, 14, or 24 h, and whole-ovary mRNA levels of known FSH and LH-
responsive genes were determined by RT-qPCR. Specifically, we investigated the levels 
of prostaglandin-endoperoxide synthase 2 (Ptgs2), progesterone receptor (Pgr), and 
ADAM metallopeptidase with thrombospondin type 1 motif, 4 (Adamts4) (18) to assess 
the LH response (48h eCG + 4, 14, or 24 h hCG). We quantified the mRNA levels of 
cytochrome P450, family 19, subfamily A, polypeptide 1 (Cyp19a1) and luteinizing 
hormone/choriogonadotropin receptor (Lhcgr) to assess the FSH response (48h eCG). 
As expected, hCG treatment increased Pgr, Ptgs2, and Adamts4 mRNA levels in 
Efna5+/+ ovaries (Figure 3-4, A-C). However, in response to the same treatment, Pgr, 
Ptgs2, and Adamts4 mRNA levels in Efna5-/- females were 58%, 54%, and 80% lower, 
respectively, than in Efna5+/+ controls (P < 0.0001, Figure 3-4, A-C). To determine if 
this reduced response to hCG was due to a reduction in LH receptor (Lhcgr) gene 
expression, the mRNA levels of Lhcgr were determined after 48h eCG (Figure 3-4F). 
There was no significant difference in Lhcgr mRNA levels between genotypes, 
suggesting that loss of Lhcgr in Efna5-/- females was not responsible for the attenuated 
response to hCG. 
Since Lhcgr is a well-known FSH-responsive gene, this result also suggested that 
the response to FSH was intact in Efna5-/- females. To test this, we investigated the 
mRNA levels of another well-known FSH-responsive gene, Cyp19a1, after 48h eCG 
treatment. No significant difference in Cyp19a1 mRNA levels was observed between 
genotypes (Figure 3-4D), which is consistent with the lack of a difference in circulating 
estradiol levels between genotypes (Figure 3-2A). No differences were observed in Fshr 
mRNA levels (Figure 3-4E). In total, the results of these gene expression studies suggest 
that the ovarian response to LH, but not FSH, is disrupted in Efna5-/- females. 
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In order to understand why superovulated Efna5-/- females produced fewer oocytes 
than wildtype controls, we examined the histology of ovaries from superovulated 
wildtype and Efna5-/- females. 
3.3.6 Efna5-/- ovaries exhibit increased numbers of expanded COCs after 
gonadotropin stimulation 
Since cumulus expansion is necessary for ovulation to occur, we assessed the 
number of follicles containing expanded COCs in ovaries of superovulated Efna5+/+ and 
Efna5-/- females. Examination of ovaries from Efna5-/- and wildtype control females 
treated with eCG (48 h) followed by hCG (10 h) revealed a 2.6-fold increase in the 
number of follicles that had undergone cumulus expansion in Efna5-/- females than in 
controls, with an average of 26 per mouse in Efna5-/- females compared to 10 per mouse 
in Efna5+/+ females (Figure 3-5A). Based on this observation, we wondered if there 
would be a difference in the number of CLs/mouse between genotypes. However, ovaries 
from Efna5+/+ and Efna5-/- females treated with eCG (48 h) followed by hCG (14 h) 
exhibited no significant difference in the total number of corpora lutea/mouse (Figure 
3-5B). However, Efna5-/- females contained a significantly higher number of oocytes 
aberrantly retained in CLs (1.5 fold) than control females (Figure 3-5C). 
3.3.7 Abnormal follicle rupture, hemorrhaging, and fibrin thrombus formation in 
Efna5-/- ovaries after gonadotropin stimulation 
In ovaries of Efna5-/- mice, follicles at all stages of growth were observed (Figure 
3-6, A-J). However, Efna5-/- ovaries exhibited a number of abnormal and fascinating 
histological features (Figure 3-6, A-J) that were not observed or were less pronounced in 
Efna5+/+ controls (Figure 3-6K). These features included the presence of GCs and COCs 
in the ovarian interstitium (Figure 3-6E, black arrow and Figure 3-6G, black arrow) and 
the presence of GCs in blood vessel lumina (Figure 3-6C, black arrow, and Figure 3-6F, 
open arrow). The presence of fibrin thrombi (Figure 3-6D, black arrow and Figure 3-6G, 
open pentagon) and hemorrhaging (Figure 3-6, A-B, open stars) were also observed. 
Efna5-/- ovaries also exhibited instances of follicles rupturing in abnormal locations, 
specifically the non-apical rupture of follicles directed towards/into the interstitium as 
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opposed to the exterior of the ovary (Figure 3-6D, open arrow and Figure 3-6G, black 
arrow) and at least one occurrence of possibly premature rupture (Figure 3-6A, black 
arrow). In some cases, follicles exhibiting non-apical rupture contained luteinizing GCs 
(Figure 3-6G, open star). Finally, Efna5-/- ovaries also exhibited a significant, 50% 
increase in oocytes trapped within luteinized follicles compared to Efna5+/+ controls 
(Figure 3-6, H-J, and Figure 3-5C). 
3.3.8 Increased number of multi-oocyte follicles in adult Efna5-/- mice 
Interestingly, we observed that ovaries from 2 month-old Efna5-/- females contain 
over four times more multi-oocyte follicles (MOFs) per ovary than wildtype controls (P < 
0.05), with an average of 8.8 MOFs  (± 2.8, n=5) per Efna5-/- female compared to 2.0 
MOFs (± 0.70, n=5) per Efna5+/+ female (Figure 3-7B). Having observed this significant 
increase in MOFs in adult Efna5-/- ovaries, we wanted to determine if this increase would 
also be observed in immature Efna5-/- mice, to help understand when and how during 
folliculogenesis this increase in MOFs might be occurring. In contrast to adult mice, no 
difference in MOF number was observed between genotypes at PND 21, with an average 
of 1.5 MOFs (± 1.5, n=2) per Efna5+/+ female and 2.3 MOFs (± 0.95, n=4) per Efna5-/- 
female (Figure 3-7A). 
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Figure 3-4: hCG-stimulated ovarian expression of Pgr, Ptgs2, and Adamts4 is 
attenuated in Efna5-/- mice. 
Relative transcript abundance compared to Rpl7 (mean ±SEM) was determined by qRT-
PCR in whole ovaries of superovulated females for Pgr (A), Ptgs2 (B), Adamts4 (C), 
Cyp19a1 (D), Fshr (E), and Lhcgr (F). A) Pgr. A two-way ANOVA found a significant 
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effect for treatment, F (2, 32) = 148.7, P < 0.0001; a significant effect for genotype, F (1, 
32) = 10.09, P = 0.0033; and a significant interaction F (2, 32) = 11.13, P = 0.0002. 
Tukey's multiple comparisons test revealed a significant difference between genotypes in 
mice treated with 5.0 IU eCG (48 h) + 5.0 IU hCG (4 h), ****, P < 0.0001. B) Ptgs2. A 
two-way ANOVA found a significant effect for treatment, F (2, 32) = 132.7, P < 0.0001; 
a significant effect for genotype, F (1, 32) = 11.18, P = 0.0021; and a significant 
interaction F (2, 32) = 12.09, P = 0.0001. Tukey's multiple comparisons test revealed a 
significant difference between genotypes in mice treated with 5.0 IU eCG (48 h) + 5.0 IU 
hCG (4 h), ****, P < 0.0001. C) Adamts4. A two-way ANOVA found a significant effect 
for treatment, F (3, 32) = 12.44, P < 0.0001; a significant effect for genotype, F (1, 32) = 
15.26, P = 0.0005; and a significant interaction F (3, 32) = 11.18, P = 0.0001. Tukey's 
multiple comparisons test revealed a significant difference between genotypes in mice 
treated with 5.0 IU eCG (48 h) + 5.0 IU hCG (14 h), ****, P < 0.0001. D) Cyp19a1. A 
two-way ANOVA found a significant effect for treatment, F (2, 32) = 32.83, P < 0.0001; 
no significant effect for genotype, F (1, 32) = 1.731, P = 0.1976; and no significant 
interaction F (2, 32) = 2.303, P = 0.1163. Tukey's multiple comparisons test revealed a 
significant difference between Efna5+/+ mice treated with saline (48 h) or 5.0 IU eCG (48 
h), ****, P < 0.0001; and a significant difference between Efna5-/- mice treated with 
saline (48 h) or 5.0 IU eCG (48 h), *, P = 0.0116. E) Fshr. A two-way ANOVA found a 
significant effect for treatment, F (2, 32) = 22.57, P < 0.0001; no significant effect for 
genotype, F (1, 32) = 0.8305, P = 0.3689; and no significant interaction, F (2, 32) = 
0.2067, P = 0.8143. Tukey's multiple comparisons test revealed a significant difference 
between Efna5+/+ mice treated with saline (48 h) or 5.0 IU eCG (48 h), *, P = 0.0210; and 
a significant difference between Efna5-/- mice treated with saline (48 h) or 5.0 IU eCG 
(48 h), *, P = 0.0135. F) Lhcgr. A two-way ANOVA found a significant effect for 
treatment, F (2, 32) = 45.02, P < 0.0001; no significant effect for genotype, F (1, 32) = 
2.482, P = 0.1250; and no significant interaction, F (2, 32) = 0.8808, P = 0.4243. Tukey's 
multiple comparisons test revealed a significant difference between Efna5+/+ mice treated 
with saline (48 h) or 5.0 IU eCG (48 h), ****, P < 0.0001; and a significant difference 
between Efna5-/- mice treated with saline (48 h) or 5.0 IU eCG (48 h), ****, P < 0.0001. 
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Figure 3-5: Follicles containing expanded COCs and retained oocytes are more 
numerous in superovulated Efna5-/- mice. 
Sectioned ovaries from superovulated Efna5+/+ and Efna5-/- mice were stained with 
hematoxylin/eosin and scanned using an Aperio ScanScope (Leica Biosystems) at a 
magnification of 200x. Follicles containing expanded COCs (A) and corpora lutea (CLs) 
(mean ±SEM) (B) were counted in every fifth section throughout the entire ovary, noting 
the fraction of CLs that contained oocytes (mean ±SEM) (C). Additional sections were 
reviewed when necessary to ensure that CLs were not counted twice. A) “Number of 
follicles containing expanded COCs per mouse” was compared between Efna5+/+ and 
Efna5-/- genotypes using the Student two-tailed unpaired t-test. A statistically significant 
difference was found between genotypes as determined by Student’s unpaired t-test; 
t(10)=8.597. ****, p<0.0001. B) The number of corpora lutea per mouse was compared 
between Efna5+/+ and Efna5-/- genotypes using the Student two-tailed unpaired t-test. No 
statistically significant difference was found between genotypes as determined by 
Student’s unpaired t-test; t(4)=2.104, p=0.1031. C) “Fraction of CLs containing oocytes” 
was compared between Efna5+/+ and Efna5-/- genotypes using the Student two-tailed 
unpaired t-test. A statistically significant difference was found between genotypes as 
determined by Student’s unpaired t-test; t(4)=4.623. **, p=0.0099. 
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Figure 3-6: Superovulated Efna5-/- mice exhibit non-apical follicle rupture and an 
increased incidence of oocytes trapped within luteinized follicles. 
Sectioned ovaries from superovulated Efna5+/+ and Efna5-/- mice were stained with 
hematoxylin/eosin and scanned using an Aperio ScanScope (Leica Biosystems) at a 
magnification of 200x. Black bars represent 100 µm. A) Non-apical follicle rupture in the 
ovarian interstitium (black arrow) associated with hemorrhage near the site of rupture 
(white star). B) Hemorrhaging in the interstitium (open star). C) Blood vessel with fibrin 
thrombus and intraluminal granulosa cells (black arrow). D) Fibrin thrombus (black 
arrow) with the presence of an oocyte in the interstitium (open arrow). E) Presence of 
granulosa cells in the interstitium (black arrow). F) Non-apical follicle rupture in 
interstitium (black arrow) and blood vessel containing fibrin thrombus with granulosa 
cells. G) Fibrin thrombus (open pentagon) with the presence of an oocyte in the 
interstitium (black arrow), non-basal ovulatory cone indicating follicle rupture (open 
arrow), and luteinizing granulosa cells (open star). 
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Figure 3-6. Superovulated Efna5-/- mice exhibit non-apical follicle rupture and an 
increased incidence of oocytes trapped within luteinized follicles. 
H, I, J) Oocytes trapped within luteinizing follicles (black arrows). K) Representative 
Efna5+/+ ovary. 
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Figure 3-7: Efna5-/- adult females exhibit more multi-oocyte follicles than juveniles. 
Sectioned ovaries from superovulated Efna5+/+ and Efna5-/- mice were stained with 
hematoxylin/eosin and scanned using an Aperio ScanScope (Leica Biosystems) at a 
magnification of 200x. Multi-oocyte follicles (MOFs) were counted in every third section 
throughout both ovaries of PND 23 (A) and PND 60 (B) mice. Additional sections were 
reviewed when necessary to ensure that MOFs were not counted twice. MOF counts were 
compared between Efna5+/+ and Efna5-/- genotypes using the Student two-tailed unpaired 
t-test. A) At PND 23, no statistically significant difference was found between genotypes 
as determined by Student’s unpaired t-test; t(4)=0.4435, p=0.6803. B) At PND 60 a 
statistically significant difference was found between genotypes as determined by 
Student’s unpaired t-test; t(8)=2.313. *, p=0.0494. 
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3.4 Discussion 
To our knowledge, no reproductive assessment has been carried out using the 
Efna5-/- mouse or any other ephrin or Eph receptor knockout animal model. We now 
report that female mice lacking ephrin-A5 are subfertile and possess a number of ovarian 
defects that may underlie this reduced fertility. 
3.4.1 Efna5-/- females produce smaller litters and release fewer oocytes than 
controls 
In a continuous breeding study, Efna5-/- females produced litters that were 40% 
smaller than Efna5+/+ controls, indicating that ephrin-A5 is important for optimal fertility 
in female mice. Consistent with this observation, superovulated reproductively immature 
Efna5-/- female mice ovulated 40% fewer COCs than controls, suggesting that ephrin-A5 
is required for a maximal response to gonadotropins. This blunted response was not likely 
due to differences in gonadotropin receptor levels, as both Lhcgr and Fshr mRNA levels 
were similar in both genotypes. To further explore the basis of this attenuated ovarian 
response, we measured the ovarian expression of known FSH and LH responsive genes in 
Efna5-/- females stimulated with eCG and hCG. 
3.4.2 Efna5-/- females exhibit an attenuated response to hCG but not eCG 
After eCG treatment, no differences in the mRNA levels of the FSH-responsive 
genes Cyp19a1 and Lhcgr were observed between Efna5+/+ and Efna5-/- ovaries, 
suggesting that Efna5-/- ovaries respond normally to FSH. However, we observed 
attenuated hCG-stimulated expression of the LH-responsive genes Pgr, Ptgs2, and 
Adamts4 in Efna5-/- females compared to controls, suggesting that the ovarian response to 
LH is compromised in Efna5-/- females, and may contribute to their reduced ovulatory 
capacity. 
3.4.3 Efna5-/- ovaries exhibit numerous histological abnormalities  
Ovulation requires extensive tissue remodeling, which involves the dynamic 
regulation of cell migration and adhesion, and the deposition and degradation of 
extracellular matrix components. Like all members of the ephrin family, ephrin-A5 is 
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best known as a regulator of cell positioning and is thus well-suited to be involved in 
these processes, and ephrin-A5-Fc and EphA5-Fc influence morphology and reduce 
adhesion, respectively, of mouse GCs in culture (3). 
Gonadotropin-stimulated Efna5-/- mice possessed ovaries with an increased number of: a) 
luteinized follicles containing trapped oocytes, b) follicle rupture within the ovary 
resulting in oocyte release into the interstitium and/or blood vessel lumina, c) GCs 
present in blood vessel lumina, d) the presence of fibrin thrombi in blood vessels, and e) 
the presence of extravasated blood near sites of non-apical rupture. These histological 
features bear a striking resemblance to those observed in several loss-of-function rodent 
models, specifically for the LH-responsive genes Pgr, Ptgs2, and Adamts4, for which we 
detected reduced mRNA levels in Efna5-/- ovaries. 
3.4.4 Progesterone receptor (Pgr) 
We observed a 58% reduction in ovarian Pgr mRNA levels in superovulated Efna5-
/-
 mice. While follicle growth and cumulus expansion proceed normally in mice lacking 
Pgr, ovulation fails due to impaired follicle rupture (19). This results in the formation of 
luteinized follicles containing trapped COCs, suggesting that the primary physiological 
role of Pgr in the ovary is promoting follicle rupture (20). Similar to the Pgr-/- ovary (19), 
Efna5-/- ovaries exhibit an increased incidence of oocytes trapped within luteinized 
follicles. Within the ovary, the PR is expressed primarily in GCs in response to 
stimulation by LH, and mediates the expression of many genes involved in ovulation. 
Therefore, attenuated expression of Pgr may be responsible, at least in part, for the 
increased incidence of luteinized follicles containing trapped oocytes that we observed in 
Efna5-/- females. 
3.4.5 Prostaglandin-endoperoxide synthase 2 (Ptgs2) 
We observed a 54% reduction in ovarian Ptgs2 mRNA levels in superovulated 
Efna5-/- mice. Ptgs2 is involved in the post-LH rise in prostaglandin synthesis within the 
preovulatory follicle (21). Ptgs2-/- females are infertile, exhibit oocyte retention in CLs, 
and defective cumulus expansion (22). Rats treated with indomethacin, a PTGS2 
inhibitor, are also anovulatory and exhibit follicle rupture defects including oocyte 
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retention within luteinized follicles and non-apical follicle rupture (23). Similar to Ptgs2-/-  
females, Efna5-/- females exhibited COCs trapped within CLs, non-apical follicle rupture 
resulting in interstitial and intraluminal COC release, and formation of structures 
reminiscent of follicular fluid emboli reported in ovaries of indomethacin-treated rats 
(23). Therefore, reduced Ptgs2 expression may contribute to the reproductive phenotype 
of Efna5-/- females. 
3.4.6 ADAM metallopeptidase with thrombospondin type 1 motif, 4 (Adamts4) 
We observed an 80% reduction in ovarian Adamts4 mRNA levels in superovulated 
Efna5-/- mice. Adamts4 encodes a member of the a disintegrin and metalloproteinase with 
thrombospondin-like repeats family. Adamts4 is expressed in the ovary along with 
Adamts1 and Adamts5 in distinct spatiotemporal patterns, and is thought to be involved in 
tissue remodeling that occurs prior to, during, and after ovulation (18). However, the 
specific roles of these proteases in the context of ovulation are not currently known. 
Interestingly, expression of Adamts4 is enriched in ovulation cones/stigma, which are 
highly vascularized. Adamts4 is also enriched in endothelial cells of the forming CL of 
superovulated mice 16 h post-hCG (18), suggesting that Adamts4 plays a role in follicle 
rupture and neovascularization of the CL. Consistent with these proposed roles for 
Adamts4, Efna5-/- females exhibit abnormal follicle rupture and vascular defects such as 
fibrin thrombi. Although Adamts4-/- mice are reported as phenotypically normal (24), 
suggesting that other proteases may compensate for its loss in the ovary, given the 
dramatic reduction in Adamts4 mRNA levels we observe in Efna5-/- mice, we speculate 
that loss of Adamts4 expression may contribute to the abnormal follicle rupture in Efna5-/- 
females. 
3.4.7 Relating LH, Pgr, Ptgs2, and Adamts4 to Efna5-/- reproductive and ovarian 
defects 
In the Efna5-/- ovary, we observed follicles ruptured within the ovary resulting in 
intraovarian oocyte release, and a higher incidence of CLs containing trapped oocytes. 
We postulate that in Efna5-/- mice, these follicles fail to ovulate normally because they 
are, to varying degrees, unable to fully respond to LH. 
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LH triggers a stepwise cascade of events, with cumulus expansion occurring early, 
leading to ovulation and formation of the CL at a later stage. Therefore, it seems 
plausible that different follicles may exhibit a range of partial responsiveness to LH. 
Thus, we might expect to observe an ovulatory defect at any of the LH-triggered stages, 
with LH able to “push” some preovulatory follicles further along the “ovulation” pathway 
than others. This idea is supported by the attenuated expression of Pgr, Ptgs2, and 
Adamts4 in Efna5-/- females, all of which are proposed to be involved in follicle rupture. 
Cumulus expansion is normal in Pgr-/- mice, and although Ptgs2-/- mice exhibit reduced 
cumulus expansion, Ptgs2 is reduced by ~50% in Efna5-/- females, which may be 
sufficient for cumulus expansion to occur. Therefore, reduced expression of Pgr and 
Ptgs2 following hCG treatment could specifically impair follicle rupture, while still 
allowing cumulus expansion to occur. 
Abnormal follicle rupture may also help explain the reduced ovulatory potential of 
Efna5-/- females. A necessary condition of successful ovulation is that follicular rupture 
occurs on the apical surface of the follicle to facilitate COC release into the oviduct. In 
Efna5-/- mice, COCs released into the interstitium, blood vessel lumina, and retained in 
corpora lutea, fail to reach the oviduct. Thus, the increased frequency of abnormal 
follicular rupture, combined with the increased incidence of unruptured follicles, may 
contribute to the decreased ovulation potential that we observed in Efna5-/- females. 
3.4.8 Hemorrhaging, fibrin thrombi, and GCs in blood vessel lumina 
We observed hemorrhaging and formation of fibrin thrombi in ovaries of 
superovulated Efna5-/- females. These events likely result from non-apically released GCs 
and follicular fluid, whose proteolytic/invasive properties damage the surrounding tissue, 
including the vasculature. This vascular damage has been observed in other murine 
models. In indomethacin-treated rats, release of follicular fluid and GCs into the 
interstitium results in invasion of the stroma, rupture of blood and lymphatic vessels, 
hemorrhagia, and the formation of emboli composed of follicular fluid (25). Furthermore, 
cumulus cells from expanded COCs exhibit transiently increased invasive properties, 
with increasing migratory and adhesive capacity 4 to 12 h post-hCG (26). Under normal 
circumstances, these properties may contribute to successful fertilization by promoting 
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migration of the apically ovulated COC. However, when directed toward the ovarian 
interstitium during non-apical follicle rupture, these properties may contribute to the 
ovarian hemorrhaging and formation of fibrin thrombi observed in Efna5-/- females. 
3.4.9 How does loss of ephrin-A5 result in reduced expression of Pgr, Ptgs2, and 
Adamts4? 
We show that ephrin-A5 is necessary for optimal ovarian expression of Pgr, Ptgs2, 
and Adamts4 in response to gonadotropin stimulation. Since Pgr and Ptgs2 are known 
LH-responsive genes, and in our study, Adamts4 is also LH-responsive, it is logical that 
the reduced mRNA levels of Pgr, Ptgs2, and Adamts4 in Efna5-/- ovaries are due, at least 
in part, to an attenuated transcriptional response of GCs to LH. Reduced transcript 
stabilization is another possible mechanism. How ephrin-A5 might regulate either 
transcript production or stabilization in the ovary is currently unknown.  
Nevertheless, Eph-ephrin signaling has been linked to changes in gene expression 
in various model systems, although the mechanism(s) by which this occurs are not well 
understood. Stimulation with A-class ephrins increases expression of epidermal 
differentiation markers and suppresses expression of genes associated with cell adhesion 
in human epidermal keratinocytes (27). Furthermore, EphB4-/- embryonic stem cells 
(ESCs) exhibit impaired differentiation, with many genes dysregulated compared to 
EphB4+/+ ESCs (28). Finally, stimulation of rat epithelial small intestine IEC-6 cells with 
EphB1 results in upregulation of wound-healing genes via the ERK1/2 pathways (29). 
Currently, the mechanism by which Eph-ephrin signaling influences ovarian gene 
expression in GCs is not known. However, several reports indicate that the ERK, beta-
catenin, and PKA pathways, which are activated by LH, are influenced by Eph-ephrin 
signaling, and therefore may be disrupted by loss of ephrin-A5 in the ovary, resulting in 
reduced expression of LH-responsive genes such as Pgr and Ptgs2. 
In the mouse, extracellular regulated kinases 1 and 2 (ERK1/2) are essential for 
female fertility. Mice lacking ERK1/2 in GCs exhibit a compromised response to LH, 
including impaired cumulus expansion, ovulation, luteinization, and induction of many 
LH-responsive genes, including Pgr and Ptgs2 (30). Several reports in other model 
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systems indicate that Eph-ephrin signaling regulates phosphorylation of ERK1/2, 
inhibiting activation in most model systems (31-33) and promoting activation in some 
(34-37). EPHB4 can inhibit or enhance ERK1/2 activation depending on cell type, due to 
differences in coupling with downstream signaling elements (38). Therefore, given that 
ERK1/2 are necessary for LH-stimulated activation of Ptgs2 and Pgr in mouse GCs (30), 
and that ERK1/2 phosphorylation is elevated for at least 4 h post-LH in cultured rat 
follicles (39), GCs lacking ephrin-A5 in our model may insufficiently activate ERK1/2 
signaling to optimally induce Ptgs2 and Pgr upon stimulation with LH. Determining the 
molecular mechanism by which loss of ephrin-A5 may attenuate ERK1/2 activation, 
resulting in suboptimal LH gene activation, requires further investigation. 
Second, ephrin-A5 may also influence Ptgs2 expression by altering beta-catenin 
levels. We previously reported that stimulation of rat granulosa cells with ephrin-A5 
results in decreased beta-catenin levels (3). Beta-catenin serves as both a component of 
adherens junctions (40) and as a transcriptional activator (41,42). In the ovary, 
appropriate beta-catenin levels in GCs is critical for fertility, since mice expressing a 
granulosa cell-specific, dominant-stable form of beta-catenin exhibit impaired ovulation 
and luteinization, and attenuated hCG-stimulated expression of Ptgs2 (43). Therefore, 
FSH-induced expression of ephrin-A5 (3) may promote degradation of beta-catenin in 
mouse GCs in preparation for the LH surge. In GCs of Efna5-/- mice, loss of ephrin-A5 
may result in increased beta-catenin levels, contributing to the reduced expression of 
Ptgs2. 
Third, Eph-ephrin signaling may cross-talk with the cAMP/PKA pathway. Indirect 
crosstalk between the Eph-ephrin and cAMP/PKA pathways has been previously 
described in two model systems. In mouse cortical progenitor cells, stimulation with 
recombinant ephrin-B1 potentiates activation of the PKA target, cAMP-responsive 
element binding protein (CREB), by glutamate in an EphB2-dependent manner (44). 
Furthermore, ephrin-A5 stimulation of cultured mouse hippocampal slices promotes 
activation of PKA and CREB in an EphA5-dependent manner (45). Therefore, Eph-
ephrin signaling may indirectly activate or potentiate PKA in GCs, and loss of ephrin-A5 
may result in insufficient PKA activation for optimal induction of Pgr and Ptgs2.  
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Finally, it is possible that in Efna5-/- females, reduced Adamts4 expression is a 
consequence of attenuated induction of Pgr by LH. In Pgr-/- mice, LH-induced ovarian 
expression of Adamts4 is attenuated 12 h post-hCG , suggesting that PR regulates 
Adamts4 expression. In Efna5-/- ovaries, hCG-induced Pgr expression is reduced 4 h 
post-hCG, and Adamts4 expression is attenuated 14 h post-hCG, suggesting that the 
reduction of PR at 4 h may reduce Adamts4 expression by 14h.  
3.4.10 Efna5 is one of many neuronal guidance genes expressed in the mouse ovary 
This study has shown that Efna5 plays an important role in the mouse ovary, and 
that its absence has negative consequences for female fertility. However, ephrin-A5 has 
been characterized primarily in the context of axon guidance during embryonic 
development; thus, its role in female reproduction and in the mouse ovary are novel. In 
support of a role for a neuronal guidance gene such as ephrin-A5 in the ovary, it is 
interesting to note that expression of neuronal cell guidance genes in the ovary is not 
without precedent. In addition to Efna5, expression of several genes associated with 
neuronal cell guidance is higher in large bovine follicles than in small antral follicles (8). 
The authors speculate that these genes mediate ovarian tissue remodeling and cell 
migration in the follicle, resulting in oocyte release facing the ovarian surface (8). In line 
with this reasoning, we also observed non-apical follicle rupture of follicles in Efna5-/- 
females. Thus, ephrin-A5 may be one of many genes with roles in both neuronal cells and 
in the ovary. 
3.4.11 Experimental Considerations 
One limitation of our Efna5-/- model is that it is a global knockout, and thus it is 
possible that abnormal development of the hypothalamus, pituitary, and/or uterus may 
occur. However, our results suggest that the hypothalamic-pituitary-gonadal (HPG) axis 
is likely not largely disrupted in Efna5-/- females. First, litter frequency was unaffected, 
suggesting that estrous cyclicity is normal in Efna5-/- females, and therefore, as far as its 
capacity to coordinate the proper timing of follicle growth and ovulation, the HPG axis is 
intact. An intact HPG axis is also consistent with our observation that gonadotropin-
stimulated estradiol and progesterone levels were similar in Efna5-/- females and controls. 
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However, we cannot completely rule out the possibility that the lack of ephrin-A5 in the 
hypothalamus or pituitary may be in part responsible for the phenotype we observed. To 
do this, a granulosa cell type-specific, conditional Efna5 knockout mice would be 
required. 
3.4.12 Unexpected findings 
We observed an increased number of multi-oocyte follicles (MOFs) in ovaries of 
normally-cycling adult Efna5-/- females compared to controls. However, we did not detect 
a difference in MOF numbers in immature mice at 3 weeks of age, suggesting that in 
Efna5-/- females MOF formation is not a result of impaired oocyte nest break-down; 
otherwise, differences in MOF levels would be expected in immature mice. Instead, our 
results suggest that the increase in MOF numbers is gonadotropin-dependent, and may 
occur by gonadotropin-dependent merging of single follicles. Follicle merging has been 
proposed to increase the incidence of MOFs in mice harboring an oocyte-specific 
deletion of core-1-β1,3-galactosyl-transferase (C1galt1) (46,47), due to degradation of 
the basal lamina and initiation of aberrant granulosa cell invasion. In Efna5-/- females, we 
speculate that MOF formation may be linked to abnormal follicle rupture. Premature 
rupture of follicles prior to cumulus expansion may result in breaching of the follicle wall 
and permit joining of adjacent follicles, resulting in MOF formation, as in the oocyte-
specific C1galt1 knockout mice (46). 
3.5 Conclusion 
In conclusion, our data indicate that ephrin-A5 is required for optimal reproductive 
function in female mice. Its absence results in reduced fertility and a partially impaired 
response to hCG, which includes attenuated ovarian expression of Pgr, Ptgs2, and 
Adamts4, follicle rupture defects, and reduced ovulatory capacity. Ephrin-A5 plays an 
important and previously-unidentified role in the normal function of the mouse ovary, 
and we speculate that defective ovarian ephrin-A5 signaling accounts for some 
incidences of idiopathic infertility in women. 
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4 Chapter 4: Cyclic AMP stimulates PKA-dependent 
transcriptional activation of the mouse Epha5 upstream 
genomic region in the KGN granulosa cell line 
4.1 Introduction 
Eph receptors, encoded by Eph genes, comprise the largest known family of 
receptor tyrosine kinases (RTKs) and interact with ligands known as ephrins, which are 
encoded by Efn genes. The entire family of Eph receptors and ephrins is classified into 
two subclasses, A or B, based on receptor-ligand affinity and amino acid sequence 
similarity (1). In general, A-class receptors have greater affinity for A-class ephrins than 
for B-class ephrins, and B-class receptors have greater affinity for B-class ephrins than 
for A-class ephrins. Receptor-ligand interaction is promiscuous within classes, although 
inter-class promiscuity has been reported (2). All Eph receptors and ephrins are 
membrane-associated, and therefore Eph-ephrin signaling is initiated at points of cell-cell 
contact. Furthermore, as membrane-associated signaling elements, both Eph receptors 
and ephrins may transmit signals via their cytoplasmic domains and/or by association 
with other transmembrane signaling proteins. Eph-ephrin signaling has been studied 
primarily in the context of embryonic development, particularly in axon guidance and 
tissue segmentation (3,4). 
Despite progress in understanding Eph receptor and ephrin function, relatively little 
is known about regulation of the genes encoding them. Much of the knowledge of Eph 
and Efn transcriptional regulation emerged from efforts to understand patterns of 
expression during embryonic development. As a result, many transcriptional regulators of 
Eph and Efn expression identified thus far are well-known regulators in embryonic 
development. For example, homeobox (Hox) genes have been implicated in controlling 
Eph and Efn expression during embryonic morphogenesis (5). Chick brain factor 1, 
encoded by Cbf1, regulates expression of Efna2, Efna5, and Epha3 during axon guidance 
in the chick (6), while NFYA (nuclear transcription factor Y, alpha), MEIS1 (myeloid 
ecotropic viral integration site), and MAZ (Myc-associated zinc finger protein) regulate 
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Efnb2 expression during prenatal angiogenesis in mice (7). NF-Y has also been 
implicated in regulating EFNA4 expression in human lymphocytes (8). 
Furthermore, the expression of numerous Eph and Efn genes is dysregulated in cancer, 
where this dysregulation has been associated with tumour-promoting and suppressing 
activity (9). For example, Epha2 is upregulated in some human cancers, and its 
downregulation has been associated with decreased tumour growth and prolonged 
survival in some animal models (10). Expression of EFNA1 and EFNA5 in ovarian 
tumors negatively correlates with patient survival (11). In contrast, Ephb4 behaves as a 
tumor suppressor during intestinal tumorigenesis in a mouse model (12). Moreover, it 
was recently reported that the Eph receptor complement expressed by a cancer cell can, 
depending on ephrin expression in the surrounding tissue, determine its invasiveness 
(13). Therefore, an improved understanding of the mechanisms underlying Eph and Efn 
transcriptional regulation has implications for both developmental and cancer biology. 
While our knowledge of Eph and Efn expression in adult ovarian function is sparse, 
several reports have indicated that expression of Eph and Efn genes in the adult ovary 
changes during follicle growth. Esr2-/- females, which lack estrogen receptor beta (ERβ), 
exhibit impaired expression of multiple FSH-responsive genes in granulosa cells (GCs), 
including Efna5 (14). We previously reported that several genes that encode members of 
the Eph-ephrin family are upregulated in GCs of female mice treated with equine 
chorionic gonadotropin (eCG) (15) a horse-derived gonadotropin with FSH receptor 
(FSHR)-stimulating activity in rodents. Furthermore, expression of EFNA5 and EPHB6 is 
higher in large antral follicles than in small follicles in the cow, suggesting that FSH may 
also regulate expression of Eph and Efn genes in other species (16). In addition to 
suggesting a role for Eph-ephrin signaling in FSH-dependent follicle growth and/or 
ovulation, these data also provide insight into the transcriptional regulation of Eph and 
Efn genes. 
We previously reported that Efna5, Epha3, Epha5, Epha8, and Ephb2 are 
upregulated in mouse GCs following treatment with eCG (15). The FSHR is an integral 
Gs protein-coupled receptor composed of a FSH-binding extracellular domain, a 
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membrane-spanning domain composed of 7 transmembrane helices, and a cytoplasmic 
domain (17). Expressed in GCs of secondary and larger follicles (18), it is one of two 
gonadotropin receptors in mammals, the other being the luteinizing hormone receptor 
(LHR). Binding of FSH to the FSHR extracellular domain results in Gs protein activation, 
which in turn activates adenylate cyclase and catalyzes the hydrolysis of adenosine 
triphosphate (ATP) to generate the second messenger cyclic adenosine monophosphate 
(cAMP) (19). In GCs of many species, elevation of cytoplasmic cAMP concentration 
favours activation of protein kinase A (PKA) and its downstream pathways, including 
those that modulate gene expression (20). Therefore, activation of many genes 
downstream of FSHR activation is dependent on cAMP-associated pathways. The 
promoters of some cAMP-responsive genes are activated by cis-regulatory sequences 
known as cAMP-responsive elements (CREs), which have a consensus sequence of 5’-
TGACGTCA-3’ (full CRE) or 5’-CGTCA-3’ or 5’-TGACG-3’ (half CRE) (21). 
Estrogen receptors are nuclear hormone receptors, of which there are two forms. 
Within the ovary in mice, ERα localizes primarily to thecal and interstitial cells and is 
encoded by the Esr1 gene. ERβ is localized primarily to GCs and is encoded by the Esr2 
gene. That action of estrogens is mediated predominantly by ERα and ERβ, which bind 
estrogens and effect changes in the transcriptional activity of target genes. Esr2-/- females 
exhibit a severe reproductive phenotype that includes subfertility and impaired formation 
of antral follicles (22). GCs from Esr2-/- mice also exhibit suboptimal production of 
cAMP, a defect thought to contribute to dysregulation of FSH-responsive genes 
following treatment with FSH (14). Therefore, there is evidence suggesting that Eph and 
Efn expression in GCs changes during FSH-dependent follicle growth and is regulated by 
cAMP. Transcriptional regulation of any Eph or Efn genes by cAMP-dependent pathways 
has not been previously described in GCs or in any other model system. Therefore, we 
investigated the role of cAMP-dependent regulation in regulating Epha5 transcription in 
GCs. In particular, we focused on cAMP-dependent regulation of Epha5 transcription in 
GCs. 
In order to investigate regulation of Eph and Efn genes by cAMP, we assessed 
expression of Efna5, Epha3, Epha5, Epha8, and Ephb2 in GCs of Esr2-/- mice. In order to 
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evaluate responsiveness of the Epha5 putative promoter region to cAMP, we then 
generated a luciferase reporter construct (Epha5-Luc) containing the mouse genomic 
sequence from -1589 to +23 relative to the start of the Epha5 5’ UTR (+1). Using this 
construct with dibutyryl-cAMP and a PKA inhibitor, we investigated activation of the 
Epha5 promoter region in a human tumour-derived GC line. Furthermore, we used site-
directed mutagenesis to generate a function-disrupting point mutation in a putative CRE 
half-site within Epha5-Luc. 
4.2 Materials and Methods 
4.2.1 Cell culture and transfections 
The KGN cell line was derived from a human stage 3 GC carcinoma (23,24). KGN 
cells were maintained in Dulbecco modified Eagle medium/F-12 (DMEM/F12; Wisent) 
containing 10% fetal bovine serum (FBS; Wisent) at 37°C in 5% CO2. 
Twenty-four hours prior to transfection, KGN cells were seeded into 24-well plates 
at a density of 9.5 × 104 cells/well. Eight hours later, the culture medium was replaced 
with DMEM/F12 containing 10% charcoal-stripped fetal bovine serum (CS-FBS; 
Wisent). Sixteen hours later, transfections were performed using FuGENE HD (Promega) 
with a reagent:plasmid ratio of 5:2 (µL FuGENE HD:µg DNA) at 0.5 µg total plasmid 
per well (490 ng firefly luciferase reporter plasmid and 10 ng Renilla luciferase control 
plasmid). Transfection mix was prepared according to the manufacturer’s instructions 
(Promega). In all luciferase reporter studies, controls included KGN cells transfected with 
pGL3-basic (promoter-less vector) to establish that increases in luciferase activity were 
specific to the Epha5-Luc plasmid (pGL3-basic plasmid containing the mouse genomic 
sequence -1589 to +23 bp relative to the start of the Epha5 5’ UTR). Furthermore, 
controls also included KGN cells transfected with a known cAMP-responsive luciferase 
plasmid (CRE-Luc) obtained as a gift from Dr. Nathalie di Clemente (Institut National de 
la Santé et de la Recherche Médicale, Clamart, France). 
For qRT-PCR studies with KGN cells, human recombinant FSH was obtained from 
Dr. A.F. Parlow (National Hormone and Peptide Program, National Institute of Diabetes 
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and Digestive and Kidney Diseases, USA). Recombinant FSH was reconstituted in sterile 
water to a concentration of 50 ng/mL and stored at -80°C. 
For experiments involving the PKA inhibitor H-89 (Cell Signaling), H-89 was 
reconstituted in dimethyl sulfoxide (DMSO) to a concentration of 20 mM and stored at -
20°C. Cells were pre-treated with H-89 at a final concentration of 20 µM, 1:1000 v/v 
DMSO, or with an equal volume of DMSO (1:1000 v/v) for 30 minutes. Both H-89- and 
DMSO-treated KGN cells were treated with dbcAMP at a final concentration of 1.0 mM 
for 24 hours. 
4.2.2 Mice 
Experiments were performed in compliance with the guidelines set by the Canadian 
Council for Animal Care and the policies and procedures approved by The University of 
Western Ontario Council on Animal Care. Investigations were conducted in accordance 
with the National Research Council's Guide for Care and Use of Laboratory Animals 
(Protocol # 2008-047-02). C57BL/6 female mice (Postnatal Day [PND] 23–28) were 
used in all experiments. For quantitative RT-PCR (qRT-PCR) studies, mice were treated 
either with saline or with 5.0 IU eCG (Sigma Chemical Co.) for 48 h before isolation of 
GCs. 
4.2.3 Isolation of GCs 
48 h after treatment with saline or eCG, mice were euthanized by CO2 asphyxiation 
and whole ovaries were harvested into a 100 mm cell culture dish containing cold M199 
medium supplemented with 1 mg/mL of bovine serum albumin (BSA), 2.5 µg/mL of 
amphotericin B, and 50 µg/mL of gentamicin (all reagents from Invitrogen). Ovaries 
were pooled, and the GCs from each pool were then expressed by manual puncture with 
25-gauge needles followed by pressure applied with a sterile spatula. The GC suspension 
was filtered through a 150-µm Nitex nylon membrane (Sefar America, Inc.) mounted in a 
Swinnex filter (Millipore). The GCs were then pelleted by centrifugation at 250 × g for 5 
min at 4°C followed by two washes in DMEM/F12 medium containing 1% 
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penicillin/streptomycin solution (Invitrogen). The final cell pellet was frozen at −80°C 
for qRT-PCR studies. 
4.2.4 RNA isolation and qRT-PCR 
Frozen pellets of GCs were solubilized in TRIzol (Invitrogen), and RNA was 
isolated according to the manufacturer's protocol. RNA was further treated with DNase I, 
then reverse-transcribed using Superscript II (Invitrogen). Complementary DNA (cDNA) 
levels were detected using qRT-PCR with the ABI PRISM 7900 Sequence Detection 
System (Applied Biosystems) and SYBR Green I dye (Applied Biosystems). Primers 
were generated using Primer Express Software (Version 2.0; Applied Biosystems) (Table 
4-1). Fold-changes in gene expression were determined by quantitation of cDNA from 
target (treated) samples relative to a calibrator sample (vehicle). The gene for ribosomal 
protein L7 (Rpl7 in mouse GCs or RPL7 in KGN cells) was used as the endogenous 
control for normalization of RNA levels. Expression ratios were calculated according to 
the mathematical model described by Pfaffl (25), where ratio = 
(Etarget)ΔCt(target)/(Econtrol)ΔCt(control) and E = efficiency of the primer set, calculated from the 
slope of a standard curve of log(ng of cDNA) versus cycle threshold (Ct) for a sample 
that contains the target according to the formula E = 10−(1/slope) and ΔCt = Ct(vehicle) − 
Ct(treated sample). Three independent experiments were carried out for studies using mouse 
GCs, and the results were averaged for statistical analysis by a two-way ANOVA 
followed by a Tukey multiple comparison post-hoc test (Tukey test) (Figure 4-1). Two 
independent experiments were carried out for studies using KGN cells, and the results 
were averaged for statistical analysis by a two-tailed unpaired Student t-test (Figure 
4-4A). 
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Table 4-1: Primers used for qRT-PCR in Figure 4-1 and Figure 4-4. 
Gene GenBank 
accession no. Forward (5' to 3') Reverse (5' to 3') 
Mouse    
Rpl7 NM_011291 AGCTGGCCTTTGTCATCAGAA GACGAAGGAGCTGCAGAACCT 
Efna5 NM_207654 TCTGCAATCCCAGACAACGGAAGA TCATGTACGGTGTCATCTGCTGGT 
Epha3 NM_010140 CCGCAGTCAGCATCACAACT TTTCTGGAAGTCCGATCTTTCTTAA 
Epha5 NM_007937 GCTGGTTCCCATTGGGAAAT CACATTGGTGACTGGAGAAGGA 
Epha8 NM_007939 CTCGGATGAAGAGAAGATGCATT TGGTTCAAGGGCAAGAAGACA 
Ephb2 NM_010142 ACCTCAGTTCGCCTCTGTGAA GGCTCACCTGGTGCATGAT 
Human    
RPL7 NM_000971 AAATTGGCGTTTGTCATCAGAA AAGAAGCTGCAACACCTTTCG 
EPHA5 NM_004439 AGGCAGGATATGAAGAGAAAAATGG ATTTGCCGCAGCTCTGGAT 
 NM_182472   
 NM_001281765   
 NM_001281766   
 NM_001281767   
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4.2.5 Immunoblotting 
Protein lysates were generated in a 1.5 mL microcentrifuge tube by homogenizing a 
GC pellet in ice-cold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl 
[pH 8.0], 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS) 
supplemented with a protease inhibitor cocktail (1:100; P8340; Sigma). Lysates were 
then centrifuged at 15 000 × g for 20 min at 4°C. The supernatant was boiled in Laemmli 
buffer for 5 min and then analyzed using SDS-PAGE. The separated proteins were 
transferred to a polyvinylidene fluoride membrane at 100 V (constant voltage) for 2 h at 
4°C. After blocking for 1 h in Tris-buffered saline and Tween 20 (TBST)/5% nonfat milk, 
the membrane was probed with a monoclonal IgG specific to ephrin-A5 (1:200 in 
TBST/5% nonfat milk; ab60705; Abcam). The membrane was then probed with an anti-
mouse horseradish peroxidase-conjugated IgG generated in donkey (1:10 000 in 
TBST/5% nonfat milk) and visualized using ECL Plus (Amersham Biosciences) and 
Hyperfilm (Amersham). To assess equal protein loading, the membrane was subsequently 
probed using a rabbit monoclonal IgG to detect alpha-tubulin (TUBA1A, T5168; Sigma). 
4.2.6 Generation of the Epha5-Luc luciferase reporter plasmid 
The genomic sequence upstream of Epha5 was amplified by PCR using Phusion 
High-Fidelity DNA Polymerase (New England Biolabs), using the following primer 
sequences (5’  3’): Forward: AGAGGCCACCGAACTGCCCA, Reverse: 
GCTCGCTCGCTCCTGCTGTG. Amplification was performed using a bacterial artificial 
chromosome template containing the mouse genomic region of interest (NCBI clone 
RP23-331O22, Clone ID # 705829) obtained from The Centre for Applied Genomics, 
The Hospital for Sick Children, Toronto, Canada. This yielded a 1589 bp amplification 
product that was digested using the KpnI and XhoI restriction enzymes, yielding a 1571 
bp digestion product. The pGL3-basic plasmid was also digested using KpnI and XhoI. 
Both digestion fragments were purified by agarose gel extraction and then ligated, 
yielding the 6362 bp Epha5-Luc luciferase reporter plasmid. Plasmid minipreps were 
prepared using 5 mL bacterial cultures grown from transformed colonies, and sent for 
sequencing (Robarts Research Institute, The University of Western Ontario). 
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4.2.7 Generation of the mutEpha5-Luc luciferase reporter plasmid by site-directed 
mutagenesis 
In order to assess whether a conserved CRE half-site located at -389 bp relative to 
the start of the mouse Epha5 5’ UTR (Figure 4-2 and Figure 4-3) was required for 
transcriptional activation of Epha5-Luc by cAMP, the QuikChange XL site-directed 
mutagenesis kit (Agilent) was used to substitute two nucleotides in the CRE half-site to 
disrupt function (TGACG  TGATC). This strategy has been previously used to disrupt 
CRE half-site function in a construct containing part of the Tcl1 mouse promoter (26). 
QuikChange primers were designed using the QuikChange Primer Design Tool 
(http://www.genomics.agilent.com/primerDesignProgram.jsp). 
Forward (5’  3’): agagcctgtgaatgtgctgttatatgatcacaaggttgttggt. 
Reverse: (5’  3’): accaacaaccttgtgatcatataacagcacattcacaggctct. 
4.2.8 Dual-luciferase assays 
KGN cells that had been cultured, transfected, and treated in 24-well plates were 
washed twice with PBS and then lysed by adding 105 µL Passive Lysis Buffer (Promega) 
to each well followed by rocking at room temperature for 15 min. 100 µL of each lysate 
was transferred to 1.5 mL microcentrifuge tubes and centrifuged at 12 000 g for 15 
seconds to pellet loose debris. 20 µL of each lysate was transferred to a white, opaque 96-
well plate (82050-726; VWR) and assessed for firefly and Renilla luciferase activity 
using the Dual-Luciferase Assay (E1960; Promega). Fluorescence was measured using a 
Synergy H4 Microplate Reader (Biotek). 
4.3 Results 
4.3.1 Induction of FSH-responsive Efn and Eph genes is reduced in GCs of Esr2-/- mice 
We previously reported that eCG enhances expression of Efna5, Epha3, Epha5, 
Epha8, and Ephb2 in mouse GCs (15). In order to determine whether eCG-stimulated 
expression of FSH-responsive Efn and Eph genes is altered in mice that exhibit impaired 
production of cAMP, we assessed mRNA transcript levels for these genes in GCs of 
eCG-treated, reproductively immature Esr2-/- mice. PND 23-28 Esr2+/+ and Esr2-/- 
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females were treated with saline or 5.0 IU eCG (48 h) and GCs were harvested. Relative 
mRNA transcript abundance was determined by qRT-PCR for Efna5, Epha3, Epha5, 
Epha8, and Ephb2. In GCs of eCG-treated Esr2+/+ females, we observed 3-, 2.5-, 5.2-, 
3.7-, and 2.7-fold increases in mRNA levels, respectively, for these genes compared to 
saline-treated controls. In GCs of eCG-treated Esr2-/- females, we did not detect changes 
in mRNA levels for any of these genes (Figure 4-1). Protein levels for ephrin-A5 were 
lower in GCs from Esr2-/- compared to Esr2+/+ females (Supplemental Figure 6-4). 
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Figure 4-1: Induction of FSH-responsive Efn and Eph genes by eCG is significantly 
reduced in Esr2-/- GCs. 
Relative transcript abundance compared to Rpl7 (mean ±SEM) was determined by qRT-
PCR in GCs of eCG-treated females for Efna5 (A), Epha3 (B), Epha5 (C), Epha8 (D), 
and Ephb2 (E). A) Efna5. A two-way ANOVA found a significant effect for treatment, F 
(1, 8) = 35.09, P = 0.0004; a significant effect for genotype, F (1, 8) = 79.47, P < 0.0001; 
and a significant interaction, F (1, 8) = 28.92, P = 0.0007. A Tukey test revealed a 
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, ***, P = 0.0002. B) 
Epha3. A two-way ANOVA found a significant effect for treatment, F (1, 8) = 16.78, P = 
0.0035; a significant effect for genotype, F (1, 8) = 24.03, P = 0.0012; and a significant 
interaction, F (1, 8) = 25.43, P = 0.0010. Tukey's multiple comparisons test revealed a 
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, ***, P = 0.0009. C) 
A B
C D
E
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Epha5. A two-way ANOVA found a significant effect for treatment, F (1, 8) = 22.85, P = 
0.0014; a significant effect for genotype, F (1, 8) = 21.82, P = 0.0016; and a significant 
interaction, F (1, 8) = 10.57, P = 0.0117. Tukey's multiple comparisons test revealed a 
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, **, P = 0.0021. D) 
Epha8. A two-way ANOVA found a significant effect for treatment, F (1, 8) = 26.25, P = 
0.0009; a significant effect for genotype, F (1, 8) = 53.72, P < 0.0001; and a significant 
interaction, F (1, 8) = 22.95, P = 0.0014. Tukey's multiple comparisons test revealed a 
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, ***, P = 0.0005. E) 
Ephb2. A two-way ANOVA found a significant effect for treatment, F (1, 8) = 11.00, P = 
0.0106; a significant effect for genotype, F (1, 8) = 24.87, P = 0.0011; and a significant 
interaction, F (1, 8) = 21.11, P = 0.0018. Tukey's multiple comparisons test revealed a 
significant difference between eCG-treated Esr2+/+ and Esr2-/- mice, **, P = 0.0023. 
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4.3.2 Epha5-Luc is transcriptionally activated by cAMP in KGN cells 
In order to determine whether the proximal genomic region upstream of Epha5 is 
responsive to cAMP, we carried out a promoter-reporter (luciferase) assay. We generated 
a luciferase reporter construct (Epha5-Luc) containing the mouse genomic sequence from 
-1589 to +23 bp relative to the start of the Epha5 5’ UTR, inserted upstream of the 
luciferase gene (Figure 4-2). This plasmid was then transfected into KGN cells, a cell 
line derived from a human GC tumor (23). In KGN cells treated with FSH, we observed a 
significant 2.5-fold increase in endogenous EPHA5 mRNA levels compared to vehicle-
treated cells (p=0.0099) (Figure 4-4A). KGN cells transfected with Epha5-Luc reporter 
plasmid were co-transfected with the pRL-SV40 Renilla luciferase control plasmid, and 
were treated with 1.0 mM dibutyryl-cAMP (dbcAMP), a cell membrane-permeable form 
of cAMP, for 24 hours. Cells were then lysed and luciferase activity was measured. In 
KGN cells treated with dbcAMP, we observed a 56% increase in normalized luciferase 
activity compared to vehicle-treated cells (p=0.0461) (Figure 4-4B). 
4.3.3 cAMP-stimulated activation of Epha5-Luc is reduced by co-treatment with H-89 
Elevated intracellular concentration of cAMP is known to activate several PKA-
independent pathways, such as RAPGEF3 (Rap guanine nucleotide exchange factor 3) 
and RAPGEF4 (Rap guanine nucleotide exchange factor 4) (27,28), as well as PKB 
(protein kinase B) (29). In order to determine whether activation of Epha5-Luc by 
dbcAMP in KGN cells was PKA-dependent or PKA-independent, we used the PKA 
inhibitor H-89. KGN cells transfected with Epha5-Luc were co-treated with 1.0 mM 
dbcAMP (24 h) and either DMSO (vehicle control, 1:1000 v/v) or 20 µM H-89 (in 
DMSO, 1:1000 v/v). In DMSO-treated cells, we observed a 2.3-fold cAMP-induced 
enhancement of normalized luciferase activity (p=0.0143) (Figure 4-5A). In the presence 
of 20 µM H-89, this enhancement was reduced (Figure 4-5B). 
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Figure 4-2: A putative consensus CRE half-site upstream of Epha5 is conserved 
across several species. 
The genomic sequence from -5000 to +1 bp relative to the start of the Epha5 5’ UTR 
from several species was aligned using Multiple Alignment using Fast Fourier Transform 
(http://mafft.cbrc.jp/alignment/software) (A) and T-Coffee (http://www.tcoffee.org) (B). 
The putative CRE half-site at -389 bp is highlighted in yellow. “cons” = conserved 
nucleotides. 
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Figure 4-3: Generation of the Epha5-Luc luciferase reporter construct. 
The 1589 bp genomic region upstream of the mouse Epha5 5’ UTR (+1) was amplified, 
digested with KpnI and XhoI restriction enzymes, and then ligated into the pGL3-basic 
luciferase reporter plasmid to assess capacity to drive transcription of luc+ (luciferase). A 
putative consensus CRE half-site is present (-389). The Epha5-Luc plasmid map was 
generated using Geneious Pro Trial. 
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Figure 4-4: Endogenous EPHA5 is induced by FSH, and Epha5-Luc is activated by 
dbcAMP in KGN cells 
Relative transcript abundance for EPHA5 compared to RPL7 (mean ±SEM) was 
determined by qRT-PCR in FSH-treated (24 h) KGN cells (A). Firefly luciferase activity 
normalized to Renilla luciferase activity (mean ±SEM) was determined for water- and 
dbcAMP-treated KGN cells transfected with the Epha5-Luc luciferase reporter construct 
(B). A) A statistically significant difference was found between water- and FSH-treated 
KGN cells as determined by an unpaired, two-tailed Student’s t-test; t(2)=9.967. **, 
p=0.0099. B) A statistically significant difference was found between water- and 
dbcAMP-treated KGN cells as determined by an unpaired, two-tailed Student’s t-test; 
t(4)=2.857. **, p=0.0461. 
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Figure 4-5: Activation of Epha5-Luc by dibutyryl-cAMP is reduced by co-treatment 
with the PKA inhibitor H-89. 
Stimulation of Renilla-normalized firefly luciferase activity (mean ±SEM) was 
determined for dbcAMP-treated (1.0 mM) KGN cells transfected with Epha5-Luc, in the 
absence (A) and presence (B) of H-89 (20 µM). A) A statistically significant difference 
was found between dbcAMP-treated KGN cells transfected with Epha5-Luc in the 
absence of H-89 as determined by an unpaired, two-tailed Student’s t-test; t(4)=4.147. *, 
p=0.0143. B) No statistically significant difference was found between dbcAMP-treated 
KGN cells transfected with Epha5-Luc in the presence of H-89 as determined by an 
unpaired, two-tailed Student’s t-test; t(4)=0.8134. *, p=0.0.4616. 
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4.4 Discussion 
We previously reported that expression of Efna5, Epha3, Epha5, Epha8, and Ephb2 
is increased in GCs isolated from mice treated with eCG (15). Furthermore, microarray 
studies indicate that eCG-stimulated expression of Efna5 is attenuated in GCs of Esr2-/- 
females, which exhibit impaired cAMP production (14). Since eCG stimulates the FSHR, 
which in turn activates responsive genes via cAMP-dependent pathways, we investigated 
the transcriptional regulation of Eph and Efn genes by cAMP in GCs. Transcriptional 
regulation of Eph and Efn genes by cAMP-dependent pathways has not been previously 
described. Here, we present evidence that stimulation of Efna5, Epha3, Epha5, Epha8, 
and Ephb2 by eCG is attenuated in GCs of mice with impaired cAMP production. 
Furthermore, the proximal genomic region upstream of the mouse Epha5 gene is 
responsive to dbcAMP in a PKA-dependent manner. 
4.4.1 hCG-stimulated induction of Efna5, Epha3, Epha5, and Ephb2 is significantly 
reduced in GCs of Esr2-/- mice 
During our investigation into the roles of Eph receptors and ephrins in the mouse 
ovary, we assessed expression of Eph and Efn genes in GCs from eCG-stimulated, 
reproductively immature Esr2+/+ and Esr2-/- females. Esr2 encodes estrogen receptor beta 
(ERβ), the predominant form of estrogen receptor in GCs (22). In addition to subfertility 
and impaired antral follicle formation, eCG-stimulated Esr2-/- mice exhibit attenuated 
expression of Efna5 in GCs compared to Esr2+/- controls. The same study revealed that 
GCs from these mice also exhibit impaired cAMP production (14). 
Since a common mechanism by which FSH enhances expression of its responsive 
genes occurs via cAMP-dependent pathways (20), we first confirmed that Efna5 was 
dysregulated in GCs of eCG-stimulated Esr2-/- females, and determine whether other Efn 
and Eph genes were similarly dysregulated. We found that eCG enhanced expression of 
Efna5, Epha3, Epha5, Epha8, and Ephb2 in Esr2+/+ but not Esr2-/- females. This is 
consistent with the report that GCs from Esr2-/- females exhibit attenuated activation of 
many FSH-responsive genes including Inhba (inhibin beta-A) (Inhba), Hsd3b1 (3-beta-
hydroxysteroiddehydrogenase 1), and Comp (cartilage oligomeric matrix protein) in Esr2-
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/-
 GCs. The same study proposed that a deficiency in cAMP production underlies the 
reduced induction of FSH-responsive genes. In addition, GCs of Esr2-/- females produce 
50% less cAMP in response to the adenylate cyclase activator forskolin, and exhibit 
attenuated phosphorylation of CREB following treatment with FSH, compared to GCs 
from Esr2+/+ mice (14). Therefore, impaired production of cAMP is associated with loss 
of eCG-stimulated Efna5, Epha3, Epha5, Epha8, and Ephb2 expression in mouse GCs. 
4.4.2 The 1589 bp region upstream of Epha5 is transcriptionally activated by cAMP in 
a PKA-dependent manner in KGN cells 
Since FSHR is a Gs protein coupled receptor, its activation results in stimulation of 
adenylate cyclase and an associated elevation of intracellular cAMP concentration (20). 
In GCs, the major downstream target of cAMP seems to be PKA, although PKA-
independent targets including cAMP-dependent guanine exchange factors (27,28) and 
protein kinase B (PKB) (29) may also mediate the response to FSH. 
PKA is a serine-threonine protein kinase that is composed of two catalytic and two 
regulatory subunits. In the inactive state, kinase activity of the catalytic subunits is 
suppressed by the presence of the regulatory subunits. Elevated levels of cAMP favour 
disengagement of the regulatory subunits, permitting translocation of the catalytic 
subunits into the nucleus (30) where PKA alters the activity of target proteins by 
phosphorylation. One target of PKA in the nucleus is cAMP response element binding 
protein (CREB), a member of the basic region leucine zipper (bZIP) family of DNA-
binding proteins. Upon stimulation with cAMP, CREB is activated by phosphorylation at 
serine 133 (30). Activated CREB then binds to cis-regulatory elements that are associated 
with cAMP-responsive genes and recruits CREB-binding protein (CBP), a transcriptional 
coactivator. These cis-regulatory sequences are known as cAMP-responsive elements 
(CREs), and have a consensus sequence of 5’-TGACGTCA-3’ (full CRE) or 5’-CGTCA-
3’ or 5’-TGACG-3’ (half CRE) (21). These sequences are typically found near the 
transcriptional start site, with ~60% of consensus CREs and variants found within 500 bp 
of the 5’ UTR (31). Other transcriptional regulators known to bind CREs include the 
transcriptional activator activating transcription factor 1 (ATF1) and the transcriptional 
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repressor cAMP responsive element modulator (CREM). However, the current body of 
evidence suggests that CREB is the primary CRE-binding protein in most cell types (32). 
Among the FSH-responsive genes transcriptionally regulated via CREB in GCs is 
Cyp19a1, which encodes the enzyme CYP19A1 (cytochrome P450, family 19, subfamily 
A, polypeptide 1), commonly referred to as aromatase. CYP19A1 catalyzes the 
aromatization of testosterone and androstenedione, and is the rate-limiting step in the 
synthesis of estradiol in biological systems. Furthermore, increased Cyp19a1 expression 
and elevated estradiol production are hallmarks of FSH-induced GC differentiation (33). 
CREB directly binds the rat promoter region of the rat Cyp19a1 gene (34). Furthermore, 
binding of CREB to a CRE in the human CYP19A1 promoter region is required for 
cAMP-dependent activation of this region (35). We examined the genomic region 
upstream of the mouse Epha5 gene and identified a putative consensus CRE half-site 
located 389 bp upstream of the 5’ UTR that was conserved in multiple species (Figure 
4-2). 
We postulated that this CRE half-site is required for activation of Epha5 by cAMP 
via the PKA pathway. In order to test this idea, we cloned 1589 bp of the mouse genomic 
region upstream of the Epha5 5’-UTR into the pGL3-basic luciferase reporter plasmid, 
generating the Epha5-Luc luciferase reporter construct. We then assessed the capacity of 
this construct to respond to cAMP in KGN cells, a cell line derived from a human GC 
tumor (23). KGN cells have been previously used as a model system to study the 
regulation of CYP19A1 by FSH and cAMP (36). We observed that treatment with FSH 
increased endogenous expression of EPHA5 in KGN cells (Figure 4-4A), which is 
consistent with our previous finding that Epha5 is a FSH-responsive gene in mouse GCs 
(15). We then found that treatment with dbcAMP increased luciferase activity in KGN 
cells transfected with Epha5-Luc (Figure 4-4B), indicating that the 1589 bp genomic 
region upstream of Epha5 is responsive to cAMP. 
Since cAMP is known to activate several targets other than PKA (27-29), we then 
determined whether activation of Epha5-Luc by dbcAMP was PKA-dependent or PKA-
independent. In order to make this distinction, we co-treated KGN cells transfected with 
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Epha5-Luc with dbcAMP and the PKA inhibitor H-89. Co-treatment with H-89 
attenuated activation of Epha5-Luc by dbcAMP (Figure 4-5), indicating that activation 
was PKA-dependent. It should be noted that while H-89 is a widely-used PKA inhibitor, 
it is known to effectively inhibit at least 7 other kinases (37). Therefore, the possibility 
that H-89 inhibits other targets should be considered. Future studies investigating 
regulation of Eph and Efn genes by cAMP-dependent pathways should include other H-
89 specific inhibitors that exhibit reduced cross-inhibition, such as the commercially 
available molecule Rp-cAMPS (38). 
In order to test whether stimulation of the Epha5-Luc construct by dbcAMP was 
dependent on the CRE half-site 389 bp upstream of the Epha5 5’ UTR, we used site-
directed mutagenesis to introduce two CRE-disrupting base pair substitutions into the 
site, generating the mutEpha5-Luc luciferase reporter construct, which we will use in 
future studies of Epha5 regulation. Current studies (Supplemental Figure 6-5) using the 
mutEpha5-Luc construct have been unsuccessful due to difficulties with transfections that 
occurred after a change in reagent suppliers. Re-optimization of transfection conditions 
are ongoing. 
Our findings indicate that in GCs, cAMP transcriptionally activates the proximal 
upstream genomic region of Epha5 in a PKA-dependent manner. Given the observation 
that induction of FSH-responsive Efn and Eph genes by eCG is reduced in GCs of mice 
that exhibit impaired cAMP production, it is reasonable to speculate that Efna5, Epha3, 
Epha5, Epha8, and Ephb2 are regulated in a similar manner in GCs. In other tissues, 
hormones such as thyroid-stimulating hormone (TSH) in the thyroid gland and 
adrenocorticotrophic hormone (ACTH) in the adrenal cortex stimulate their respective 
GPCRs, resulting in elevated cAMP concentrations. Activation of these and other Gs 
protein-associated signaling pathways may stimulate Efn and Eph expression, and their 
associated physiological processes may involve Eph-ephrin signaling. 
Regulation of Eph and Efn genes by FSH may also be important in cancer. FSHR 
mRNA has been detected in a large percentage of ovarian epithelial inclusions and 
ovarian epithelial tumors (OETs) (39), while FSHR protein is detected in endothelial 
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cells from a wide range of tumors, and may be involved in tumour angiogenesis (40). 
Furthermore, overexpression of FSHR in cultured MCV152 OET cells increases cell 
proliferation and invasiveness (41). These reports suggest that cAMP-dependent 
enhancement of Eph and Efn expression may be involved in the formation, invasiveness, 
and growth of such FSHR-expressing tumors, particularly in light of the evidence 
indicating that Eph and Efn dysregulation is common in cancer (9). 
4.4.3 Conclusion 
Taken together, our findings indicate that in GCs, Epha5 expression is induced by 
FSH via the cAMP-dependent PKA pathway. Our findings in Esr2-/- mice suggest the 
possibility that Efna5, Epha3, Epha8, and Ephb2 are similarly regulated. Thus, PKA 
represents a novel upstream regulator of Epha5, and potentially other members of the 
Eph-ephrin family, in GCs. 
  
129 
 
4.5 Bibliography 
1. Himanen JP, Nikolov DB. Eph signaling: a structural view. Trends in 
neurosciences. 2003;26(1):46-51. 
2. Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, Vearing 
C, Geleick D, Feldheim DA, Boyd AW, Henkemeyer M, Nikolov DB. Repelling 
class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. 
Nat Neurosci. 2004;7(5):501-509. 
3. Cayuso J, Xu Q, Wilkinson DG. Mechanisms of boundary formation by Eph 
receptor and ephrin signaling. Dev Biol. 2014. 
4. Laussu J, Khuong A, Gautrais J, Davy A. Beyond Boundaries - Eph:Ephrin 
Signaling in Neurogenesis. Cell adhesion & migration. 2014:0. 
5. Arvanitis DN, Davy A. Regulation and misregulation of Eph/ephrin expression. 
Cell adhesion & migration. 2012;6(2):131-137. 
6. Takahashi H, Shintani T, Sakuta H, Noda M. CBF1 controls the retinotectal 
topographical map along the anteroposterior axis through multiple mechanisms. 
Development. 2003;130(21):5203-5215. 
7. Sohl M, Lanner F, Farnebo F. Characterization of the murine Ephrin-B2 
promoter. Gene. 2009;437(1-2):54-59. 
8. Munthe E, Aasheim HC. Characterization of the human ephrin-A4 promoter. The 
Biochemical journal. 2002;366(Pt 2):447-458. 
9. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and 
beyond. Nat Rev Cancer. 2010;10(3):165-180. 
10. Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. 
Expert opinion on therapeutic targets. 2005;9(6):1179-1187. 
11. Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S, 
Lincoln D, Boyle G, Parsons PG, Boyd AW. Over-expression of Eph and ephrin 
genes in advanced ovarian cancer: ephrin gene expression correlates with 
shortened survival. BMC cancer. 2006;6:144. 
12. Dopeso H, Mateo-Lozano S, Mazzolini R, Rodrigues P, Lagares-Tena L, Ceron J, 
Romero J, Esteves M, Landolfi S, Hernandez-Losa J, Castano J, Wilson AJ, 
Ramon y Cajal S, Mariadason JM, Schwartz S, Jr., Arango D. The receptor 
tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. 
Cancer research. 2009;69(18):7430-7438. 
13. Astin JW, Batson J, Kadir S, Charlet J, Persad RA, Gillatt D, Oxley JD, Nobes 
CD. Competition amongst Eph receptors regulates contact inhibition of 
locomotion and invasiveness in prostate cancer cells. Nat Cell Biol. 
2010;12(12):1194-1204. 
14. Deroo BJ, Rodriguez KF, Couse JF, Hamilton KJ, Collins JB, Grissom SF, 
Korach KS. Estrogen receptor beta is required for optimal cAMP production in 
mouse granulosa cells. Molecular endocrinology. 2009;23(7):955-965. 
130 
 
15. Buensuceso AV, Deroo BJ. The ephrin signaling pathway regulates morphology 
and adhesion of mouse granulosa cells in vitro. Biol Reprod. 2013;88(1):25. 
16. Hatzirodos N, Irving-Rodgers HF, Hummitzsch K, Harland ML, Morris SE, 
Rodgers RJ. Transcriptome profiling of granulosa cells of bovine ovarian follicles 
during growth from small to large antral sizes. BMC genomics. 2014;15:24. 
17. Rajkovic A, Pangas SA, Matzuk MM. Chapter 10 - Follicular Development: 
Mouse, Sheep, and Human Models. In: Wassarman JDNMPWPRGCMdKSRM, 
ed. Knobil and Neill's Physiology of Reproduction (Third Edition). St Louis: 
Academic Press; 2006:383-423. 
18. Bianchi E, Barbagallo F, Valeri C, Geremia R, Salustri A, De Felici M, Sette C. 
Ablation of the Sam68 gene impairs female fertility and gonadotropin-dependent 
follicle development. Human molecular genetics. 2010;19(24):4886-4894. 
19. Johnson GL, Dhanasekaran N. The G-protein family and their interaction with 
receptors. Endocr Rev. 1989;10(3):317-331. 
20. Hunzicker-Dunn M, Maizels ET. FSH signaling pathways in immature granulosa 
cells that regulate target gene expression: branching out from protein kinase A. 
Cell Signal. 2006;18(9):1351-1359. 
21. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-
dependent factor CREB. Nature reviews Molecular cell biology. 2001;2(8):599-
609. 
22. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach 
KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice 
lacking estrogen receptor beta. Proceedings of the National Academy of Sciences 
of the United States of America. 1998;95(26):15677-15682. 
23. Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, Saito M, Nomura M, Mukasa C, 
Okabe T, Goto K, Takayanagi R, Kashimura Y, Haji M, Nawata H. Establishment 
and characterization of a steroidogenic human granulosa-like tumor cell line, 
KGN, that expresses functional follicle-stimulating hormone receptor. 
Endocrinology. 2001;142(1):437-445. 
24. Havelock JC, Rainey WE, Carr BR. Ovarian granulosa cell lines. Mol Cell 
Endocrinol. 2004;228(1-2):67-78. 
25. Pfaffl MW. A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acids Res. 2001;29(9):e45. 
26. Kuraishy AI, French SW, Sherman M, Herling M, Jones D, Wall R, Teitell MA. 
TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote 
B cell development and inhibit transformation. Proceedings of the National 
Academy of Sciences of the United States of America. 2007;104(24):10175-10180. 
27. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, 
Housman DE, Graybiel AM. A family of cAMP-binding proteins that directly 
activate Rap1. Science. 1998;282(5397):2275-2279. 
131 
 
28. Chin EC, Abayasekara DR. Progesterone secretion by luteinizing human 
granulosa cells: a possible cAMP-dependent but PKA-independent mechanism 
involved in its regulation. The Journal of endocrinology. 2004;183(1):51-60. 
29. Zeleznik AJ, Saxena D, Little-Ihrig L. Protein kinase B is obligatory for follicle-
stimulating hormone-induced granulosa cell differentiation. Endocrinology. 
2003;144(9):3985-3994. 
30. Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene 
transcription by phosphorylation of CREB at serine 133. Cell. 1989;59(4):675-
680. 
31. Conkright MD, Guzman E, Flechner L, Su AI, Hogenesch JB, Montminy M. 
Genome-wide analysis of CREB target genes reveals a core promoter requirement 
for cAMP responsiveness. Molecular cell. 2003;11(4):1101-1108. 
32. Brindle PK. Chapter 253 - Transcriptional Regulation via the cAMP Responsive 
Activator CREB. In: Dennis RABA, ed. Handbook of Cell Signaling (Second 
Edition). San Diego: Academic Press; 2010:2077-2081. 
33. Couse JF, Hewitt SC, Korach KS. Chapter 15 - Steroid Receptors in the Ovary 
and Uterus. In: Wassarman JDNMPWPRGCMdKSRM, ed. Knobil and Neill's 
Physiology of Reproduction (Third Edition). St Louis: Academic Press; 2006:593-
678. 
34. Fitzpatrick SL, Richards JS. Identification of a cyclic adenosine 3',5'-
monophosphate-response element in the rat aromatase promoter that is required 
for transcriptional activation in rat granulosa cells and R2C leydig cells. 
Molecular endocrinology. 1994;8(10):1309-1319. 
35. Michael MD, Michael LF, Simpson ER. A CRE-like sequence that binds CREB 
and contributes to cAMP-dependent regulation of the proximal promoter of the 
human aromatase P450 (CYP19) gene. Mol Cell Endocrinol. 1997;134(2):147-
156. 
36. Parakh TN, Hernandez JA, Grammer JC, Weck J, Hunzicker-Dunn M, Zeleznik 
AJ, Nilson JH. Follicle-stimulating hormone/cAMP regulation of aromatase gene 
expression requires beta-catenin. Proceedings of the National Academy of 
Sciences of the United States of America. 2006;103(33):12435-12440. 
37. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action 
of some commonly used protein kinase inhibitors. The Biochemical journal. 
2000;351(Pt 1):95-105. 
38. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovascular drug 
reviews. 2006;24(3-4):261-274. 
39. Zheng W, Lu JJ, Luo F, Zheng Y, Feng Y, Felix JC, Lauchlan SC, Pike MC. 
Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and 
inhibition of the effect by luteinizing hormone. Gynecologic oncology. 
2000;76(1):80-88. 
132 
 
40. Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, 
Hai MT, Ghinea N. Expression of follicle-stimulating hormone receptor in tumor 
blood vessels. The New England journal of medicine. 2010;363(17):1621-1630. 
41. Zhang Z, Jia L, Feng Y, Zheng W. Overexpression of follicle-stimulating 
hormone receptor facilitates the development of ovarian epithelial cancer. Cancer 
letters. 2009;278(1):56-64. 
 
133 
 
5 Chapter 5: Discussion 
5.1 Summary 
Previous studies have reported detection of numerous Eph and Efn mRNA 
transcripts (1-4) and protein (5) in the ovary, suggesting that Eph-ephrin signaling plays a 
role in ovarian function. The first evidence indicating a functional role in fertility was a 
microarray screen of genes dysregulated in granulosa cells (GCs) of Esr2-/- mice, which 
are subfertile and exhibit impaired antral follicle growth and ovulation (6). Among the 
FSH-responsive genes dysregulated in GCs of these mice is Efna5 (4), suggesting that 
altered expression of this gene contributes to their ovarian phenotype. Based on these 
reports, we hypothesized that Efna5 is required for optimal gonadotropin-dependent 
follicle growth and ovulation in the mouse. 
This thesis presents findings gathered over the course of this investigation, 
beginning with a characterization of Eph and Efn expression in mouse GCs and 
confirmation that these cells are competent to respond to stimulation with recombinant 
ephrin-A5 and EphA5 in culture, which induce altered morphology and reduced 
adhesion, respectively. Based on study of a mouse model that lacks ephrin-A5, we 
present evidence that this ephrin is required for optimal fertility and a complete ovarian 
response to human chorionic gonadotropin (hCG). Specifically, loss of ephrin-A5 impairs 
follicle rupture and alters expression of several genes thought to be involved in oocyte 
release. Furthermore, we use a luciferase reporter system in a GC line to demonstrate that 
the cAMP-dependent PKA pathway regulates transcription of the mouse Epha5 gene. We 
also present evidence indicating that stimulation of FSH-responsive Eph and Efn genes is 
attenuated in GCs of Esr2-/- mice, which exhibit impaired cAMP production. This 
suggests that Efna5, Epha3, Epha8, and Ephb2 are regulated in a similar manner. 
Therefore, our findings indicate that in the mouse, FSH enhances expression of Efna5, 
Epha3, Epha5, Epha8, and Ephb2. Efna5 is required for a complete response to LH, and 
its loss results in reduced expression of several genes involved in ovulation and is 
associated with impaired follicle rupture. The evidence presented in this thesis establishes 
a place for Eph receptors and ephrins within the current model of gonadotropin-
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dependent follicle growth and ovulation in the mouse, and identifies the cAMP-
dependent PKA pathway as a novel regulator of Epha5 transcription. 
5.2 Expression of Efna5, Epha3, Epha5, Epha8, and Ephb2 is enhanced in GCs 
of mice stimulated with equine chorionic gonadotropin (FSH) 
Prior to our investigation, several studies reported Eph and Efn expression in the 
ovary. EPHB1, EPHB2, EPHB4, EFNB1, and EFNB2 mRNA transcripts were detected in 
the human corpus luteum by RT-PCR (1) and beta-galactosidase-linked EFNB2 protein 
was localized to blood vessels of the mouse thecal layer and corpus luteum by X-gal (5-
bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) staining (5). Moreover, mRNA 
transcripts for Epha1, Epha2, Ephb1, and Ephb3 were reported to be more abundant in 
dominant follicles compared to subordinate follicles in the cow (3). However, these 
studies did not investigate Efn and Eph expression in the context of a fertility-
compromised or FSH-stimulated animal model. The report that Efna5 is dysregulated in 
GCs isolated from FSH-stimulated (and subfertile) Esr2-/- mice (4) suggested that Eph-
ephrin signaling contributes to optimal fertility. 
Since ephrins initiate signaling upon interaction with cognate Eph receptors, we 
surmised that GCs are likely to express Eph genes, which encode Eph receptors. In 
Chapter 2, we detected mRNA transcripts for numerous Eph and Efn genes in GCs of 
saline-treated mice. Of these genes, expression of a subset of Eph and Efn genes is 
enhanced when mice are stimulated with equine chorionic gonadotropin (eCG), a horse-
derived gonadotropin that activates the FSH receptor. In GCs, FSH enhances expression 
of genes that are required for the generation of a preovulatory follicle that is competent to 
respond to the surge in luteinizing hormone (LH) that triggers ovulation. Chapters 2 and 
4 identify Efna5, Epha3, Epha5, Epha8, and Ephb2 as FSH-responsive genes in mouse 
GCs, and represents the first evidence for gonadotropin-regulated Efn and Eph expression 
in GCs. Consistent with our findings, a recently published microarray comparison of gene 
expression in small and large follicles in the cow ovary found that expression of Efna5 
and Ephb6 is enhanced 8.6- and 3.8-fold, respectively, in large compared to small 
follicles (7). Since follicle growth is driven primarily by FSH, this supports the idea that 
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Eph and Efn expression increases under the influence of FSH. Furthermore, it was 
recently reported that expression of EFNB2 is enhanced in human luteal cells in response 
to human chorionic gonadotropin (hCG) (8), a placenta-derived gonadotropin with the 
capacity to activate the LH receptor. Complemented by our own findings, these studies 
are adding to a growing body of evidence indicating that Eph receptors and ephrins are 
part of the ovarian response to gonadotropins, encompassing follicle growth, ovulation, 
and formation of the corpus luteum. 
5.3 Efna5 is required for a complete response to human chorionic 
gonadotropin (LH) 
To date, no Eph receptor or ephrin knockout mouse has been reported to exhibit 
altered ovarian function. A partially-penetrant reproductive phenotype has been reported 
in Epha7-/- females, but this was attributed to a developmental uterovaginal defect 
resulting in complete vaginal obstruction (9). Chapters 2 and 4 of this thesis demonstrate 
that eCG enhances expression of Efna5, Epha3, Epha5, Epha8, and Ephb2 in mouse 
GCs. Of these genes, only Efna5 encodes an ephrin ligand, while the remainder encode 
Eph receptors that bind ephrin-A5. Therefore, we chose to investigate gonadotropin-
dependent follicle growth and ovulation in the Efna5-/- mouse, based on the observation 
that eCG does not enhance expression of other Efn genes in GCs that might compensate 
for the loss of Efna5. 
In Chapter 3, we present evidence that Efna5-/- females are subfertile and exhibit an 
incomplete response to hCG. The impaired response to hCG included reduced ovulatory 
potential, attenuated ovarian expression of the LH-responsive genes Pgr, Ptgs2, and 
Adamts4, as well as impaired follicle rupture. Furthermore, adult Efna5-/- females 
exhibited an increased incidence of multi-oocyte follicles (MOFs). 
5.3.1 Morphological and adhesive responses in the context of the Efna5-/- phenotype 
In Chapter 2, we demonstrated that in a two-dimensional cell culture model system, 
GCs respond to recombinant ephrin-A5 and EphA5, exhibiting altered morphology and 
cell-substrate adhesion, respectively. Specifically, seeding primary mouse GCs or rat 
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GFSHR-17 cells onto an ephrin-A5-coated surface impedes cell spreading, while a 
surface coated with recombinant EphA5 reduces cell-substrate adhesion. These responses 
are indicative of repulsion, and it is reasonable to speculate that Eph-ephrin signaling 
contributes to cell repulsion during ovulation, but whether loss of these morphological 
and adhesive responses contributes to the ovarian phenotype we observed in Efna5-/- mice 
is unknown. Nevertheless, these findings may provide insight into the way Eph-ephrin-
stimulated changes in morphology and adhesion are involved in follicle growth and 
ovulation. 
In the context of the growing follicle, such repulsive responses may contribute to 
formation of the antrum, which occurs during FSH-dependent follicle growth and 
requires movement of GCs relative to each other (10). Furthermore, cumulus cells exhibit 
transiently increased migratory and adhesive properties at the time of ovulation. This is 
proposed to facilitate adhesion of the COC to follicle wall extracellular matrix (ECM) 
exposed by thinning of the granulosa layer at the site of rupture (11). Given our 
observation that stimulation with ephrin-A5 and EphA5 induces a repulsive response in 
cultured GCs (12), Eph-ephrin signaling may reduce granulosa cell adhesion at the time 
of ovulation. In Efna5-/- mice, GC adhesion may remain sufficiently high as to impede 
oocyte release. Interestingly, expression of other genes associated with cell repulsion 
during axon guidance is increased in large compared to small follicles in the cow, such as 
Slit (Slitrk1), roundabout (Robo1, Robo2), and semaphorin (Sema6a) (7). This suggests 
that multiple pathways may be involved in regulating cell adhesion during follicle growth 
and/or ovulation. 
Given that ephrinA5 and Eph receptor A5 trigger morphological and adhesive 
changes in granulosa cells in culture, Eph-ephrin signaling may contribute to cell 
migration during release of the COC from the rupturing follicle. In Chapter 2, our data 
indicate that in antral follicles of eCG-stimulated mice, immunoreactivity corresponding 
to both ephrinA5 and Eph receptor A5 protein is stronger in mural granulosa cells than in 
cumulus cells. This observation is consistent with the idea that FSH and oocyte-
stimulated SMAD2/3 signaling establish opposing gradients of gene expression in the 
follicle, such that expression of FSH-responsive genes is stronger in mural granulosa 
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cells than in cumulus cells (13). Differential Eph receptor and ephrin expression that 
gives rise to differences in adhesive affinity has been implicated in the segregation of 
human colorectal cancer cells (14). In the follicle, differential Eph receptor and ephrin 
expression in mural granulosa cells and cumulus cells may facilitate COC release through 
differences in adhesive affinity that contribute to guiding the COC towards the site of 
follicle rupture. In Efna5-/- females, FSH-stimulated expression of ephrinA5 and the 
resulting gradient would be abolished, potentially altering the capacity of the follicle to 
facilitate COC release and resulting in an increased likelihood of oocyte retention. Such a 
scenario would complement the observation that the COC exhibits transiently increased 
invasive migration at the time of ovulation (11) as well as the idea that in large antral 
follicles, increased expression of ephrins and other signaling elements with roles in axon 
guidance promote migration of the oocyte to the site of follicle rupture (7). 
5.3.2 A possible role for Efna5 in follicle atresia 
Our investigation yielded the unexpected finding that follicles containing expanded 
COCs were more numerous in gonadotropin-stimulated (48 h eCG + 10 h hCG) Efna5-/- 
females than in Efna5+/+ controls. Since the majority of follicles that are recruited for 
FSH-dependent growth are destined for atresia (15), an increased number of follicles 
containing expanded COCs may indicate disruption of atresia in Efna5-/- mice. The 
possibility that ephrin-A5 is required for follicular atresia is supported by the observation 
that expression of Efna4 and Efna5 is enhanced 4.2- and 3.3-fold, respectively, in small 
atretic follicles compared to small healthy follicles in the cow (16). Given our 
observation that Efna5 expression in GCs is enhanced by eCG, this is seemingly at odds 
with the generally accepted idea that FSH serves as a survival signal that rescues follicles 
from atresia (17). Therefore, enhancement of Efna5 expression in atretic follicles may 
occur independently of FSH. 
Cell death during atresia occurs by several biological mechanisms, including 
apoptosis, autophagy, cornification, and necrosis (18). However, apoptosis is thought to 
be the primary mechanism by which cell death occurs in atretic follicles (16). Eph-ephrin 
signaling is required for apoptosis in some cell types, supported by the observation that 
stimulation with recombinant ephrin-A5 promotes apoptosis in Epha7-expressing mouse 
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cortical progenitor cells, while apoptosis is suppressed by loss of Epha7 (19). 
Furthermore, Epha2-/- mouse embryonic fibroblasts are resistant to UV-induced apoptosis 
compared to Epha2+/+ controls (20). Given the observations that expression of Efna4 and 
Efna5 is higher in atretic bovine antral follicles than in healthy follicles (16) and the 
increased numbers of follicles containing expanded COCs in ovaries of superovulated 
Efna5-/- females, it is reasonable to speculate that Eph-ephrin signaling contributes to 
follicular atresia. During the follicular phase of the ovarian cycle, a decline in serum FSH 
concentration is thought to be a key mediator of atresia, resulting in the death of 
subordinate follicles and selection of the dominant follicle (21). If Efna5 is required for 
follicular atresia in the mouse, the absence of ephrin-A5 may permit some fraction of 
subordinate follicles to acquire some competency to respond to hCG, and achieve 
cumulus expansion. 
5.3.3 Putative Eph-ephrin signaling mechanisms in GCs 
One of the most interesting questions raised by our findings pertains to the nature 
of the signaling mechanisms that act downstream of Eph-ephrin signaling in GCs. 
Chapter 2 demonstrated that FSH enhances expression of Efna5 and several genes that 
encode its cognate receptors, affects GC morphology and adhesion, and identified beta-
catenin as a possible downstream signaling target. Chapter 3 provides evidence that 
ephrin-A5, the sole ephrin ligand upregulated in response to FSH in GCs, is required for 
a complete ovarian response to LH. Its loss impairs ovulation and attenuates LH-
stimulated expression of two genes known to be important for follicle rupture, Pgr and 
Ptgs2. However, the molecular mechanism(s) by which activation of Eph-ephrin 
signaling contributes to GC functions and gene expression is unknown. 
5.3.3.1 Crosstalk at the RAF-MEK-ERK pathway 
One possibility is that Eph-ephrin signaling in GCs contributes to activation of 
extracellular regulated kinases 1 and 2 (ERK1/2). Mice that lack ERK1/2 in GCs exhibit 
a compromised response to LH, including impairment of cumulus expansion, ovulation, 
luteinization, and abolished expression of many LH-responsive genes, including Pgr and 
Ptgs2 (22). Therefore, ERK1/2 play a critical role in mediating the response to LH in the 
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mouse ovary. Consequently, signaling pathways that impinge on ERK1/2 may have the 
potential to modulate the response to LH in GCs. 
Eph-ephrin signaling has been reported to impinge on ERK1/2 signaling, increasing 
phosphorylation in some cell types and decreasing phosphorylation in others. Eph 
receptor activation decreases phosphorylation of ERK1/2 in pRNS1-1 and PC-3 human 
prostatic epithelial cells, mouse embryonic fibroblasts, and primary bovine aortic cells 
(23). Furthermore, treatment of EPHB2-expressing MCF-7 cells with the EphB2 cognate 
ligand ephrin-B2 or an agonistic EPHB2 antibody results in activation of ERK1/2 (24). 
However, Eph receptor activation increases phosphorylation of ERK1/2 in MDA-MB-
231 breast cancer cells (25), mouse neural progenitor cells (26), and rat PC12 
pheochromocytoma cells (27). This suggests the possibility that in follicles growing 
under the influence of FSH, enhanced expression of Efna5 and genes encoding its 
cognate Eph receptors results in increased Eph-ephrin-mediated ERK1/2 activation. 
Therefore it is reasonable to speculate that in GCs, Eph-ephrin and LH signaling 
converge at ERK1/2 to promote expression of genes that are important for ovulation. In 
the Efna5-/- mouse, absence of ephrin-A5 may result in ERK1/2 phosphorylation that is 
insufficient to achieve optimal induction of Pgr and Ptgs2, which in turn impairs follicle 
rupture during ovulation. 
Another possible mechanism by which ephrin-A5 may impinge on ERK1/2 
involves suppression of Eph receptor activation by co-expressed ephrin-A5. The current 
body of evidence primarily describes interactions between Eph receptors and ephrins in 
trans, that is, between Eph receptors expressed on one cell and ephrins expressed on an 
adjacent cell. Several reports have described Eph receptor-ephrin interactions in cis, that 
is, co-expressed Eph receptors and ephrins interacting within the same cell membrane, 
although the body of evidence supporting cis as opposed to trans interactions is smaller. 
In EPHA3-expressins human embryonic kidney 293 (HEK293) cells, co-expression of 
EPHA3 and EFNA5 abolished activation of EPHA3 by soluble, recombinant ephrin-A5 
(28). The physiological importance of Eph-ephrin interactions in cis was demonstrated in 
a report describing how attenuation of Eph receptor signaling by co-expressed ephrins is 
required for proper migration of chick spinal motor axons (29). In Chapter 2, we detected 
140 
 
transcripts for a number of Efn and Eph genes in mouse GCs. Expression of a subset of 
these genes, which included only one ephrin (ephrin-A5) was enhanced by eCG. This 
suggests the possibility of a scenario where a basal level of Eph-ephrin signaling 
suppresses phosphorylation of ERK1/2 in GCs, as has been previously described (23). 
Increased expression of Efna5 in response to FSH may then serve to attenuate activation 
of co-expressed Eph receptors in cis, thereby relieving suppression of ERK1/2 signaling. 
In the Efna5-/- mouse, eCG does not enhance expression of Efna5, and relief of ERK1/2 
suppression by attenuation of Eph receptor forward signaling would not occur. In this 
scenario, ERK1/2 phosphorylation may be insufficient to achieve optimal expression of 
Pgr and Ptgs2, resulting in impaired follicle rupture. 
5.3.3.2 Ephrin-A5 alters beta-catenin protein levels in GFSHR-17 cells 
In Chapter 2, we reported that ephrin-A5 has the capacity to alter beta-catenin 
protein levels in the GFSHR-17 rat GC line. Specifically, stimulation with recombinant 
ephrin-A5 resulted in decreased beta-catenin protein levels. Beta-catenin is known to 
have dual functions in the cell, serving as a component of adherens junctions (30) and as 
a transcriptional activator (31,32). Targeting of beta-catenin protein to proteasomal 
degradation is mediated by a constitutively-active degradation complex that consists of 
APC (Adenomatous polyposis coli), axin, GSK3 (glycogen synthase kinase 3), and CK1 
(casein kinase 1), resulting in constant turnover of beta-catenin. Activation of cell 
membrane-associated FZD (Frizzled) receptors by WNT (secreted wingless/int1) proteins 
promotes dissociation of this degradation complex, which results in increased beta-
catenin protein levels by accumulation (33). In the context of the ovary, maintenance of 
appropriate beta-catenin protein levels in GCs is critical for fertility. Mice expressing a 
dominant-stable (resistant to degradation) form of beta-catenin in GCs exhibit impaired 
ovulation and luteinization. The same study found that when stimulated with eCG and 
hCG, these mice exhibit attenuated expression of Ptgs2 in GCs compared to controls 
(34). Therefore, in mouse GCs, FSH-stimulated enhancement of Efna5 expression may 
serve as a mechanism to promote degradation of beta-catenin. In GCs of Efna5-/- mice, 
loss of ephrin-A5 may result in increased beta-catenin protein levels, contributing to the 
reduced expression of Ptgs2 and impairment of ovulation we observed in these mice. 
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5.3.3.3 Attenuated expression of Adamts4 in Efna5-/- mice 
In Chapter 3, we present data indicating that hCG-stimulated enhancement of 
whole-ovary A disintegrin and metalloproteinase with thrombospondin-like repeats-4 
(Adamts4) expression at 14 h post-hCG is 80% lower in Efna5-/- than in Efna5+/+ mice. In 
the mouse ovary, expression of Adamts4 exhibits a biphasic pattern of expression 
following stimulation with hCG, increasing at 4 h and falling by 8 h, and then increasing 
again at 12-16 h. The same study found that in hCG-treated progesterone receptor (PGR)-
null (Pgr-/-) mice, ovarian expression of Adamts4 increases normally at 4 h, but is 
significantly reduced at 12 h compared to Pgr+/- mice, indicating that Pgr is required for 
optimal Adamts4 induction (35). This is also consistent with the current view that PGR 
regulates the expression of numerous proteases during the periovulatory period (36). This 
suggests that in hCG-treated Efna5-/- females, attenuated expression of Pgr at 4 h 
contributes to the absence of Adamts4 induction at 14 h. Previously published 
immunohistochemistry studies revealed that at 16 h post-hCG, ADAMTS4 protein is 
substantially enriched at the site of ovulation, suggesting that it is involved in tissue 
remodeling at this site (35). However, Adamts4-/- mice are phenotypically normal and 
have not been reported to exhibit reproductive defects, suggesting that other proteinases 
can compensate for its loss (37) or that its contribution to fertility is too small to be 
detected using reasonable sample sizes. In Efna5-/- females, attenuated induction of Pgr 
may result in reduced expression of other proteases that would normally compensate for 
the loss of Adamts4. Therefore, attenuation of Adamts4 expression in Efna5-/- ovaries at 
14 h post-hCG may be caused by inadequate ovarian induction of Pgr in these mice. 
5.3.3.4 Reduced prostaglandin synthesis in follicles of Efna5-/- mice may allow non-
apical rupture 
Our observations suggest that reduced expression of Pgr and Ptgs2 in ovaries of 
Efna5-/- mice contributes to abnormal follicle rupture in these animals. Release of 
ovulated oocytes into the extraovarian space requires that follicle rupture occurs at the 
apical surface, which lies closest to the ovarian surface epithelium. Localization of 
rupture to the apical surface of the follicle has been attributed to the observation that the 
follicle is thinnest at this region, the apex (38). However, proper localization of rupture 
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may also be regulated by prostaglandin-stimulated expression of proteolytic inhibitors. In 
granulosa cells of primate follicles, hCG stimulates expression of PLAT (tissue-type 
plasminogen activator) and SERPINE1 (plasminogen activator inhibitor, type I) in a 
prostaglandin-dependent manner (39). Prostaglandin receptor expression in primate 
follicles differs between GC subtypes, with PTGER1 (Prostaglandin E receptor 1, 
subtype EP1) predominant in mural GCs and PTGER2 (Prostaglandin E receptor 1, 
subtype EP2) and PTGER3 (Prostaglandin E receptor 1, subtype EP3) predominant in 
cumulus cells. The same study demonstrated that while PLAT protein levels are  
uniform in mural GCs, EP1 and SERPINE1 protein levels are lower in mural GCs at the 
follicle apex than in non-apex mural GCs. This suggests that follicle rupture is regulated 
by a balance of activation and inhibition of proteolysis, with reduced inhibition favouring 
rupture at the apex (40). In Efna5-/- females, attenuated Ptgs2 expression may result in 
reduced prostaglandin synthesis, such that prostaglandin levels are insufficient to inhibit 
proteolysis at non-apex follicle sites. This could potentially result in occasional instances 
of non-apical follicle rupture. 
5.3.4 A potential link between abnormal follicle rupture and multi-oocyte follicle 
formation 
Multi-oocyte follicles (MOFs) have been reported in a number of mouse models, 
most of which exhibit decreased fertility (41). Our observations indicate that at PND 120, 
MOFs are more numerous in ovaries of adult Efna5-/- mice than in Efna5+/+ controls. 
However, there is no difference in MOF number between genotypes at PND 21, an age at 
which mice are reproductively immature. This suggests a gonadotropin-associated 
mechanism underlying MOF formation, as well as the possibility that MOF formation in 
these mice occurs by joining of follicles. Incomplete prenatal oocyte nest breakdown 
during has been proposed to cause MOF formation (42), however the observation that 
increased MOF number is not seen in immature Efna5-/- females but is observed in adults 
indicates that MOF formation likely occurs by joining of follicles. Breaching of the 
follicle wall resulting in joining of follicles has been proposed to underlie MOF 
formation in oocyte-specific C1galt1 (core 1 synthase, glycoprotein-N-
acetylgalactosamine 3-beta-galactosyltransferase, 1)-deficient mice (41). 
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In Chapter 3, we present evidence that absence of ephrin-A5 results in non-apical 
follicle rupture. Furthermore, we observed one occurrence of premature follicle rupture at 
the antral stage. These observations suggest that ephrin-A5 is involved in localizing 
follicle rupture to an apical region of the follicle wall, and may also be important for 
maintaining integrity of the follicle wall. Based on the histological similarity between 
ovaries of Efna5-/- mice and PTGS2 inhibitor (indomethacin)-treated rats, and the 
observation that enhancement of Ptgs2 expression is blunted in Efna5-/- ovaries, it is 
reasonable to speculate that reduced PTGS2 activity underlies non-apical rupture in 
Efna5-/- mice. However, premature follicle rupture was not reported in indomethacin-
treated rats. This suggests that premature follicle rupture in Efna5-/- mice is caused by the 
absence of ephrin-A5, but by a mechanism that is independent of that which underlies 
non-apical follicle rupture. If ephrin-A5 is important for maintaining follicle wall 
integrity, its loss may result in an increased occurrence of follicle wall breaching and 
merging, resulting in an increased occurrence of MOFs. 
5.3.5 cAMP-dependent pathways regulate Epha5 expression in GCs 
In Chapter 2, we demonstrated that FSH enhances expression of Efna5 and genes 
encoding several of its cognate Eph receptors, suggesting a role for Eph-ephrin signaling 
in follicle growth and/or ovulation. However, since the FSH receptor is a G protein 
coupled receptor (GPCR), this also suggested that expression of these genes is regulated 
by cAMP-dependent pathways. In Chapter 4, we present evidence that eCG-stimulated 
enhancement of Efna5, Epha3, Epha5, Epha8, and Ephb2 is attenuated in GCs of Esr2-/- 
mice. Esr2-/- mice exhibit impaired cAMP production in GCs, and this defect is the 
proposed basis of the severely attenuated expression of FSH-responsive genes observed 
in GCs of these mice. Using reporter assays, we also demonstrated that the 1589 bp 
genomic sequence upstream of the Epha5 5’ UTR in the mouse is responsive to cAMP, 
and that this response is suppressed by co-treatment with an inhibitor of protein kinase A 
(PKA), H-89. Our findings are consistent with the idea that H-89 inhibits GC 
differentiation, which is promoted by both FSH and cell-permeable cAMP analogs (43), 
and with the idea that Eph receptors are part of the response to gonadotropins. 
Transcriptional regulation of Eph and Efn genes by cAMP-dependent pathways has not 
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been previously described. Our studies suggest that regulation by cAMP may also occur 
in other tissues. Furthermore, GPCRs make up the largest known family of signaling 
molecules associated with the cell surface, and many GPCRs impinge on cAMP-
dependent pathways (44). Therefore, our findings suggest that Eph and Efn expression 
may be altered, and Eph-ephrin signaling involved, in GPCR-associated signaling events 
where Eph-ephrin signaling has not been previously investigated as a potential source of 
cross-talk. 
5.4 Experimental Considerations 
5.4.1 Germline Efna5-/- mouse model 
In Chapter 2, we demonstrated that in GCs, expression of Efna5 and genes 
encoding several of its cognate receptors is enhanced by FSH. Based on this finding, we 
performed a reproductive characterization of the Efna5-/- mouse. It should be noted that 
this mouse model is a germline knockout, and therefore lacks Efna5 at all stages of 
development in all cell types. Therefore, we cannot rule out the possibility that loss of 
ephrin-A5 during embryonic development impairs ovarian function in the adult. 
Furthermore, non-GC types in the ovary, such as the oocyte, thecal cells, endothelial 
cells, or the ovarian stroma may require ephrin-A5 for normal function. In future studies, 
these concerns may be addressed through the use of a Cre/loxP approach to generate a 
GC-specific Efna5 knockout mouse. Cyp19-Cre transgenic mice have been previously 
generated (45) and used as a model system to investigate the role of ERK signaling in 
GCs during FSH-dependent follicle growth (22). To some extent, the breeding and serum 
steroid concentration data presented in Chapter 3 address these concerns. We detected no 
difference in litter frequency between Efna5+/+ and Efna5-/- females, suggesting that 
estrous cyclicity is not affected by loss of ephrin-A5. This in turn suggests that regulation 
of the hypothalamic-pituitary-gonadal (HPG) axis is normal in Efna5-/- females. 
Furthermore, we detected no difference in serum concentrations of estradiol and 
progesterone between superovulated Efna5+/+ and Efna5-/- females. This suggests that 
ovarian production of estradiol and progesterone, steroid hormones that act on the 
hypothalamus, pituitary, uterus, and other tissues, is normal in Efna5-/- females. 
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5.5 Future Directions 
5.5.1 Delineating Eph-ephrin signaling pathways in GCs 
In Chapter 3, we demonstrated that loss of ephrin-A5 attenuates hCG-stimulated 
enhancement of Pgr and Ptgs2 expression in the ovary. While the mechanism by which 
ephrin-A5 contributes to increased expression of these genes in the ovary is not known, 
we speculated on the possibility that Eph-ephrin signaling impinges on ERK1/2 in mouse 
GCs. In order to identify signaling pathways regulated by ephrin-A5, immunoblotting 
could be used to analyze GC lysates from gonadotropin-stimulated Efna5+/+ and Efna5-/- 
mice. Proven antibodies against total and phosphorylated forms of candidate targets we 
have proposed are readily available, such as RAF, MEK, and ERK. Furthermore, 
commercially available phosphorylated protein kinase detection arrays may reveal 
additional pathways regulated by ephrin-A5 in GCs. These arrays would permit rapid 
screening of multiple kinase targets to determine whether other pathways are 
differentially regulated between Efna5+/+ and Efna5-/- GCs in superovulated mice. Any 
targets identified by such screens would then be verified by immunoblotting. 
If and when ephrin-A5-regulated pathways are identified in GCs of intact mice, a 
cell culture approach could be used to distinguish between forward (downstream of Eph 
receptor activation) and reverse (downstream of ephrin activation). In Chapter 2, we 
stimulated cultured GCs with recombinant ephrin-A5 or EphA5 to demonstrate effects on 
morphology and adhesion. The same experimental system could be used to specifically 
stimulate forward or reverse signaling, and immunoblotting would then be used to assess 
activation of identified signaling targets. 
5.6 Conclusion 
The work presented in this thesis demonstrates that ephrin-A5 plays an important 
role in ovarian function. In the mouse, FSH enhances expression of Efna5, Epha3, 
Epha5, Epha8, and Ephb2 in GCs. Loss of Efna5 results in subfertility and a partially 
impaired response to hCG that includes reduced ovulatory potential, attenuated 
expression of Pgr, Ptgs2, and Adamts4 (Figure 5-1), as well as abnormal follicle rupture. 
We also present evidence that cAMP is a transcriptional regulator for genes encoding 
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several members of the Eph-ephrin family. In the case of Epha5, the proximal upstream 
genomic region is activated by cAMP in a PKA-dependent manner, and contains a 
conserved, putative consensus CRE half-site. This indicates that Eph and Efn expression 
may be regulated by GPCRs in other tissues. The body of evidence indicating the 
importance of Eph-ephrin signaling in the ovary has only recently begun to grow. Our 
current knowledge of Eph-ephrin function in the ovary is limited, particularly with 
respect to the signaling pathways by which these signaling elements influence the ovarian 
response to gonadotropins. Continued investigation will delineate these mechanisms to 
generate a more accurate model of ovarian function. 
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Figure 5-1: Putative model for Eph-ephrin involvement in gonadotropin-stimulated 
gene expression in mouse granulosa cells. 
Activation of FSHR (1) stimulates expression of Efna5, Epha3, Epha5, Epha8, and 
Ephb2 via the protein kinase A (PKA) signaling pathway (1a). Stimulation of LHR and 
Eph receptors cognate to ephrinA5 results in activation of the PKA (2a) and extracellular 
signal regulated kinase (ERK1/2) (2b) signaling pathways, respectively. This results in 
optimal expression of Pgr, Ptgs2, and Adamts4. Pgr and Ptgs2 are necessary for 
ovulation, while Adamts4 may play a role in tissue remodeling at the follicle rupture site. 
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6 Appendix 
6.1 Supplementary Material, Chapter 2 
 
Supplemental Figure 6-1: Screening study to determine mRNA levels of all known 
mouse ephrin (Efn) genes in granulosa cells isolated from immature female mice in 
response to FSH. 
Wild-type postnatal day (PND) 23-28 C57Bl/6 mice were treated with saline or equine 
chorionic gonadotropin (eCG) (5.0 IU per mouse) for 48 hours. Granulosa cells (GCs) 
were isolated by ovarian puncture, pooled, and mRNA isolated. mRNA levels were 
determined by quantitative RT-PCR and compared to an Rpl7 control. Data are expressed 
as average gene expression compared with the Rpl7 control (± SEM of three independent 
experiments). All resulting values were normalized to the Efna3 vehicle (the Efn gene 
with the lowest expression level) to approximate relative levels of gene expression 
between Efn genes. 
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Supplemental Figure 6-2: Screening study to determine mRNA levels of all known 
mouse ephrin receptor (Eph) genes in granulosa cells isolated from immature female 
mice in response to FSH. 
Wildtype postnatal day (PND) 23-28 C57Bl/6 mice were treated with saline or equine 
chorionic gonadotropin (eCG) (5.0 IU per mouse) for 48 hours. Granulosa cells (GCs) 
were isolated by ovarian puncture, pooled, and mRNA isolated. mRNA levels were 
determined by quantitative RT-PCR and compared to an Rpl7 control. Data are expressed 
as average gene expression compared with the Rpl7 control (± SEM of three independent 
experiments). All resulting values were normalized to the Epha6 vehicle (the Eph gene 
with the lowest expression level) to approximate relative levels of gene expression 
between Eph genes. 
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Supplemental Figure 6-3: Proteome Profiler Phospho-Kinase Arrays. 
GFSHR-17 cells were seeded onto tissue culture surfaces coated with ephrinA5-Fc or Fc 
(control protein). Protein lysates were generated, and analyzed using the Human 
Phospho-Kinase Array at 15 min (A) and 20 min (B) post-seeding. Capture array layout 
is represented in (C). 
155 
 
Supplemental Table 6-1: Human Phospho-Kinase Array capture antibodies 
Spot Kinase target 
A1, A2 Reference 
A3, A4 p38-alpha 
A5, A6 ERK1/2 
A7, A8 Pan-Jnk 
A9, A10 GSK-3-alpha/beta 
A13, A14 p53 (S392) 
A17, A18 Reference 
B3, B4 MEK1/2 
B5, B6 MSK1/2 
B7, B8 AMPK-alpha-1 
B9, B10 Akt (S473) 
B11, B12 Akt (T308) 
B13, B14 p53 (S46) 
C1, C2 TOR 
C3, C4 CREB 
C5, C6 HSP27 
C7, C8 AMPK-alpha-2 
C9, C10 beta-catenin 
C11, C12 p70 S6 kinase (T389) 
C13, C14 p53 (S15) 
C15, C16 p27 (T157) 
C17, C18 Paxillin 
D1, D2 Src 
D3, D4 Lyn 
D5, D6 Lck 
D7, D8 STAT2 
D9, D10 STAT5a 
D11, D12 p70 S6 kinase (T421/S424) 
D13, D14 RSK1/2/3 
D15, D16 p27 (T157) 
D17, D18 PLC-gamma-1 
E1, E2 Fyn 
E3, E4 Yes 
E5, E6 Fgr 
E7, E8 STAT3 
E9, 10 STAT5b 
E11, E12 p70 S6 kinase (T229) 
E13, E14 RSK1/2 
E15, E16 c-Jun 
E17, E18 Pyk2 
F1, F2 Hck 
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F3, F4 Chk-2 
F5, F6 FAK 
F7, F8 STAT6 
F9, F10 STAT5a/b 
F11, F12 STAT1 
F13, F14 STAT4 
F15, F16 eNOS 
F17, F18 Negative control 
G1, G2 Reference 
G5, G6 Negative control 
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Supplemental Table 6-2: Phosphorylation of intracellular kinase targets in response 
to ephrinA5-Fc, 15 min post-seeding. 
Target Phosphorylation Ratio (ephrinA5-Fc / Fc) 
Pan-JNK 2.30 
p38alpha 1.54 
GSK-3alpha/beta 1.46 
AMPKalpha1 1.44 
MSK1/2 1.21 
MEK1/2 1.19 
c-Jun 1.15 
STAT5a/b 1.09 
Fgr 1.08 
STAT5b 1.07 
Chk-2 1.07 
Akt - S473 1.06 
Pyk2 1.03 
Hck 1.02 
Lyn 1.02 
RSK1/2/3 1.02 
FAK 1.00 
Paxillin 1.00 
CREB 0.99 
Yes 0.98 
STAT6 0.98 
HSP27 0.95 
STAT3 0.94 
p53 S15 0.92 
Src 0.92 
Lck 0.89 
Akt 0.88 
p53 0.87 
eNOS 0.86 
p70 S6 kinase T229 0.86 
STAT2 0.85 
RSK1/2 0.84 
PLCgamma-1 0.83 
AMPKalpha2 0.81 
p70 S6 kinase - T421/S424 0.81 
Fyn 0.81 
TOR 0.77 
p53 S46 0.76 
p70 S6 kinase 0.73 
STAT4 0.71 
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STAT1 0.70 
p27 T157 0.65 
p27 T198 0.63 
STAT5a 0.31 
beta-catenin 0.16 
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Supplemental Table 6-3: Phosphorylation of intracellular kinase targets in response 
to ephrinA5-Fc, 20 min post-seeding. 
Target Phosphorylation Ratio (ephrinA5-Fc / Fc) 
p53 S46 1.35 
p53 1.33 
HSP27 1.29 
Akt 1.23 
Chk-2 1.19 
CREB 1.16 
TOR 1.15 
Lyn 1.13 
p53 S15 1.12 
Fgr 1.11 
Yes 1.09 
RSK1/2 1.08 
STAT1 1.07 
MEK1/2 1.07 
GSK-3alpha/beta 1.06 
p70 S6 kinase 1.06 
RSK1/2/3 1.05 
STAT4 1.03 
FAK 1.02 
p27 T198 1.00 
p70 S6 kinase T229 0.98 
eNOS 0.97 
p70 S6 kinase 0.95 
Src 0.95 
Pyk2 0.91 
MSK1/2 0.90 
STAT2 0.87 
AMPKalpha2 0.83 
c-Jun 0.82 
PLCgamma-1 0.81 
Fyn 0.80 
Hck 0.77 
p38alpha 0.76 
Pan-Jnk 0.75 
STAT6 0.64 
STAT5a/b 0.59 
Paxillin 0.59 
STAT5a 0.58 
p27 T157 0.58 
Akt - S473 0.51 
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beta-catenin 0.51 
AMPKalpha1 0.47 
Lck 0.42 
STAT5b 0.42 
STAT3 0.31 
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6.2 Supplementary Material, Chapter 3 
 
 
Supplemental Figure 6-4: EPHRIN-A5 protein levels are lower in granulosa cells of 
Esr2-/- mice compared to Esr2+/+. 
Immunoblot detection of EPHRIN-A5 in Esr2+/+ and Esr2-/- granulosa cells and in control 
HEK293 cells overexpressing EPHRINA5 (CMV-SPORT6-Efna5, black arrows). Equal 
protein loading for granulosa cell and HEK293 lysates was confirmed by detection of 
ALPHA-TUBULIN. 
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Supplemental Figure 6-5: Stimulation of KGN cells transfected with Epha5-Luc and 
mutEpha5-Luc with dibutyryl cAMP. 
Firefly luciferase activity normalized to Renilla luciferase activity (mean ±SEM) was 
determined for water- and dbcAMP-treated KGN cells transfected with the Epha5-Luc 
(A) or mutEpha5-Luc (B) luciferase reporter constructs. A) No statistically significant 
difference was found between vehicle- and dbcAMP-treated KGN cells transfected with 
Epha5-Luc, as determined by an unpaired, two-tailed Student’s unpaired t-test; 
t(4)=1.725. p=0.1596. B) No statistically significant difference was found between 
vehicle- and dbcAMP-treated KGN cells transfected with mutEpha5-Luc, as determined 
by an unpaired, two-tailed Student’s t-test; t(4)=2.088. p=0.1051. 
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